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VABSTRACT
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the following : ER 
10,
The uterine cytosolic oestrogen receptor(ER) from the Vervet
monkey (Cercopithecus aethiops pygerethrus) has been partially
characterised by means of competitive protein binding studies,
sucrose density gradients, gel permeation chromatography
iso-electric focussing, chromatofocussing and anion exchange
chromatography. Mean concentration of ER (Bmax) for a batch of 21
uteri was found to be 327±165 fmol/mg protein with a dissociation
-10constant (K^) of 3.15±1.4x10 M for oestradiol using the same
batch of uteri. Mean Bm and K, values for uterine tissuemax a
powders, representing binding data from 95 uteri in 77 assays were
Bmax=224±61 fmol/mg protein and Kq.=3.8±0.9x 
10-IUM; progesterone receptor (PR) : Bm =742±283 fmol/mg protein 
and Kd=2.9±0.71x10”yM. Mean sedimentation coefficients (Beckman 
VTi-80 rotor; 520000xg 'x120min at 2°C), calculated from sucrose 
density gradient analyses on 10-35% hypotonic sucrose gradients 
were 8.4±0.4S for the ER and 7.6±0.5S for the PR.The mean sedimen­
tation coefficient of the nuclear ER, determined in hypertonic 
10-35% sucrose gradients was calculated to be 4.6±1.2S. The mean 
sedimentation coefficient (Beckman VTi rotor) in low ionic 
strength media in the absence or presence of 10mM sodium molybdate 
was 8.4±0.4S. A marked protective effect by sodium molybdate on 
the % 8S component could be illustrated. Exposure of the oestra­
diol charged cytosolic ER complexes to 0.4 M KC1 produced a time 
dependent loss of the ^ 8S moiety with a resultant formation of 
more than one entity in the 3-5S range. Chromatography on Ultrogel 
AcA-22 in low ionic strength buffers yielded high molecular mass
components of 4.68x105 daltons with a Stokes radius of 63.28 in
5
the absence of sodium molybdate and 3.87x10 daltons with a 
Stokes radius of 60.08 in the presence of sodium molybdate. In the 
same system using higher ionic strength buffers a much smaller
4
component was observed : 8.61x10 daltons with a Stokes radius of
41.88 in 0.154 M KC1 and 9.22x104 daltons with a Stokes radius of
42.38 in buffers containing 0.4 M KC1. HPLC using a Waters 1-250
5
gel column showed a high molecular mass entities (4.85x10 and
2.01x10 daltons) in low ionic strength buffers not containing
5
sodium molybdate, while only the 2.01x10 dalton component
appeared in buffers containing 100mM KC1. High ionic strength
conditions (0.4 M KC1) produced high molecular mass aggregates 
5(7.2x10 daltons) in the absence of sodium molybdate and only one
5
macromolecular entity of 1.52x10 daltons in the presence of 
sodium molybdate. Disc gel electrophoresis on polyacrylamide gels 
yielded only one symmetrical peak displacable with 100 times 
excess levels of diethylstilbestrol. Upon iso-electric focussing 
on agarose gels two peaks were obtained : a major peak with a pi 
of 6.6±0.2 and a minor peak at pl=5.5±0.3.
Considerable receptor heterogeneity was revealed upon chromato­
focussing (Ax-500 polyamine column) of cytosols, prepared in 
molybdate-free buffer (CYT(+)). At least 7 components could be 
distinguished (pl=8.2, 8.0, 7.4, 7.1, 6.5, 5.8 and 4.5-5.4).
Cytosols prepared in buffers containing molybdate (20mM) (CYT(+)) 
revealed much simpler chromatograms with peaks shifted to more 
acidic pi values (p 1=6.1 and 5.5). These data were corroborated by 
iso-electric focussing on agarose gels. CYT(-) cytosols displayed 
3 major peaks (pi 6.8 ,6.2 and 5.9) while CYT(+) cytosols exhibited 
a single major high affinity binding component (p 1=5.9). The value 
of the findings was underlined when anion exchange chromatography 
yielded two distinct forms; one eluted at 90 mM and the other at 
230 mM HPO^ j for CYT(-) cytosols in contrast to only one single 
component eluting at 189 mM HPO^ for the CYT(+) cytosols.
Sodium molybdate affected the stability of vervet monkey uterine 
oestrogen (ER) and progesterone (PR) receptors. Yields of recep­
tors were invariably higher (20 - 40 %) when cytosols were pre­
pared in the presence of 10mM sodium molybdate. No changes were 
observed in the binding affinities for the natural ligands as 
reflected in dissociation constants. Receptor ligand association 
at 0°C and 20°C was not affected in the presence or absence of 
molybdate. Stability studies at 37°C indicated that both receptors 
were more resistant to inactivation in the presence of molybdate. 
Dissociation of ER and PR was biphasic indicating the existence of 
slow (SDC) as well as fast dissociating (FDC) complexes. Rate 
constants of dissociation were significantly affected by the 
presence of sodium molybdate. Although no significant changes in 
the sedimentation coefficients were observed, marked differences 
in the actual gradient profiles could be illustrated in the 
presence or absence of sodium molybdate. The effects observed 
could be partially reversed in sedimentation dialysis experiments. 
Proteolytic inhibitors phenylmethylsulfonylfluoride (PMSF) and 
leupeptin had no inhibitive effect on the molybdate stabilization 
of ER and PR.
It could be illustrated by in vitro studies that temperature-in­
duced activation of both ER and PR lead to the formation of a 4.5S 
(ER) or a 4.6S (PR) complex maximally at 15 min of temperature 
activation (SDG analysis). Simultaneously, binding affinity of the 
activated complexes for either uterine nuclei or DNA-cellulose 
reached a maximum at 15 min of temperature induced activation. 
Both the sedimentation shift and binding of the activated com­
plexes to nuclei and DNA-cellulose were severely inhibited in the 
presence of 10mM sodium molybdate. Furthermore it could be demon­
strated that activation of the human uterine PR-ligand complexes 
was also accompanied by a sedimentation shift (3.7-4.6 ) and to 
maximum binding of the activated complexes to human uterine nuclei 
and to DNA-cellulose. A limited number of pathological human 
uterine samples was investigated in a similar manner and it was 
found that in all the cases studied (leiomyomas and cervix 
carcinomas) the sedimentation shift of the activated complexes
vi i i
appeared to be absent, while binding of these complexes to nuclei 
and DNA-cellulose were sub-normal.
PREFACE
In the past 25 years, a large volume of data was collected on 
steroid hormone receptors and their role in the action mechanisms 
of steroid hormones. Efforts were made to use the principles, 
derived from fundamental investigations into the actual function 
of steroid hormone receptors in target tissues, (e.g. breast and 
uterine tissues) to provide a comprehensive understanding of the 
nature of hormone responsive tumours (e.g. breast tumours) and to 
formulate successful endocrine treatment regimes for e.g. breast 
cancer patients. Although some measure of success was achieved 
with antihormonal drugs like tamoxifen, clomiphene, medroxyproges­
terone acetate, etc. a statistical analysis of patient response 
data has revealed disappointingly low median response times for 
breast cancer patients. A number of reasons can be offered in 
explanation of the discrepancies between theory and practice, 
however, it was felt that the two most obvious ones are the lack 
of a proper animal model, closer to man on the species scale, and 
insufficient understanding of the actual in vivo mechanisms of 
steroid hormone action.
For this very reason it was decided to launch an in depth inves­
tigation into the properties and functions of steroid hormone 
receptors in the biological action of steroid hormones, especially 
the sex steroid hormone receptors, like the oestrogen and proges­
terone receptors. Furthermore, it was decided to employ a non­
human primate, Cercopithecus aethiops pygerythrus, commonly called 
the Vervet monkey, as the animal model, instead of the more common 
Sprague-Dawley rat. Since the field of investigation defined is 
both broad and deep, it is obvious that this thesis could not 
contain all the answers.
So, in view of the obvious limitation in time and man-power, the 
prime object for this thesis was defined as the laying of sound 
foundations for future research on the topic specified above. 
Thus, it was decided to concentrate on the molecular properties of 
the uterine oestrogen and progesterone receptors of the Vervet
Xmonkey. The basic arsenal of biochemical technology used in 
protein chemistry (competitive protein binding assays, sucrose 
density gradient analysis, size exclusion chromatography, ion 
exchange chromatography, chromatofocussing, isoelectric focussing) 
and available in the Institute of Life Sciences, Faculty of 
Medicine, University of Pretoria at the time of this investiga­
tion, was employed. In view of the information generated in the 
course of the study, attention was focussed upon a small, but 
important aspect of the mechanism of steroid hormone action, 
namely the process of activation or tranformation of receptor- 
ligand complexes and their interaction with the nuclear compart­
ment. Since disturbance(s) in these processes in abnormal uterine 
tissues may exist, a limited study of the oestrogen and progeste­
rone receptors in human uterine tissues was undertaken, because no 
abnormal Vervet monkey uterine tissues were available. Unfortuna­
tely it was also extremely difficult to obtain an abundance of 
pathological human uterine tissues necessary for an adequate 
study. The investigator consequently had to be content to study 
only a small number of pathological uterine specimens. Thus the 
latter part of this thesis only skims the surface of what could 
have been a major fait accompli with possible clinical signifi­
cance.
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1CHAPTER 1 
INTRODUCTION.
PHYSIOLOGY AND ANATOMY OF THE FEMALE SEXUAL ORGANS
The sexual organs of the human female includes : the 
ovaries, the fallopian tubes, the uterus, the vagina and the 
breasts. Reproduction begins with the development of ova in 
the ovaries. A single ovum is expelled from an ovarian 
follicle into the abdominal cavity in the middle of each 
monthly sexual cycle. This ovum then passes through one of 
the fallopian tubes into the uterus, and if it has been fer­
tilized by a sperm, it implants in the uterus where it deve­
lops into a foetus, a placenta and fetal membranes.
The breasts begin to develop at puberty, a development which 
is stimulated by the sex hormones produced by the ovaries.
These hormones stimulate the growth of the mammary stroma 
and the ductile system. During pregnancy further development 
of the ductile system occurs in preparation for lactation. 
Throughout pregnancy, large quantities of oestrogens are 
secreted by the placenta causing the ductile system of the 
breasts to grow and to branch. Moderate quantities of growth 
hormone work in conjunction with the oestrogens to produce 
their effect on the breasts. Simultaneously progesterone 
affects the growth and development of the lobules and the 
development of secretory characteristics within the cells of 
the mammary alveoli. All these changes are analogous to the 
secretory effects of progesterone on the endometrium of the 
uterus. Other hormones exerting a controllig effect on the 
function and maintenance of the breasts are prolactin and 
oxytocin. The exact interaction of these hormones with the 
steroid hormones appear to be very complex. For the purpose 
of this introduction it suffices to point out that all the 
female sex organs are under strict control of several
2hormones, including the most important steroid sex hormones 
oestrogen and progesterone.
THE FEMALE HORMONAL SYSTEM
The female hormonal system, consists of three different 
hierarchies of hormones:
1) The hypothalamic releasing factors : follicle-stimulating 
hormone releasing factor (FRF) and luteinizing hormone 
releasing factor (LRF) or one factor responsible for the 
secretion of both FSH and LH by the pituitary gland the 
gonadotrophin releasing hormone (GnRH).
2) The anterior pituitary hormones : follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH), which are 
secreted in response to the releasing factors from the 
hypothalamus.
3) The ovarian hormones : oestrogen and progesterone, which 
are secreted by the ovaries in response to the two hormo­
nes from the anterior pituitary gland.
The various hormones are not secreted in constant, steady 
amounts but instead at drastically differing rates during 
different parts of the female cycle.
THE MONTHLY OVARIAN CYCLE AND FUNCTION OF THE GONADOTROPIC 
HORMONES.
The normal reproductive years of the female are characteri­
zed by monthly rhythmic changes in the rates of secretion of 
the female hormones and corresponding changes in the sexual 
organs themselves. This rhythmic pattern is called : the 
menstrual cycle. The duration of the cycle averages 28 days. 
The two significant results of the female sexual cycle are : 
first, only a single mature ovum is normally released from 
the ovaries each month so that only a single fetus can begin 
to grow at a time. Second, the uterine endometrium is pre-
3pared for implantation of the fertilized ovum at the requi­
red time of the month.
1.3.1 The gonadotropic hormones:
The sexual cycle is completely dependent on gonadotropic 
hormones secreted by the anterior pituitary gland. Ovaries 
that are not stimulated by gonadotropic hormones remain com­
pletely -inactive.
The anterior pituitary secretes two different hormones that 
are known to be essential for full function of the ovaries:
1) follicle-stimulating hormone (FSH), and
2) luteinizing hormone (LH). Both of these are small 
glycoproteins having molecular weights about 
30,000. During each month of the female sexual 
cycle, there is a cyclic increase and decrease of 
FSH and LH as illustrated below. These cyclic 
variations in turn cause cyclic ovarian changes.
Throughout childhood the primordial follicles (primary fol­
licle) do not grow, but at puberty, when FSH from the ante­
rior pituitary gland begins to be secreted in large quanti­
ty, the entire ovaries and especially the follicles within 
them begin to grow. The first stage of follicular growth is 
enlargement of the ovum itself. This is followed by develop­
ment of additional layers of granulosa cells around each 
ovum and development of several layers of theca cells origi­
nating from the stroma of the ovary and which soon take on 
epitheloid characteristics. It is mainly these cells that 
are destinated to secrete most of the female hormones, 
the oestrogens and progesterone. Luteinizing hormone (LH) 
is necessary for final follicular growth and ovulation. With­
out this hormone, even though large quantities of FSH are 
available, the follicle will not progress to the strength of 
ovulation. The change of follicular cells into lutein cells
4is completely dependent on the LH secreted by the anterior 
pituitary gland. The corpus luteum is a highly secretory 
organ, secreting large amounts of both progesterone and 
oestrogen. In the presence of LH the degree of growth of the 
corpus luteum is enhanced, its secretion is greater and its 
life is extended. During the luteal phase of the ovarian 
cycle, the large amount of oestrogen (and perhaps to a very 
slight extent, the progesterone as well) secreted by the 
corpus luteum causes a feedback decrease in secretion of 
both FSH and LH. Therefore, during this period no new 
follicles begin to grow in the ovary. However, when the 
corpus luteum degenerates completely at the end of 12 days 
of its life, the loss of feedback suppression now allows the 
anterior pituitary gland to secrete several times as much as 
FSH as well as moderately increased quantitities of LH. The 
FSH and LH initiate growth 'of new follicles to begin a new 
ovarian cycle. At the same time, the paucity of secretion of 
progesterone and oestrogen leads to menstruation by the 
uterus. In summary: Approximately each 28 days, gonadotropic 
hormones from the anterior pituitary gland cause new 
follicles to begin to grow in the ovaries, one of which 
finally ovulates at the 14th day of the cycle. During growth 
of the follicles, oestrogen is secreted. Following 
ovulation, the secretory cells of the follicle develop into 
a corpus luteum that secretes large quantitites of the 
female hormones progesterone and oestrogen. After another 
two weeks the corpus luteum degenerates, whereupon the 
ovarian hormones, oestrogen and progesterone, decrease 
greatly and menstruation begins. A new ovarian cycle then 
follows.
1.3.2. The ovarian hormones - oestrogen and progesterone.
The two types of ovarian hormones are the oestrogens and 
progesterone. The oestrogens mainly promote proliferation 
and growth of specific cells in the body and are responsible 
for development of most secondary sexual characteristics of
the female. On the other hand, progesterone is concerned 
almost entirely with final preparation of the uterus for 
pregnancy and of the breasts for lactation.
CHEMISTRY OF THE SEX STEROID HORMONES:
The oestrogens: In the normal, non-pregnant female, 
oestrogens are secreted in major quantitites only by the 
ovaries, though minute amounts are also secreted by the 
adrenal cortices. In pregnancy tremendous quantities are 
also secreted by the placenta. At least six different 
natural oestrogens have been isolated from the plasma of the 
human female, but only three are present in significant 
quantitites : p-oestradiol, oestrone and oestriol. However, 
the oestrogenic potency of p-oestradiol is 12-times that of 
oestrone and 80 times that of oestriol, so that the total 
oestrogenic effect of p-oestradiol is usually many times 
that of the other two together.
Progesterone:Almost all the progesterone in the non-pregnant 
female is secreted by the corpus luteum during the latter 
half of each ovarian cycle. However, during pregnancy 
progesterone is formed in extreme quantities by the placen­
ta, about 10 times the normal monthly amount, especially 
after the fourth month of gestation.
FUNCTIONS OF OESTROGEN AND PROGESTERONE
Functions of oestrogens:
The principal function of the oestrogens is to cause cellu­
lar proliferation and growth to the tissues of the sexual 
organs and of other tissues related to reproduction. During 
childhood oestrogens are secreted only in small quantities, 
but following puberty the quantity of oestrogens secreted 
under the influence of the pituitary a gonadotropic hormones 
increases some 20-fold or more. At this time the female
6sexual organs change from those of a child to those of 
an adult. In addition, oestrogens change the vaginal epithe­
lium from a cuboidal into stratified type. More important 
however, are the changes that take place in the endometrium 
under the influence of oestrogens, for oestrogens cause 
marked proliteration of the endometrium and development of 
glands that will later be used to aid in nutrition of the 
implanting ovum. Oestrogens cause fat deposition in the 
breasts, development of stromal tissues of the breasts, 
and growth of an extensive ductile system. The lobules and 
alveoli of the breasts develop to a slight extent, but it is 
progesterone and prolactin that cause the determinative 
growth and function of these structures.Oestrogens cause 
increased osteoblastic activity. However, oestrogens have an 
other potent effect on skeletal growth: they cause early 
uniting of the epiphyses with the shafts of the long bones. 
This effect is much stronger in the female than is the 
similar effect of testosterone in the male. Oestrogens cause 
deposition of increased quantities of fat in the subcuta­
neous tissues. Oestrogens cause the skin to become more 
vascular than normal; this effect is often associated with 
increased warmth of the skin.
1.5.2 Functions of the progesterone :
The most important function of progesterone is to promote 
secretory changes in the endometrium, thus preparing the 
uterus for implantation of the fertilized ovum. Progesterone 
also promotes secretory changes in the mucosal lining of 
the fallopian tubes. Progesterone promotes development of 
the lobules and alveoli of the breasts, causing the alveolar 
cells to proliferate, to enlarge and to become secretory in 
nature.
1.6 THE ENDOMETRIAL CYCLE AND MENSTRUATION:
Associated with the cyclic production of oestrogens and
7progesterone by the ovaries is an endometrial cycle 
operating through the following stages: First, proliteration 
of the uterine endometrium; second, secretory changes in the 
endometrium; and third, desquamation of the endometrium,a 
which is known as menstruation.The different stages will now 
be briefly discussed.
1.6.1 Proliterative phase (oestrogen phase) of the endometrial 
cycle:
At the beginning of each menstrual cycle, most of the 
endometrium is desquamated by the process of menstruation. 
After menstruation, only a thin layer of endometrial stroma 
remains at the base of the original endometrium and the only 
epithelial cells left are those located in the remaining 
deep portions of the glands and crypts of the endometrium. 
Under the influence of oestrogens, secreted in increasing 
quantities by the ovary during the first part of the ovarian 
cycle, the stromal cells and the epithelial cells prolife­
rate rapidly. The endometrial surface is re-epithelia- 
lized within three to seven days after the beginnning of 
menstruation.,
1.6.2 Secretory phase (progestational phase) of the endometrial 
cycle.
During the latter half of the sexual cycle, progesterone as 
well as oestrogen is secreted in large quantity by the 
corpus luteum. The oestrogens cause additional cellular 
proliferation, and progesterone causes considerable swelling 
and secretory development of the endometrium. The thickness 
of the endometrium approximately doubles during the secreto­
ry phase so that toward the end of the monthly cycle the en­
dometrium has a thickness of 4-6 mm.
81-6.3 Menstruation.
Approximately 2 days before the end of the monthly cycle, 
the ovarian hormones, oestrogens and progesterone, decrease 
sharply to low levels of secretion. The first effect has 
decreased stimulation of the endometrial cells by these two 
hormones, followed rapidly by involution of the endometrium 
itself .to about 65 % of its previous thickness. Vasospasm 
and loss of hormonal stimulation cause beginning necrosis in 
the endometrium, as a result blood seeps into the vascular 
layer of the endometrium. Within 3-7 days after menstruation 
starts, the loss of blood ceases, for by this time the 
endometrium has become completely reepitheliallzed.
Secretion of most of the anterior pituitary hormones is con­
trolled by releasing factors formed in the hypothalamus and 
transmitted to the anterior pituitary gland by way of the 
hypothalamic-hypophyses portal system.
1-7 HISTORY OF STEROID HORMONE RECEPTORS
As early as 1835 (1), Sir Astley Cooper in his book "Lectu­
res on the Principles and Practice of Surgery" noted a cor­
relation between the size of breast tumours and the phase of 
the menstrual cycle. He also observed a relationship between 
multiparity and an increased risk of breast cancer an obser­
vation which stood the test of time.
More than 50 years later, Schinzinger (1889) (2) noted that 
the mortality among premenopausal breast cancer patients was 
higher than that in postmenopausal patients. He suggested 
that the life expectancy of the younger patients could be 
increased by prophylactic oophorectomy.
A great advance in the pioneering work of establishing the
hormonal dependence of some breast cancers came in 1896 when 
Sir George Beatson (3) reported the beneficial effect of 
oophorectomy in two premenopausal women with advanced breast 
cancer. This finding preceded the isolation of oestrogen 
from ovarian tissue and the explanation for Beatson's obser­
vation was therefore not realized at the time. During his 
studies of lactating cows, Beatson noted that cells from 
cancerous breasts multiplied rapidly and often penetrated 
the breasts lymph system instead of undergoing fatty degene­
ration and being cast off in the milk. He reasoned that 
since farmers spayed lactating cows in order to maintain a 
long period of fatty degeneration and milk production the 
same procedure might induce fatty generation of the cance­
rous breast. In 1895, Beatson performed an oophorectomy on a 
premenopausal women with advanced breast cancer and found to 
his amazement that her metastatic chest wall lesion also 
disappeared. After Beatson's now classical paper, "On the 
treatment of inoperable cases of carcinoma of the mamma : 
suggestions for a new method of treatment with illustrative 
cases" was published in the Lancet several workers tried to 
repeat the same treatment, but noted that it was difficult 
to predict which patients would respond to oophorectomy (4­
5).
Decourmelles (1926) and others (6) subsequently popularized 
irradiation castration rather than oophorectomy, but because 
some patients continued to manifest reproductive function, 
surgical oophorectomy again came into vogue in the 1950s
(7) .
A significant advance in the understanding of the chemical 
basis of endocrine response occurred with the isolation and 
identification of oestrogen from sow ovaries by McCorquoda- 
le, Thayer & Doise (1926)), in which they reported the iso­
lation of crystalline oestrogenic hormone from sow ovaries,
( 8 )
The modern era of endocrine therapy; based on the concept 
that hormones may influence the growth of certain forms of 
cancer, commenced when Charles Huggins showed that orchidec- 
tomy or the administration of estrogens caused regression of 
canine prostatic cancer (9). After several important con­
tributions in the field of prostatic cancer (10-11) Huggins 
turned his attention to mammary cancer, and illustrated that 
adrenalectomy was often effective after a relapse following 
oophorectomy (12-13).
Huggins' concepts can best be summarized from his Nobel lec­
ture given in 1967, entitled "Cancer is not necessary auto­
nomous and intrincisally selfperpetuating. Its growth can be 
sustained and propagated by hormonal function in the host" 
(14).
Until 1953, only sporadic reports of successful hypophysec- 
tomy in humans were published. Luyt and Olivecrona (1953) 
were the first to report that hyphophysectomy induced re­
missions similar to that obtained by oophorectomy and adre­
nalectomy in metastatic breast cancer (15). These results 
were later confirmed by Pearson and Ray who reported objec­
tive remission following hypophysectomy in 21 out of 41 ca­
ses of advanced mammary cancer (16-17).
Glascock and Hoekstra (1959) (18) succeeded in synthesizing 
tritium-labelled hexoestrol (anti-estrogen) and using this 
labelled hormone analogue in goats, noted the hormone was 
concentrated and retained by 'target' organs such as the 
uterus and vagina. During the past two decades, there has 
been an overwhelming proliferation of research contribu­
tions made towards the understanding of the mechanism of 
steroid hormone action. Jensen and Jacobson made an inva­
luable contribution when they synthesized |3Hj-oestradiol 
with a high specific activity, which made it possible to ob­
serve differential accumulation and retention of |3H’|oestra-
diol by the uterus and other target tissues (19). Mobbs (20) 
found that endocrine-dependent dimethylbenzanthracene-indu- 
ced (DMBA-induced) rat mammary tumours retained labelled 
oestradiol, in contrast to autonomous tumours which did not.
Jensen, De Sombre and Jungblut (21) and Terenius (22), inde­
pendently demonstrated, the enhanced specific binding of ra­
dioactively labelled estrogens to breast cancer specimens in 
vitro which exhibited objective clinical responsiveness. 
These experiments indicated that there were at least two 
general classes of breast cancer, those that exhibited a 
significant uptake of labelled estradiol in vitro and those 
that showed no or very low hormonal uptake.
Toft and Gorski (23) established the usefulness of sucrose 
gradient sedimentation analysis in the characterization of 
the oestrogen receptors present in the cytosol of rat ute­
rus. A year later Jensen, De Sombre and Jungblut (24) using 
sucrose gradient analysis could demonstrate that tumours 
from patients who responded to hormonal therapy contained 
relatively high levels of oestrogen receptor (ER) in the 
cytoplasm, while unresponsive tumours lacked oestrogen 
receptors. These experiments provided a method for 
distinguishing hormonedependent from autonomous tumours 
prior to actual therapy. The careful observations of Jensen 
et al 2^1) and Gorski et al (25) led to the proposal of the 
classical 'two-step mechanism' for the hormone-induced 
transfer' of the receptor from the cytoplasm to the nucleus. 
Stumpf (26) employed autoradiography to confirm the rapid 
movement of steroid hormone to the nucleus.
Initial binding of steroid to the cytosolic receptor seems 
to initiate a cascade reaction currently incompletely 
underunderstood. Toft and Gorski (23), as well as Erdos 
(27), observed that the ^ 8 S oestrogen receptor species, 
usually obtained in low ionic strength SDG could be disso­
ciated into % 4 S complexes at higher ionic strength condi-
12
tions. Jensen et aj_ (28) found that cytosolic receptors 
could be 'transformed1 into a 5 S form, by a hormone- 
dependent, temperatureinduced process. Higgins et aj_ (29) 
and Milgrom, Atger and Baulieu (30) furthermore proved that 
the 'transformed' receptor showed an increased affinity for 
polyanions especially DNA, following this process, which 
they termed receptor 'activation' .
Up to this time very little fruitful information had been 
obtained on the progesterone receptor mainly due to techni­
cal problems experienced with the receptor assays.Milgrom et 
al (31) however first reported the presence of PR in guinea 
pig uterus. Subsequently, a synthetic progestin (promoges- 
tone, R 5020) was developed by Philibert and Raynaud (32) 
and employed in progesterone receptor studies. This proges­
tin appeared to form significantly more stable complexes 
with the PR than the natural ligand progesterone. Horwitz 
and Me Guire (33) subsequently demonstrated the presence of 
PR in breast cancer tissues, and demonstrated that the syn­
thesis of this receptor can serve as a means of monitoring 
oestrogen responsiveness.
In 1974, a workshop was held under the auspices of the 
Breast Cancer Task Force. The results of 14 different in­
stitutions were analysed and were found to be in general 
agreement with each other, namely that patients with breast 
cancers lacking in significant amounts of ER had very little 
chance of responding to hormonal manipulations. At the same 
time they concluded that the majority of patients with re­
ceptor-positive cancers would benefit from such treat­
ments.
Numerous subsequent investigations have confirmed, ampli­
fied, elucidated and embelished these pioneering investiga­
tions.
One of the functions of the serum steroid-binding proteins 
is the transport of the specific hormone in a bound state, 
acting as a resrvoir from which the active hormone can be 
mobilized rapidly by dissociation in the proximity of the 
target ceil. The steroid-binding proteins also conserve and 
protect the steroid against enzymatic attack, against ad­
sorption to the walls of blood vessels, and against excre­
tion by the kidney and metabolism by the liver.
In some cases, metabolism of hormones is important after en­
trance into target cells, as has been shown for the conver­
sion of testosterone to dihydrotestosterone (by the enzyme 
5a-reductase) and 4-androstenedione (38).
Oestrogen and progesterone do not however require metabolic 
conversion for biological activity (19), but metabolism may 
be involved in the interconversion of various forms of oes­
trogen and in the elimination of hormone from target tissues 
(39).
THE MECHANISM OF ACTION OF STEROID HORMONE RECEPTOR
A multitude of different techniques are presently employed 
in the investigation of the action mechanism of steroid 
hormones, e.g. oestradiol, in normal and neoplastic tissues. 
The analytical techniques that were established in the 
1960 's and early 1970's to study the ER through the binding
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of L Hj-oestradiol have provided much valuable information. 
However, the studies over the past 20 years have generally 
served only to consolidate the established ER model because 
each technique used to study the receptor depends upon cell 
disruption and extraction of receptors followed by detection 
methods that require binding of [ H]-oestradiol to the ER. 
Clearly further progress and a critical study on the sub­
cellular effects and mechanisms of oestradiol action via the 
ER would require new approaches. Receptor dynamics must be 
studied in intact cells in order to investigate subcellular
compartmentalization, receptor recycling or resynthesis. The 
development of monoclonal and polyclonal antibodies which 
can be labelled to identify the position of unoccupied and 
occupied receptors in the cell is one possible approach. 
Similarly, the recent synthesis of a radioactive covalent 
antioestrogen affinity label, L3Hj-tamoxifen aziridine (40), 
should prove to be an extremely useful tool to study confor­
mation, physicochemical properties, and subcellular locali­
zation .of ER. The availability of a broad spectrum of high- 
affinity, radiolabelled anti-oestrogens will facilitate stu­
dies on the physicochemical properties of oestrogen- and an­
tioestrogen-receptor complexes. Although it is well-esta­
blished that the ER is present in oestrogen target tissues, 
the exact role of the receptor and its interactions with 
other subcellular components to modulate oestrogen-induced 
events is unclear.
Examination of steroid-induced responses in mutant cell li­
nes that contain reduced levels or abnormal receptor (41) is 
a useful approach to determine which steroid-stimulated 
events are receptor-dependent. Furthermore, the study of 
oestrogen-induced events in antioestrogen-sensitive and re­
sistant cell lines may provide additional information about 
the molecular biology of the oestrogen receptor mechanism 
(42-43). The ultimate site of action of steroid receptor in 
the nucleus is not known (44). No doubt the rapid advances 
in molecular biological techniques will elucidate the struc­
ture and control of the ER gene as well as ER control of 
oestrogen-stimulated gene products. A critical application 
of new methodologies will confirm or evolve the models for 
ER mechanism.
The rapid application of these investigations to the clinic 
may offer more precise and accurate detection of hormone- 
dependent cancer and the possibility of improved or novel 
treatment regimes that might exploit the ER system.
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1.8.1 Possible models for steroid hormone receptors.
One aspect of steroid hormone receptor action has been ele­
vated to the status of dogma since its elucidation fifteen 
years ago, following the first detection of oestradiol 
receptor in rat uterine cytosol (23). E. Jensen and his 
collaborators demonstrated by cell fractionation and 
autoradiography that within an hour of hormone administra­
tion, the receptor accumulates in the nucleus of target 
cells (24). Their finding led to the 'two step' hypothesis. 
According to this model, represented schematically in Fig. 
1.1, oestradiol enters the uterine cell, binds to a specific 
cytoplasmic receptor and then is translocated to the nucleus 
by a temperature-dependent 'activation' process. This 'acti­
vation' of the steroid receptor complex is reflected both by 
a change in its sedimentation coefficient from 4 s to 5 S 
(in the presence of high ionic strength buffer) and by its 
ability to bind to isolated uterine receptors which can 
exist either as steroid filled or unfilled receptors, but 
nuclear receptors can exist only when steroid filled. The 
investigations were repeated and extended to numerous other 
steroid hormone receptor systems with similar conclusions. 
Now a number of workers (45-47) challenge the dogma : it 
would seem that steroid receptors may not be cytoplasmic 
proteins after all, and a number of reports have appeared 
which are difficult to reconcile with the two-step model of 
steroid hormone intracellular interaction. Important amongst 
these is the observation that unfilled receptors do in fact 
exist in the nucleus of both normal (49-51) and tumourous 
oestrogen target tissues (52-53). In these studies careful 
attention was paid to the purity of the nuclei, thereby 
ensuring no contamination of the preparation with cytoplas­
mic receptors. Physicochemical analyses indicated that the 
unfilled sites possess properties characteristic of 'classi­
cal' type 1 (54) nuclear oestrogen receptors in terms of
their binding affinity, association (dissociation) kinetics, 
specificity and sedimentation behaviour in high ionic
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strength sucrose density gradients; However they differ in 
one important respect : they are not steroid filled (unoccu­
pied receptors).
The origin of these unfilled sites is unknown, although se­
veral authors have reported that oestrogen receptor binding 
sites are present in purified preparations of nuclei (55­
56). In the rat uterus, autoradiography shows tritiated oes- 
tradiol . even after short periods of _i_n vitro incubations at 
low temperatures, conditions which normally minimize the 
translocation of receptor complexes from the cytoplasm (57) 
to the nucleus. These observations have led to the hypo­
thesis that in intact cells, unfilled receptors may exist in 
a state of equilibrium between the cytoplasm and nucleus. 
This equilibrium can be shifted in favour of the cytoplasm 
during tissue homogenization (57). Based on this model, 
(Fig. 1.1 b) unfilled nuclear receptors assayed using con­
ventional techniques may only represent a small fraction of 
the total cellular content of unfilled sites actually pre­
sent, with the bulk of unfilled sites having been solubili­
zed during the course of nuclear isolation.
In order to overcome the inherent problem of receptor solu­
bilization during preparation of cell nuclei,a technique was 
recently described by Welshons et al (48): Cytochalasin B- 
induced enucleation was employed in obtaining cytoplasts and 
nucleoplasts from receptor - rich CH3 cells derived from rat 
pituitary tumours.In contrast to the predictions of the two- 
step model, the cytoplasts were found to contain little oes­
trogen-binding activity, with most of the unfilled receptor 
residing within the nucleoplasts. This finding supports the 
notion that unfilled oestrogen receptors do reside within 
the cell nucleus of steroid-sensitive cells. These observa­
tions led Welshons et aj_ (48) to propose that no nuclear 
translocation of receptor can be found in the intact cell as 
part of the steroid response, but rather an increase in re­
ceptor affinity for nuclear elements.
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One of the most convincing studies indicating that'oestrogen 
receptors may reside exclusively in target cell nuclei of 
oestrogen sensitive tissues' is the study of King and 
Greene(47). Here, rather than using radiolabel led ligands to 
detect the oestrogen receptor, they used immunochemical 
staining with a monoclonal antibody generated against the 
oestrogen receptor protein. Specific staining was found to 
be confined to the nucleus of all stained cells, which in­
cluded human breast tumours and uterus, rabbit uterus, ovi­
duct, corpus luteum. mammary gland, pituitary and liver, as 
well as MCF-7 cell cultures. The distribution of oestrogen 
receptors as would be predicted from the study described 
above can be schematically represented by Fig 1.1. The ap­
plication of the new model (1.1.c) on the process of activa­
tion will be discussed in more detail later in Chapter 5.
It is an experimental fact that hormone agonists alter gene 
expression, and hence some aspect of the receptor structure 
must change by interaction with its ligand. Receptors are 
probably permanently associated with the gene they regulate, 
and thus have only to rotate or change conformation to 
achieve their effects. There still are two identifiable 
states of a steroid receptor : an active (ligand associated) 
state and an inactive (unliganded) one. The real signifi­
cance of the original two-step idea is retained: Steroid- 
receptor complexes are nuclear regulatory elements wherever 
they originate in the cell.
It is obvious that much work is still to be done in unravel­
ling the nature of the interaction between steroid hormones 
and their receptors.
Common events in steroid hormone-receptors mechanism of bin­
ding.
Most workers agree that the entry of steroids into cells
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from the extra cellular space appears to occur by diffusion. 
Gurpide and Welch (58) studied uptake dynamics using a 
double-isotope steady-state technique, and found that target 
and non-target tissues accumulated steroid with equal faci­
lity, at a rate proportional to steroid concentration, sug­
gesting a mechanism of simple diffusion. However, the pos­
sibility of specific recognition sites on the plasma mem­
brane of target cells has not been finally excluded. Zanker, 
Prokscha and Blumel (59) proposed that plasma membranes from 
breast cancer cells contain receptors of relatively high af­
finity (K^ = 6.4x10"1^ M) and high capacity,working apparent­
ly in tandem with the high-affinity and low capacity recep­
tors described for the cytosol. They postulated that these 
membrane receptors may serve a modulator function.
Following entry into the target cell, the hormone may either 
bind to its specific cytoplasmic receptor or bind to the 
more abundant, lower affinity binding sites. Sometimes a 
given hormone may interact with more than one high-affinity 
receptor.Baulieu (60) demonstrated that oestradiol interacts 
with androgen receptor with a of approximately 3nM, while 
oestradiol binds to oestrogen receptor with a of 0.1 nM. 
Several hormones may bind to one class of receptor, and re­
ceptor concentrations may vary under different conditions 
such as changes in the menstrual cycle.
The Kj is a measure of the affinity of the receptor for the 
steroid and is approximately the concentration of free ste­
roid at which one-half of the receptors are saturated. The 
which is the reciprocal of the association constant (KQ) 
can also be obtained from a Scatchard plot (61).
After oestrogen enters a target cell, the physiological form 
of the receptor is at present uncertain. Such factors as 
ionic strength, temperature, presence of molybdate, or enzy­
me inhibitors such a leupeptin, can cause the receptor to 
exist in a certain form or to interconvert between several
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molecular forms, any or none of which may be the true endo- 
geneous receptor(62). After reaction with oestrogen, the ER 
complex 'Undergoes a temperature-dependent conformational 
change or 'transformation' that is associated with receptor 
activation and an increase avidity for nuclear binding.
The dissociation kinetics of a hormone from the receptor 
provides a sensitive criterion for measuring receptor acti­
vation. The rate of dissociation of a hormone from its acti­
vated receptor complex is an indication of the effectiveness 
of that particular hormone in maintaining the receptor in 
the activated state. The dissociation of oestradiol from the 
receptor occurs as a biphasic process (63). The low affinity 
for oestradiol binding by the non-activated receptor causes 
the first,rapid exponential phase, while the higher affinity 
of the activated state of the receptor produces the second, 
slower phase (64).Oestradiol binding, then, shifts the equi­
librium from a lower-affinity state to a high-affinity, ac­
tivated, slower-dissociating phase (63).
Several investigators have suggested that the multiple forms 
of ER detected in human breast cancer may be due to degrada­
tion of native receptors. Sherman et aj (65) have shown that 
the steroid receptors degraded by endogeneous proteases to 
lower-molecular weight 'meroreceptors1 contained hormone­
binding sites. Puca et al (66) described a partially puri­
fied 'receptor-transforming factor' which was responsible 
for degradation of ER in calf uterus to a smaller size.
After entering the cell nucleus, the 5 S oestrogen-receptor 
complex binds to 'putative acceptor' sites on chromatin (30), 
where the expression of specific genes occurs at a different 
locus on the chromosomes called the 'effector' site.
Recently two groups have suggested preferential binding of 
steroid hormone receptors to specific DNA sequences (68). 
Mu 1vlhi 11, Le Pennec and Chambon (69) found that specific
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double-stranded DNA sequences from hormonal’nly responsive 
genes coding for egg-white proteins were recognized by ovi­
duct progesterone receptor in vivo. These works are signi­
ficant, because they suggest that steroid receptors may mo­
dulate transcription by recognizing specific DNA sequences 
within or near hormone-regulated genes. Acceptor sites on 
chromosomes have been suggested to be a specific complex of 
DNA and non-histone proteins, which the oestrogen receptor 
complex recognizes and binds with a very high affinity (70). 
There are also believed to be secondary sites present in 
large numbers on chromatin, where the ER-complex can bind 
with lower affinity (71). Besides primary binding sites 
associated with activated ER-complexes which are transloca­
ted to the nucleus, called type I sites, secondary sites 
also appear, called type II sites (72). These type II sites 
are found in increased number after oestradiol stimulation 
and appear to be a specific hormonally-induced nuclear 
response. The type II sites, which are not translocated from 
the cytoplasm, are present in larger quantities than type I 
sites and remain elevated for a longer period.
The binding of ER to acceptor sites is thought to increase 
the rate of transcription of specific genes, possibly by al­
tering their affinity for interaction with RNA polymerase. 
In some systems, rapid increases in transcription are appa­
rent after oestrogen stimulation (73) and mitosis is accela- 
rated (74).
One of the important actions of oestrogen seen in some hor­
mone-sensitive target cells, including oestrogen-sensitive 
human breast cancer cells is the induction of progesterone 
activity (75), which may be involved in the further hormonal 
regulation of the cells. Other workers (76) have demonstra­
ted that peroxidase also appeared to be an oestrogen-induci­
ble enzyme in both normal malignant tissues. It seems that 
most steroid effects are reguylated at the level of primary 
transcription, however, some of the short term effects like 
water inhibition and eosinophilia may not necessitate regu­
lation at the genetic level.
When oestradiol enters the responsive breast cancer cell or 
uterine tissue in vitro, the newly formed hormone-receptor 
complex is rapidly translocated to nuclear acceptor sites, 
from which it can only be extracted using high ionic 
strength buffers. Horwitz and McGuire (77) have proposed 
that bound nuclear receptors then undergo rapid 'processing' 
in which approximately 70 % of the nuclear receptor sites 
are lost from the cells over a few hours1 duration without 
reappearance of unfilled sites. They found that this 'pro­
cessing1 was essentially complete by five hours, after which 
time the nuclear receptor complex stabilizes at a new steady 
state level (78). Lippman et aj_ (79) found that processing 
is not a disappearance of the nuclear receptor, as had been 
previously proposed, but a receptor modification to a less 
KCJZ-soluble and less exchangeable form. Oestrogen receptor 
inactivation which follows translocation and nuclear binding 
to the acceptor site has been proposed to be due to dephos­
phorylation of the receptor secondary to the action of nu­
clear phosphatase (80). Auriccio's group has also hypothe­
sized that the inactive receptor may be reactivated through 
phosphorylation by an ATP-dependent enzyme in the cytoplasm 
(81). These findings suggest that the receptor is cycled by 
the dephosphorylation process in the nucleus, followed by a 
rephosphorylation event in the cytoplasm, contributing in 
this manner to cytoplasmic replenishment.
The process of activation will be discussed and studied in 
detail in Chapter 5.
STEROID HORMONE-RECEPTOR RELATIONSHIPS WITH SPECIAL REFEREN­
CE TO THE OESTROGEN AND PROGESTERONE RECEPTORS :
The oestrogen receptor system is only part of a complex hor­
monal mechanism which influences breast cancer growth and 
function. Many other hormone receptors have been identified 
in cultured breast cancer cells, such as progesterone,
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androgen, insulin, glucocorticoid, retinoid, prolactin, 
transferrin, epidermal growth factor, calcitonin, and 
Vitamin D receptors, but the unique physiological role of 
each has not been fully elucidated. Tumours may contain a 
heterogeneous population of cells with a mixture of various 
receptor positivities, as well as completely autonomous cell 
types, a situation that profoundly influences the effective­
ness of hormonal therapy. The presence of PR in ER-positive 
tumours suggests that these tumours are capable of synthe­
sizing at least one oestrogen-regulated product, but it does 
not imply that all the oestrogen-induced responses will 
necessarily be intact. In many systems in vivo or in vitro, 
the administration of oestradiol to an oestrogen-responsive 
cell causes an 8 to 20-fold rise in PR, which can be pre­
vented by the inhibition of protein or RNA synthesis (82 - 
83). The measurement of progesterone receptors was hamper­
ed initially by the lack of a suitable ligand, since proges­
terone binds readily to other plasma proteins such as 
transcortin (84). R-5020 (17,2l-dimethyl-19-nor-4,9-preg- 
nadiene-3,20-dione) which is synthetic progestin, shows high 
affinity for progesterone receptor, lack of tight plasma 
binding, a slow dissociation rate, and negligible inter­
ference with other hormone receptors (85).
The PR has been studied extensively in the chick oviduct 
system by Schrader and O'Malley who have purified the recep­
tor into an A and B components (86-87). The A subunit binds 
tightly to naked DNA, while the B component binds selective­
ly to non-histone protein-DNA complexes (88) and has little 
affinity for DNA. When present as an AB dimer, the DNA 
binding site of the A subunit is masked. It is hypothesi­
zed that initial binding of the receptor to chromatin takes 
place exclusively through the B subunit, but that the A sub­
unit subsequently interacts directly with DNA and stimulates 
messenger RNA synthesis (89). Progesterone therapy in sys­
tems in vivo and in vitro may mediate either growth, regres­
sion, or no growth change in mammary cancer, and the speci-
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fic mechanisms involved are not fully understood. Huggins 
and Young(90) showed that both pregnancy and the administra­
tion of progesterone promoted the growth of DMBA-induced rat 
mammary tumours. In contrast to it stimulatory effects, pro­
gesterone can cause regression of animal and human breast 
tumours, and the response appears even more significant if 
an oestrogen progesterone combination is used (91-92). Sha- 
fie et al (93) using MCF-7 human mammary hetero-transplanted 
tumours . in nude mice, demonstrated that progesterone given 
alone did not change either the latent period, growth rate, 
nor frequency of tumour appearance.
1.10 STEROID RECEPTORS IN NORMAL, HYPERPLASTIC AND MALIGNANT HU­
MAN UTERUS
Human endometrium has been subjected to biochemical analysis 
by many investigators. The majority of these have confined 
their attention either to premenopausal samples or to neo­
plastic tissue from postmenopausal women (114). A few pu­
blications refer to analyses performed on endometria of nor­
mal histology from postmenopausal women receiving various 
oestrogen and progestin combinations (96,115).
The endometrium is composed of several different cell types 
which can be divided into epithelium and stroma. The 
epithelium is mainly glandular together with some luminal 
epithelium. The stroma is more heterogeneous, the major con­
stituent bring stromal cells together with variable numbers 
of erythrocytes, leukocytes and endothelial cells. Stromal 
morphology varies depending on the hormonal status of the 
woman (116). Despite the complex cellular composition of the 
human endometrium, almost all receptor studies have reported 
on whole endometrium and have largely been interpreted as 
though it was a homogeneous cell population. Few workers 
(117) demonstrated that when epithelium and stroma from 
premenopausal endometria were separately analysed, the 
stromal cells may contain less oestrogen receptors than epi-
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the1ium.
Human endometrium is a tissue in which the female sex ste­
roids exert their actions during a woman's reproductive 
life. Endometrial carcinoma is at present the commonest ma­
lignancy of the female genital tract (118) and together with 
breast carcinoma it is the most important target for endo­
crine cancer therapy. While surgery and regional irradia­
tion are the primary treatments for patients with endome­
trial carcinoma, hormone therapy is widely used for advanced 
and recurrent disease, and is also used prophylactically 
after the initial therapeutic measures. There is a striking 
similarity between patients with endometrial and breast car­
cinoma in their response rate to endocrine therapy (118).
Normal endometrium
There are great inter-individual variations in endometrial 
ER and PR levels, which cannot be explained by methodologi­
cal reasons. Moreover, the receptor levels measured in the 
uteri of premenopausal women fluctuate during the menstrual 
cycle. In normally cycling women, cytosol endometrial ER 
levels are maximum during the proliferative phase around the 
midcycle, and the lowest levels are seen near the end of the 
menstrual cycle (118)(100). The maximal nuclear ER concen­
tration is seen later during the proliferative phase and 
extends to the early luteal phase (118). The highest levels 
of cytosol PR are present during the preovulatory period of 
the cycle, and then rapidly become depleted subsequent to 
ovulation (98). Tsibris et al measured ER and PR receptors 
in human endometrium during the menstrual cycle to determine 
their hormonal regulation and establish their usefulness in 
understanding normal reproduction and in managing gynaeco- 
logic disorders (106). However, the clinical use of such 
receptor data, obtained mainly from tissues removed by cure-
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tage or aspiration, may be impeded by the observations that 
the normal uterus has an uneven distribution of these recep­
tors along its longitudinal axis(88,107). Tribis et al (106) 
tried to map possible variations in the distribution of en­
dometrial cytoplasmic and nuclear receptors during the men­
strual cycle and used accurately placed endometrial samples 
obtained from 45 uteri removed for benign diseases. A number 
of other investigators (98, 107-109) have measured ER and PR 
levels in unspecified regions of human endometrium and in 
cervical epithelium. There are a few facts where there is 
agreement among most of the investigators :
1) Dissociation constants do not vary significantly 
from the different sections of endometrium, at dif­
ferent times during the menstrual cycle nor after 
menopause.
2) Endometrial levels of ER and PR may vary up to 
5-fold among women on the same day of their cycle. 
This finding is not surprising considering that 
inter-individual differences have been reported for 
plasma and endometrial tissue concentrations of ER 
and PR.
3) there is an "asymmetry" in human endometrium in the 
distribution of cytoplasmic and nuclear receptors 
for ER and PR.
There are two potentially important considerations which are 
dictated by the uneven distribution of endometrial ER and PR 
: Whereas ER and PR assays have proven useful in the manage­
ment of patients with breast cancer, similar attempts to 
correlate endometrial ER-PR with the stage of endometrial 
cancer or make a prognosis of the patient's response to pro­
gestin therapy have not been as successful (110). On this 
point though some authors expressed different opinions (118) 
The difficulty in establishing these correlations is probab­
ly due to the technique of endometrial biopsy (use of curet­
te or
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aspirator) the existence of receptor "gradients" along the 
endometrial cavity and the normal fluctuation of receptor 
levels during the cycle which may or may not fluctuate in 
the diseased tissue. Uteroscopic directed endometrial biop­
sies of diseased and adjacent normal tissue are expected to 
diminish the above difficulties and also provide meaningful 
receptor data for the management of infertile patients. Each 
hysterectomy specimen could become an excellent model to 
test whether certain endometrial enzymes are regulated via 
ER or PR because,in addition to the normal receptor oscilla­
tions during the menstrual cycle, the uneven distribution of 
endometrial ER and PR could provide an "internal control" in 
such studies. For example, if we assume that endometrial 
carcinogen activating enzymes (111) or plasminogen activator 
(112) are regulated through the ER, then these enzyme levels 
along the long endometrial axis ought to parallel the levels 
of cytoplasmic or nuclear ER, in addition to the expected 
decrease in enzyme activity in the secretory phase.The in­
tracellular concentration of oestrogen in human endometrium 
has been considered to be regulated by the circulating oes­
trogen and the extent of the intracellular oestrogen metabo­
lism, i.e. conversion of potent oestrogen (E2) to less 
potent oestrogen (E^ or conjugate oestrogens which have no 
oestrogenic potency (113).
These data, together with other observations about the in­
terrelationship between oestrogens and progestins, and sex 
steroid receptor levels in normal human endometrium (119­
120) and in animal tissues (121-122) support the idea that 
oestradiol stimulates de novo synthesis of ER and PR in hu­
man endometrium, and that progesterone leads to the deple­
tion of the target cell content of these receptors.
1.10.2 Hyperplastic endometrium
ER and PR concentrations vary greatly in different reports, 
at least partly because of methodological variations. The
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marked interindividual variation of the receptor levels even 
in tissues with the same histological appearance makes com­
parisons with normal tissue difficult. The development of 
endometrial hyperplasia is characterized by an unopposed 
oestrogen action, which suggests that the receptor levels 
should be raised, or at least not decreased. The data avail­
able for ER partially support this assumption. Gurpide and 
Tseng (121) found the cytosol ER levels in the endometrial 
hyperplasia to be similar to those of proliferative endome­
trium, and cytosol ER tends to be high in hyperplastic endo­
metrium, although not significantly higher than in the normal 
endometrial tissue (119). By contrast, it has also been re­
ported that the cytosol ER concentration of hyperplastic en­
dometrium is lower than in normal tissue (99). The concen­
tration of cytosol PR in hyperplastic endometrium has been 
reported not to differ significantly from that in normal 
tissue (119).
1.10.3 Malignant endometrium
It is well known that in patients with elevated oestrone 
production in peripheral tissues or in their ovaries show 
an increased risk of developing endometrial cancer (94). 
Epidemiologic studies have established an association 
between oestrogen use during menopause and occurrence of 
endometrial cancer (95). Some workers have reported that 
oestrogens used in combination with progesterone reduce the 
incidence of endometrial abnormalities markedly (86-97). 
Several investigations have demonstrated the presence of 
oestradiol and progesterone receptors in normal and neoplas­
tic human endometrium (98-101). Attempts to quantitate 
receptor concentrations and variations give conflicting 
results. Differences in analytical techniques and insuffi­
cient histological grading of the endometrium may have 
caused these variations in receptor values (102).
In endometrial carcinoma, the measurement of cytosol oestro­
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gen and progestin receptors can be recommended for clinical 
use (103). The main application at present is in the cate­
gorization of patients with advanced disease into groups 
which will most likely respond to endocrine treatment or are 
most likely to benefit from combination cytotoxic chemothe­
rapy. For this categorization of cytosol progestin recep­
tors seems to be most suitable. The importance of measure­
ments of nuclear receptors and progestin-regulated proteins 
(104-105) and the application of endocrine challenge tests 
(105) needs further clarification. ER and PR have associa­
tions with known prognostic risk indicators of endometrial 
carcinoma. However, in each indicator category there are 
individual patients with receptor data diverging from the 
general pattern. It is therefore likely that receptor mea­
surements give information which is additive to that obtain­
able by conventional risk analysis. The role of female sex 
steroid receptors in ovarian carcinoma is obscure. Their 
assays may be useful in predicting the clinical behaviour of 
ovarian carcinoma. They may also find applications in the 
characterization of the potential hormone dependency of such 
tumours.
1.11 STEROID HORMONE RECEPTORS IN THE TARGET ORGANS OF NON­
HUMAN PRIMATES:
There has not been an increasing interest over recent years 
in the application of non-human primates as models for stu­
dies on human reproduction. Despite limited data many 
primates have been proposed as suitable models for man for 
studies on steroid endocrinology. The rhesus monkey has up 
to now been the best-studied non-human primate in the inves­
tigation of the factors regulating normal reproductive func­
tion in man (124-125).
It was decided to study the molecular properties of recep­
tors of a different monkey - the Vervet monkey (Cercopithe- 
cus aethiops pygerythrus). While this species is not widely
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employed in biomedical research, the limited data presently 
available (126-129) suggest that C. aethiops pygerythrus 
C.a.p. might be a suitable alternative for the rhesus monkey 
in studies of reproductive function including embryology and 
teratology. The reproductive cycle of the Vervet monkey, has 
been found to be 30 days, indicating a remarkably close 
similarity to that of the human female especially with re­
spect to progesterone and oestrogen metabolism and excretion 
(130). . Initial studies of steroid excretion by the Vervet 
monkey proved a much closer endocrinological similarity to 
man than any other species of the Old World monkeys pre­
viously studied.
Setchell et aj_ (130) found two phenolic compounds which he 
designated as Compound 180/410 and Compound 180/442 that 
have been shown to exhibit significant quantitative changes 
during the menstrual cycle of the monkey. The chromato­
graphic behaviour of these compounds resemble oestrogen 
steroids but preliminary studies suggest their structures 
may be non-steroidal. Both compounds have been detected in 
human urine.
The Vervet monkey's name is borrowed from the French Verna­
cular name of this species, cercopitheque vervet (131). This 
monkey has a wide distribution in Africa from Southern 
Ethiopia and Somalia to the Cape Province. The Vervet monkey 
is predominately a Savanna woodland species, being generally 
absent from open grassland and open scrub. They are diurnal 
and gregarious, occurring in small troops up to 15 or 20. 
These troops may join others without aggression at watering 
places or at preferred feeding sites, forming aggregations 
of up to about 100. Within the troops there is a clear order 
of dominance. Vervet monkeys are predominately vegetarians 
living on wild fruits, flowers, leaves, seeds and seed pods. 
Other monkeys' menstrual cycle and steroid receptors have 
also been studied. Chrousos et aj_ (132) investigated the 
oestrogen and progesterone receptors in an oestrogen - and
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progesterone "resistant" primate the squirrel monkey. This 
monkey which is a New World primate, has elevated plasma 
oestradiol and progesterone concentrations compared to those 
in the cynomolgus macaque, an Old World primate (133-136). 
Uterine progesterone receptor concentrations examined in 
ovariectomized squirrel monkeys 2 days after oestrogen 
treatment were about one eighth those in identically treated 
cynomolgus macaques. McMillin et aj_ (137) studied the effect 
of oestramustine phosphate on pituitary, gonadal and adrenal 
function in the green monkey. Their results are consistent 
with a pure oestrogen effect produced by hydrolysis of the 
carbamate-ester bond at a site distant from oestrogen target 
tissues and could explain most of the reported in vivo ef­
fects of this compound. Baulieu et aj_ (138) investigated 
hormonal and immunological aspects of sex steroid-binding 
plasma protein of different primates and their cross-reacti­
vity with antibodies against human steroid binding SBP plas­
ma proteins. Their results agree with others (139-141), that 
human and the chimpanzee steroid binding proteins appear to 
be very similar and their concentrations are identical. Al­
though showing total cross-reactivity with human SBP, goril­
la SBP binds oestrone as do the SBPs of other primates spe­
cies, but not those of man and chimpanzee. Brenner et 
(142) studied the cyclic changes in oviductal morphology and 
residual cytoplasmic oestradiol binding capacity induced by 
sequential oestradiol-progesterone treatment of spayed Rhe­
sus monkey.
CHAPTER 2.
Optimization of conditions for quantitative and qualitative 
determination of ER and PR VMU.
METHODS OF RECEPTOR ASSAY 
INTRODUCTION.
A number of methods have been used to detect the presence of 
steroid hormone receptors. In practice, the best assay for 
receptor detection should be simple, sensitive, rapid, re­
liable, and economical.An 'ideal' assay exhibiting all these 
features does not yet exist.The advantages and disadvantages 
of currently used and newer promising assays should be care­
fully considered and evaluated. The large array of assays 
presently available can be functionally grouped by the fol­
lowing classification:
I. Removal of the unbound hormone
1. Dextran-coated charcoal (DCC) assay
2. Gel filtration
3. Immobilized antisteroid antibodies
II. Removal of the bound receptor from free hormone
1. Sucrose density gradient ultracentrifugation
2. Protamine sulphate precipitation
3. Hydroxylapatite assay
4. DEAE chromatography
5. Controlled pore glass beads
6. Agar gel electrophoresis
7. Isoelectric focussing (IEF)
8. High-performance liquid chromatography (HPLC)
III. Exchange assays:
A. Temperature-dependent methods:
1. Protamine sulphate exchange assay
2. Hydroxylapatite exchange procedure
B. Temperature-independent methods:
1. Silver nitrate dithiothreitol(DTT) method
2. Mersalyl assay method
3. NaSCN method
IV. Histochemical methods
1. Antihormone antibody methods 
.a. Immunofluorescent techniques
b. Immunoperoxidase techniques
2. Steroid-f1uoresceinated conjugates
3. Antireceptor antibody methods
Prior to giving details on the assay methods, some factors 
regarding specimen collection and preparation should be con­
sidered.
COLLECTION AND PREPARATION OF BIOPSIES
Hormone receptors are heat-labile proteins. Immediately 
after surgical removal of the specimen, the tissue should 
be chilled and kept at 4°C to ensure receptor stability. 
Freshly excised tissue should be rinsed in isotonic saline 
to remove blood, but all contact with formalin should be 
strictly avoided. The tumour should be trimmed from adjacent 
fat and normal tissue, preferably in a container with iced 
saline. The specimen should be examined by a pathologist to 
ensure that a representative sample of tumour has been 
chosen.
If there is a delay of more than an hour.before the selected 
receptor assay is performed, the specimen should be frozen, 
preferably in liquid nitrogen, but at least on dry ice. Re­
sults with several human breast tumour samples examined at 
intervals of two months indicate that ER showed no signifi­
cant loss in binding capacity over several months in tissues 
that were quick frozen at -86°C(143). Preliminary studies
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have shown that lyophi!ization of cytosol followed by 
storage at 4°C may be a possible method for conveniently 
preserving samples of ER assay, but PR may be too unstable 
for this technique(143-145). The receptor stability is mar­
kedly influenced by pH, with maximum stability at approxi­
mately pH 7.4(145) to pH 7.8(147). High salt concentra­
tions can cause changes in receptor form without a loss of 
binding properties(148-149). When using the DCC assay, low 
protein . concentrations in the assayed nuclear or cytosol 
fraction may influence the estimation of binding capacity 
and binding affinity, particularly with receptor-poor tu­
mours (150). The lowest acceptable limit of protein for most 
standard assays is 1 mg/mj? in tumour cytosols with high 
receptor activity and 3 mg/ml in cytosols with low receptor 
values.
Miller etaj_ (151) found that receptor integrity is promoted 
if 10 to 20 mM molybdate is included in the extraction buf­
fer. It was proposed that molybdate may provide protection 
against specific proteolytic cleavage by stabilization of a 
phosphate group. In a study by Anderson et a 1(152) the ad­
dition of molybdate to the buffer increased both the percen­
tage of PR-positive breast tumour samples and the absolute 
receptor levels. The effect of molybdate on ER assays was 
less evident, although in some samples all increases in ER 
level occurred. The effect of molybdate will be studied in 
detai1 in Chapter 3.
Some workers have found that buffers containing DTT also 
exert a stabilizing action of receptor(11) through protec­
tion of sulphydryl groups(153), while others have found no 
effect on receptor binding sites(155).
The addition of glycerol to the buffer during progesterone 
assays markedly improves the stability of the receptor(156).
A tumour with a receptor concentration of 3 fmol/mg(157-158)
to 10fmol/mg(159-160) or higher is usually considered oes­
trogen receptor positive, although the definition of 'posi­
tive' and' 'negative' may vary slightly according to the 
laboratory and type of assay.
Quality control of receptor assays is mandatory for their 
reliable use in the clinical management of breast cancer pa­
tients. Several groups, such as the EORTC Breast Co-opera­
tive Group(1980) and NCI Sponsored Consensus Meeting on Ste­
roid Receptors in Breast Cancer(1979), have recommended an 
interchange of duplicate tumour specimens or lyophilized 
calf uterus homogenates to ensure standardization and qua­
lity control(161). Specific guidelines have been establi­
shed by these groups to help avoid pitfalls in performance 
and interpretation of receptor assays(162-163).
METHODS WHICH REMOVE UNBOUND HORMONE
Dextran-coated charcoal assay:
The DCC assay relies on the capacity of charcoal to adsorb 
free hormone, while the addition of dextran limits the ad­
sorption of the hormone-receptor complex to the charcoal 
(164). By using increasing concentrations of radiolabel led 
hormone and a concurrent range of unlabelled hormone compe­
titor, titration of the receptor to a saturation endpoint 
occurs. This titration procedure provides an accurate 
measure of the binding capacity and affinity of the recep­
tor. Scatchard(61) analysis or some other technique of data 
transformation are performed to quantify the number of 
binding sites, usually expressed as femtomoles per mg pro­
tein, and to obtain the or dissociation constant, which 
is equal to the negative reciprocal of the slope of the 
line. Several groups have demonstrated excellent quantita­
tive correlation regarding ER analysis between the DCC assay 
and sucrose gradient methods(148,152,165), although Chester 
et al (166) found the DCC assay for ER more sensitive than
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the sucrose gradient or gel electrophoresis methods. Ander­
son et a 1(152) found the DCC assay significantly more sensi­
tive for PR than sucrose gradient analysis, and this diffe­
rence was more pronounced when molybdate was absent.
The DCC assay is currently the most popular method for eva­
luating ER and PR receptor because it is relatively easy and 
inexpensive, as well as sensitive and accurate. Several 
samples, can be processed simultaneously.This method does not 
allow identification of receptor form, and when performed at 
0 to 4°C only unoccupied receptors are measured.
If only a single concentration of labelled hormone and com­
petitor is used in a 'one-point assay' the potential for 
error in quantifying the amount of receptor is increased, 
and the Kd cannot be obtained.
2.3.2 Gel filtration.
Gel filtration is an infrequently used method which offers 
no advantages over more practical assays. In a typical gel 
filtration assay, cytosol is incubated with labelled hor­
mone, then applied to a Sephadex column, a filtration column 
containing a suspension of packed porous gel beads. The re­
ceptor-bound radiolabel led hormones are excluded from the 
gel beads by reason of their geometry and mass, and are 
eluted most rapidly(170). The free and non-specifically 
bound hormone is retained by the accessible space within the 
gel interstices(17 1). Since Sephadex itself has consider­
able affinity for oestradiol, about 15 per cent of the re­
ceptor complex can be dissociated by this procedure, leading 
to false decrease in the amount of measured receptor(165).
When thin-layer gel filtration procedures are performed, 
which are a variation of the column method, the gel can be 
cut into strips for quantitative recovery and for elucida­
tion of receptor forms(172).
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2.3.3 immobilized antisteroid antibodies.
Specific antisteroid antibodies can be used to separate free 
hormone from hormone-receptor complexes and non-receptor 
proteins. The antibodies, usually bound to Sepharose(174), 
polyacrylamide beads(175) or polyvinylidene removing free 
steroid from solution after incubation with receptor-con­
taining cytosol (176-177). There have been some problems 
with quantitation and some risk of cross-reaction with 
extraneous antigens, but the method is fast and small 
samples can be used.
2.4 METHODS WHICH REMOVE BOUND RECEPTOR FROM FREE HORMONE
2.4.1 Sucrose density gradient ultracentrifugation.
Sucrose gradient ultracentrifugation gives information re­
garding the sedimentation velocity of proteins as a function 
of their molecular weight and density(178-23). In the usual 
method, cytosol is first incubated with radiolabel led li­
gand, with or without competitor, and then layered on prepa­
red sucrose gradients. The gradients are centrifuged for 
about 16 hours if swinging buckets are used, and for a
shorter time if a fixed-angle vertical-tube rotor is used 
(179). Fractionated samples are collected and counted.
Standards are run in the gradient tubes for comparison with
14known markers, such as C-labelled bovine serum albumin 
(4.6 S) or human IgG (approximately 6.8 S). In the past when
molybdate was not usually used most tumour cytosols dis­
played the presence of an 8S oestrogen and progesterone 
receptor form, while some contained an additional 4S
form(45) for both receptors. Steroid receptor complex in the 
absence of molybdate sediments in the 8S region of the 
gradient(180), but with molybdate the density is increased, 
and the absolute amounts of receptor are markedly 
increased(181). Since only one concentration of steroid is 
usually used, no information is obtained regarding 
affinity of the ligand for the receptor. The method
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gives useful information regarding molecular forms of the 
receptor, although it is a slow and expensive way to quanti­
fy steroid receptor binding.
2.4.2 Protamine sulphate precipitation.
In this method developed by Steggles and King(182) the re­
ceptor is precipitated with protamine, after which the pro­
tamine-receptor complex is incubated with labelled hormone. 
At 4°C unoccupied receptor sites bind to radiolabel led ste­
roid, leaving unbound hormone in solution. This assay has 
several variations and modifications.
2.4.3 Hydroxylapatite assay.
In the hydroxylapatite assay (HAP) the hormone-receptor com­
plex is absorbed to hydroxylapatite either in 'batch' or in 
column form, and the free steroid and plasma contaminants 
are removed by multiple washes (183,144). Although this 
procedure is tedious, the assay is more reliable than the 
DCC assay at low protein concentrations and can be performed 
on very small tumour samples(184).
2.4.4 DEAE chromatography.
Ion-exchange chromatography separates proteins by taking 
advantage of net charge differences(185).Steroid receptors 
are acidic proteins which can be adsorbed to a DEAE-cellu- 
lose column, which is an anion exchanged 186). The unbound 
free steroid can be washed through the column using increas­
ing concentrations of low ionic strength buffers. The method 
is reproducible and allows the measurement of receptor in 
dilute samples. The major problems of this method include 
the tendency of free oestradiol and testosterone to bind to 
DEAE at low ionic strength, and the inability of receptors 
to bind to the column at high ionic strength. Analysis of 
molecular forms of the receptor and separation from non­
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receptor binding proteins is easily achieved.
2.4.5 Controlled pore glass beads.
This promising new method, based on the ability of the 
receptor to bind tightly to controlled pore glass beads, may 
greatly simplify the commercial receptor assays(54-55). 
Cytosol or nuclear extract is poured over a column of the 
beads where the receptors, retained in the crevices of the 
porous beads, are saturated by labelled hormone. Excess 
steroid is washed away, after which the receptor-bound 
steroid is eluted with ethanol for counting.
2.4.5 Agar gel electrophoresis.
Agar gel electrophoresis separates the hormone-receptor com­
plex from free steroid on the basis of electrophoretic mobi- 
1ity(189). After electrophoresis, the labelled hormone- 
receptor complex is found on the anodal side of the well, 
while two peaks representing steroid hormone-binding globu­
lin and free steroid are bound on the cathodic side. Agar 
gel electrophoresis compares fabourably with other quantita­
tive receptor assays, especially if the cytosol is treated 
briefly with DCC before electrophoresis to remove most of 
the free and albumin-bound steroid(190).
Polyacrylamide gel electrophoresis has shown some promise in 
the measurement of ER in breast tumours(191), although 
receptor aggregation often poses a problem in this method, 
owing to the small pore size of the gel.
2.4.7 Isoelectric focussing.
The technique of isoelectric focussing, using slabs of poly­
acrylamide gel or other stabilizing matrix, allows the sepa­
ration of free and non-specifically bound steroid hormones 
from hormone-receptor complexes on the basis of their charge
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properties(170-192). This procedure, often combined with 
limited proteolysis, may be used for oestrogen or progeste­
rone receptor analysis, or the two different receptors can 
be analysed concomitantly on the same gel(193). In compari­
son with other methods,isoelectric focusing is more sensiti­
ve and rapid(1.5 to 2 hours /gel) than other commonly used 
methods( 193,-144). Several samples can be analysed per gel, 
only one incubation with labelled steroid is needed, and 
fractionated macromolecules can be recovered. The special 
problems inherent in this method are analogous to those 
encountered with other types of electrophoresis, such as 
receptor aggregation and damage from potential reactants in 
the gel(170-192).
2.4.8 High-performance liquid chromatography.
0
High-performance liquid chromatography(HPLC) has exciting 
potential as a method for the analysis and characterization 
of steroid receptors based on parameters such as molecular 
weight. Qualitative relationships and multiple forms of the 
receptor can be maintained by this rapid gel-exclusion 
system, and contaminants can be identified easily(194). In 
addition to rapid analysis time and minimal receptor modifi­
cation, this approach represents improved resolution and 
high reproducibility. The analysis are economical, after the 
initial investment in equipment has been made.
2.5 EXCHANGE ASSAYS
In clinical samples, the relative quantities of unbound 
nuclear and cytoplasmic receptors vary according to the hor­
monal milieu at the time of tumour excision. In a premeno­
pausal woman or a postmenopausal tamoxifen-treated patient, 
for example, one would predict that unbound cytoplasmic re­
ceptors would be lowest and nuclear receptors highest, while 
the opposite would be true in postmenopausal women. In or­
der to evaluate both occupied and unoccupied nuclear recep­
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tor sites, various direct and indirect exhange methods have 
been designed.
2.5.1 Protamine sulphate temperature-dependent assay
In a variation of the protamine sulphate assay Incubation of 
a KCi-extracted nuclear fraction at 25 to 30°C for several 
hours permits exchange of any previously bound hormone, 
while at 4°C only unoccupied receptor sites bind to radio­
labelled hormones (195). This is a temperature-dependent 
phenomenon, and optimum time, temperature, and concentration 
of steroid must be established. A major disadvantage of this 
method is degradation of the receptor due to the proteolytic 
activity found in human tumour nuclear extracts.
2.5.2 Hydroxylapatite temperature-dependent exchange procedure.
Both bound and unbound receptor bind to hydroxylapatite(HAP) 
which makes it an ideal tool for an exchange assay. After 
HAP-bound receptors from the KC£-extracted nuclear fraction 
are pelleted by centrifugation, they are incubated with la­
belled hormone in a temperature-dependent exchange assay. 
Unbound steroid is removed in several wash-centrafugation 
steps, after which the bound hormone is extracted with etha- 
no1(196). This method, which is only minimally affected by
monovalent ions, appears to be superior to the protamine 
sulphate exchange procedure.
2.5.3 AgNO^/DTT temperature-independent exchange method.
In this novel method developed by Hospelhorn et al(187) ex­
change is carried out at 0 to 4°C without raising the tempe­
rature as in previously described exchange assays. This 
exchange assay is based on modification of the methods using 
controlled pore glass beads. Bound and unbound receptor is
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extracted with KN03 and bound oestradiol is released by re­
action with AgNO^. The sulphydryl bonds are then reduced by 
DTT to allow the binding of labelled oestradiol to nuclear 
receptors(184,188). The potential of this interesting assay 
has not been fully explored.
2.5.4 Mersalyl temperature-independent exchange method.
In this, assay, developed by Traish, Muller and Wotiz(197) 
exchange of bound nuclear receptor complexes may be achieved 
at 0 to 4°C in the presence of molybdate and mercurial re­
agent, mersalyl acid. Specific binding is subsequently mea­
sured by the hydroxylapatite procedure. Mersalyl does not 
appear to alter binding affinity or sedimentation characte­
rises of the receptor. This assay circumvents problems such 
as receptor degradation or incomplete exchange that occur 
more commonly with temperature-dependent exchange assays.
2.5.5 NaSCN temperature-independent exchange assay.
Bresciani et aj_( 198) have developed a precise temperature- 
independent exchange assay using NaSCN, which solubilizes 
receptor from the nuclear pellet more efficiently than KC1 
extraction. The nuclear fraction is incubated for 16 hours 
at 4°C in the presence of excess labelled hormone and NaSCN, 
and virtually complete exchange of bound oestradiol is 
achieved. In this assay quantitative extraction of recep­
tor from nuclei and exchange is achieved in a single step. 
This method allows the release of even the KC1 extraction- 
resistant receptor, thus permitting reliable and accurate 
quantitation of receptor.
2.6 HISTOCHEMICAL METHODS
The histological detection of steroid hormone and specific 
receptors in morphologically intact tissue allows the inves­
tigator to visualize the uptake, transport and distribution
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of hormones, and to understand more fully hormone-receptor 
interactions under varying physiological and pathophysiolo­
gical conditions.
2.6.1 Antihormone antibody methods.
Several studies(199,200) have used anti-oestradiol antibody 
or antibody involving a polymeric oestradiol(201,202) to lo­
calize oestrogen receptor in human breast tumours. The tu­
mour tissue is evaluated with a double antibody technique 
using anti-oestradiol antiserum followed by a fluorescein 
conjugated anti-immunoglobulin antiserum. Indirect immuno­
fluorescence techniques using sheep anti-oestradiol and rab­
bit anti-progesterone antiserum plus fluorescein isothiocya­
nate (FITC)-conjugated antiserum have been used by Mercer et 
a_l_(200) in an attempt to detect simultaneously the presence 
of both these hormones in human breast cancer cell lines and 
biopsies.
The results of these studies using antihormone antibody sug­
gest the presence of hormone-specific binding, but problems 
with non-specific binding yield less than satisfactory re­
sults in some of the studies(201).
Various immunoperoxidase techniques, each using anti-steroid 
antibody plus the enzymatic activity of horseradish peroxi­
dase with a chromogenic substrate, have been used to loca­
lize oestrogen in breast cancer cells(203). The peroxidase 
anti-peroxidase(PAP) method can enhance sensitivity 100 to 
1000 times compared with immunofluorescence methods, and can 
be performed on fixed rather than frozen specimens(77). The 
principal disadvantage of this method, as in other histoche- 
mical methods, is the difficulty in quantitation of recep­
tor.
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2.5.2 Steroid-fluoresceinated conjugates.
Another cytochemical approach to trace steroid receptors 
using the fluorescence microscope utilizes steroid analogues 
that carry a visual tracer and retain binding affinity for 
steroid receptors. For the most part, these steroid deriva­
tives consist of steroid molecules covalently linked to a 
protein carrier that has been previously substituted with 
FITC(202-205). These macromolecular derivatives, as is also 
true of polymeric oestradiol, cannot penetrate the membrane 
of intact cells, but the fluorescein tag can mark receptor 
positive cells. Pertschuk et aj_(205), using 17g-oestradiol 
and 11a-hydroxyprogesterone conjugated to fluoresceinated 
BSA, found a 92 per cent correlation with a biochemical as- 
assay in 314 breast cancer specimens assayed for ER and 85 
per cent correlation in 85 specimens assayed histochemically 
for PR. Pertschuk et al also found a similar correlation 
with the DCC assay using androgen-1igand conjugates of fluo- 
resceinated BSA in a double-blind study of 108 prostatic 
cancer specimens.
In another method, a fluorescein-labelled oestrogen (17FE) 
with a fluorescein moiety coupled to the 17 position of oes­
tradiol can enter the cell membrane and can trace receptor 
sites in target tissues in a manner reflecting the interac­
tion of native oestrogen(202). Another group found no direct 
quantitative relationship between this cytochemical method 
utilizing 17FE and the DCC assay.They did find, however,that 
the cytochemical technique was useful in measuring the pro­
portion of ER-positive cells in a tumour sample, and that 81 
per cent of tumours with ER values of 10 to 99 fmol measured 
by DCC assay were associated with greater than 10 per cent 
marker-positive cells. Fluorescence of the entire receptor­
positive cell occurs most commonly, but sometimes only the 
nucleus or the cytoplasm is stained selectively. While 
further refining of this cytochemical technique is necessa­
ry, the assay is simple, rapid, inexpensive and deserving of
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more thorough evaluation. The same 17FE that is used for the 
histological assay may also be used in separation methods 
such as the DCC assay. This fluorometric DCC assay is simi­
lar to the radiometric assay, except that fluoroscent-label- 
led hormones are utilized and measured, instead of employing 
radiolabel led hormones(206).
Unfortunately, none of the histochemical assays has been e- 
valuated.independently in a prospective and blinded fashion. 
While obviously appealing, their routine use cannot be con­
sidered appropriate at the present time. Further studies 
will be required before more traditional assay methods are 
abandoned.
2.6.3 Receptor antibodies.
The recent development of specific monoclonal antibodies to 
the oestrogen receptor protein allow detection of the recep­
tor independent of the binding of labelled hormone by the 
receptor(207). Part of the difficulty in obtaining specific 
antibody to receptor is related to the very low concentra­
tion of oestrogen receptor, even in target tissues. Anti­
bodies to calf uterine oestrogen receptor generated in rab- 
bits(208) or goats(209) crossreact with oestrogen receptor 
from many species, while those obtained from immunization of 
the Lewis rat react only with calf oestrogen receptor (208). 
Splenic lymphocytes from a rat immunized with partially pu­
rified receptor from human breast cells were fused with 
three different mouse myeloma cell lines, yielding several 
different hybridoma cell 1ines(210-211). These hybridoma 
cells secreted specific monoclonal antibody against human ER 
that cross-reacts with ER of several other mammalian species 
(207). Recent work from the laboratory of DeSombre, Greene 
and Jensen (209-211) has been directed toward optimizing a 
plastic bead radioimmunoassay, using two of the monoclonal 
antibodies. This assay, as well as others using immunope- 
roxidase or immunofluorescence methods, may provide a basis
for simple, efficient detection and localization of oestro­
gen receptor in clinical samples. Monoclonal antibodies also 
provide useful reagents in the purification of oestrogen re­
ceptor.
QUANTITATIVE ASSAYS FOR OESTROGEN AND PROGESTERONE RECEPTORS 
IN VERVET MONKEY UTERI
REAGENTS:
(a) Steroids:
The radioligands [2,4,6,73 H(N)]-l7p-oestradiol (3 H-E2 ; speci- 
specific activity:92Ci mmole), [I7a-methyl-3H]promogesterone 
(3H-R5020;specific activity:85Ci/mmole) and [1,2,6,7,213H(N)]- 
progesterone (3 H-P; specific activity : 195.4 Ci/mmole) were 
obtained from New England Nuclear. Unlabelled 17p-oestradiol 
(E2 ).oestriol(E3 ), oestrone( Ex ), testosterone(T), dihydrotes- 
tosterone(DHT), dehydroepiandrosterone(DHEA), diethylstil- 
bestrol(DES), Norethindrone(NE) and hydrocortisone (corti­
sol; HC) were all purchased from Sigma while progesterone 
(P) and promogestone (R5020) were bought from New England 
Nuclear. Ethinyloestradiol (EEZ) was obtained from Merck 
Chemicals. Radioligands were initially checked for purity by 
thin layer chromatography in a benzene : ethylacetate (9:1) 
system, or by high performance liquid chromatography (HPLC) 
on a reverse phase column (ijBondapak C18 ; Waters Associates).
Scintillation counting was performed in a Beckman LS 9000 
counter using Ready-Solv HP (Beckman Instruments) as cock- 
tai 1.
(b) Buffers:
The main buffer (TEDAG^q ) contained 10mM Tris HC1, 1.5mM 
EDTA, 1mM dithiothreitol (DTT, Sigma) 1mM sodium azide and 
10 % (m/v) glycerol (Merck Chemicals) and the pH was adjus-
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ted to 7.4 at 4°C.
A second incubation buffer (TEDAG^g), employed in the assay 
of PR contained the same ingredients as the TEDAG^g buffer, 
except that the glycerol content was 60 % (m/v).
A third buffer (TEDAG-MO) was prepared from TEDAG^ by the 
addition of sodium molybdate to a final concentration of 
10mM. •
A very concentrated solution of KC1(2M) was prepared in 
TEDAG^g buffer.
(c) Dextran coated charcoal (DCC):
The dextran coated charcoal suspension consisted of 0.5 % 
(m/v) pre-washed,activated charcoal (Merck Chemicals), 0.1 % 
(m/v) gelatine (Carrageenan Type 1; Sigma) 0.5 % dextran 170 
(Pharmacia Fine Chemicals) in TEDAG^g buffer. Fresh DCC so­
lutions were prepared every fortnight.
(d) Ligands and competitors:
The [3Hj-173-oestradiol was received, dissolved in ethanol. 
A series of concentrations ranging from 0.25 to 8nM was 
prepared in buffer (TEDAG^) as well as an identical range 
of the 3H-E2 .containing a 100 fold excess of either unlabel­
led E2 , EE2 or DES.
The same procedure was followed for the 3H-R5020 as descri­
bed above. A series of concentrations ranging from 0.25 to 
32nM was prepared with or without a hundred fold excess un­
labelled promogestone (R5020).
Solutions (1mM) of the following unlabelled competitors were 
prepared in absolute ethanol:17B-oestradiol(E2 ),oestriol(E^) 
oestrone(E1), testosterone(T), dihydrotestosterone(DHT), de-
hydroepiandrosterone(DHEA), progesterone(P), promogestone 
(R5020), DES, EE2 , norethindrone (NE) and hydrocortisone 
(HC). From these solutions were prepared a series of 8 con-
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centrations of each ranging from 0.675nM to 10 M in TEDAG^g 
buffer.
STANDARD ASSAY FOR CYTOSOLIC PROTEIN:
A modification of Lowry's method (240) for protein determi­
nation was employed in the assay for cytosolic protein con­
centration.
(a) Procedure:
0.2 ml of cytosol was diluted 1:20 with distilled water. To 
1 ml of this solution, 1 ml of alkaline buffer (1 M NaCO^, 
0.25 M NaOH) was added. 0.4 ml of copper reagent (0.1 % 
(CuS04.5FI.-,0,0.2 % NaK tartarate) was added and the mixture
was allowed to stand at room temperature 10 min.
After that 0.75 ml of Folin Ciocateau reagent (diluted 1:4) 
was added to the incubation mixture and it was allowed to 
stand another 10 min at room temperature. In this time, a 
blue colour was developed which was read at 700 nm. A stan­
dard curve was drawn with 13 different dilutions of BSA.
(b) Results:
Fig 2.1 depicts the standard curve for the modified Lowry 
assay, employing bovine serum albumin (BSA) as standard and 
it seems that there is a straight correlation between the 
concentration of BSA and the absorbance of 700 nm.
COLLECTION OF VERVET MONKEY UTERI (VMU):
Uteri were obtained from the National Institute of Virology, 
Edenvale, South Africa on a regular basis from animals sa-
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crificed for vaccine production. Monkeys were kept in qua­
rantine for six weeks after being tested for tuberculosis. 
The estimated age of the monkeys varied between 2 and 3 
years and they weighed between 3 and 3.5 kg. On the day of 
bilateral nephrectomy they were washed and the abdominal 
areas shaved, following sedation with ketamine (lOmg/kg). 
Intravenous infusion of a 6 % saline solution of sodium nem­
butal (1 - 1.5 ml) followed until a level of surgical anaes­
thesia was attained.Uteri were quickly excised following the 
removal of the kidneys, placed into sterile sample bottles 
and then packed into crushed ice before being transferred to 
a - 70°C deepfreeze.
2.10 PREPARATION OF CYTOSOL:
(a) Preparation of cytosols from uterine slices:
Uteri were trimmed of fat and connective tissues and cut 
longitudinally into "identical" halves. The uterine tissue 
(packed in powdered dry ice on a petri dish) was cut into 
thin slices with a very sharp scalpel, taking care never to 
let the tissue thaw. The slices were then suspended in 5 
volumes of TEDAG^ buffer kept on crushed ice. Often indi­
vidual uteri or groups of uteri were totally sliced up and 
the slices mixed thoroughly, prior to homogenization and 
preparation of cytosols. Homogenization was executed by 3 
bursts of 10 seconds duration, alternated with 50 seconds 
cooling periods (crushed ice) using a TP Ultra Turrax (Janke 
and Kunkel). The collagen rich homogenate was centrifuged 
in a SW 50.1 rotor at 105000xg' for 30 min at 4°C (Beckman 
L8-80 centrifuge). The thin layer of fat was removed and 
clear cytosol drawn off with a pre-cooled syringe. Protein 
concentration was quantified by means of the modified Lowry 
procedure (240). Cytosols, not immediately processed, were 
divided into 2.5nu2 aliquots and then stored at -70°C until 
assays could be performed.
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Cytosols employed in sucrose density gradient assays in the 
presence of 10mM sodium molybdate were prepared as described 
above, except that the tissue was homogenised in TEDAG-MO 
buffer.
(b) Preparation of cytosols from tissue powders:
Uteri were pooled (5 - 35) and then cut into thin slices in 
powdered, dry ice. A large amount of powdered dry ice was 
added to and mixed with the tissue slices and the mixture 
then poured into a pre-cooled (-86°C) mortar. The tissue 
slices were then ground to a fine tissue powder with a por­
celain pestle ensuring that the temperature of the powder 
was kept at -86°C. The powder was then divided into smaller 
batches of % 5 g quantities and stored at -70°C in a deep­
freeze.
Whenever tissue powder was needed for an experiment, an 
amount of the powder was weighed out, taking care that 
spatulas and vials are pre-cooled to -70°C (or 86°C) before 
handling the powder. Tris-buffer (0-4°C) was added to the 
tissue powder prior to homogenization. Homogenization and 
preparation of the cytosols were executed in the same way as 
described in Section 2.10(a) above.
2.11 RECEPTOR ASSAYS:
(a)Oestrogen Receptor Assays:
Aliqouts (100pj2)of cytosol were thoroughly mixed and then 
incubated with 100 of 3H-E2 at 5 different concentra­
tions (0.25-8nM) for 30 min at 20°C. Non-specific binding 
was assayed as described above, but the 3H-ligand solu­
tions also contained a 100 fold excess of unlabelled or 
DES. The reaction was terminated with the addition of 
500m£ DCC. The suspension was vortexed, left on ice for 
10 min and centrifuged at 2000xg' for 15 min. Aliquots
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(500hj?) of the supernatants were assayed for radioactivi­
ty,following the addition of 4 rrui scintillation cocktail.
(b)Progesterone Receptor Assays:
These assays were carried out simultaneously with the ER 
assay on aliquots of the same cytosols. Standard condi­
tions used were the following:
Cytosols were incubated on crushed ice for 2 h, following 
the addition of 100^4 of the radioligand (0.25-32nM). 
After the first 2 h, 10Opje of TEDAG1Q was added to the 
incubation mixture and thorough vortexing was followed by 
a reincubation in crushed ice for another 2 h. The incu­
bation was terminated by the addition of 500^1 of DCC. 
The reaction mixture was vortexed and the charcoal 
pelleted at 2000xg' for 15 min (0°-4°C) and the superna­
tants monitored for radioactivity as described above.
(c)Results:
A typical Scatchard plot of the titration analysis data 
appear in Fig. 2.2, and 2.3.
In the course of this investigation well over a hundred 
uteri were employed in numerous experiments, including 
titration assays, sucrose density gradient analyses and 
studies on the molecular properties of VMU ER and PR. In 
a large number of experiments cytosols derived from tis­
sue powders were employed in order to obtain batches of 
cytosols consistent in the levels of ER and PR. Problems 
of experimental reproducibility were often experienced 
when groups of experiments were executed on cytosols 
produced from individual uteri and it was therefore 
deemed necessary to prepare batches of cytosols prior to 
a set of related experiments.
Table 2.1 summarizes the binding data for a group of
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21 individual uteri, while Table 2.2 represents bin­
ding data obtained on tissue powders.
Values for the ER range from 151 and 822 femtomoles per
mg protein (fmp) with a mean of 327+165 fmp while PR
values range from 444 to 2267 fmp (mean : 1285±511). Mean
dissociation constants found for this batch of VMU were 
_ 1 n _ q
3.15±1.4x10 M and 2.38±D.2x for the ER and PR re­
spectively. A mean ratio for PR to ER levels of 4.5±2.4 
per uterus was observed. Mean correlation coefficients 
(r) obtained, following regression analyses on binding 
data were 0.967 for the ER and 0.985 for the PR assays. 
A weak, positive correlation (r = 0.31) was found to 
exist between the levels of ER and PR in the VMU.
For the tissue powders a means of 224±61 fmp and 742±288
fmp were obtained for ER and PR respectively. Mean K,
-10 -9avalues were found to be 3.8±0.9x 10 M and 2.9±0.7x10 *M
respectively for ER and PR. The mean ratio for PR/ER was
3.3 and a correlation coefficient of 0.95 between the
levels of ER and PR could be illustrated.
2.12 OPTIMIZING CONDITIONS FOR ASSAYS OF CYTOSOLIC ER AND PR IN 
VMU:
2.12.1 Effect of temperature on the stability of the VMU ER and PR:
(a) Experimental
A group of four VMU were cut longitudinally into two 
"identical" halves. The one half was immediately proces­
sed and analysed for ER and PR, while the other part 
was first stored in Medium 199 for 60 min at room tempe­
rature prior to analysis.
(b) Results:
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A loss of specific binding 16 - 35 % (ER) and 10 - 25 % 
(PR) was observed when uteri were left at room tempe­
rature in Medium 199 (Fig. 2.4). This finding indi­
cated that posthysterectomy treatment of the assay ma­
terial was very important in preserving the labile ma­
cromolecular components in the intact tissue. Although 
a significant decrease in binding capacity (Bm, ) could 
be observed for both receptors, only the progesterone 
receptor exhibited a drop in binding affinity (increase 
in Kj) following the incubation of the uteri in Medium 
199 at room temperature. Binding data is summarised in 
Tables 2.3 and 2.4.
2.12.2 Effect of freezing and thawing on the ER and PR Receptors. 
(a) Experimental:
A small number of VMU were cut into small pieces; the 
pieces were thoroughly mixed and subsequently homogeni­
zed. The protein concentration of the cytosol was adjus­
ted to ^ 2 mg/mi. One batch of cytosol was immediately 
analysed for ER and PR, while another was stored in the 
deepfreeze at -70°C and analysed 24 hours later.
A batch of cytosol was subjected to repeated freezing 
and thawing (3 cycles) and the process followed on su­
crose density gradient centrifugation (10-35%) by cen­
trifugation at 520000xg' for 2 h in a vertical rotor 
(VTi-890; Beckman Instruments). This procedure is de­
scribed in detail in Section 2.5.1.
(b) Results:
Scatchard plots and binding data are represented in Ta­
ble 2.5 and 2.6 and Fig 2.5.
Freezing and thawing caused a slight, but significant 
(p=0.001) decrease in the binding capacity of the cyto­
55
sol. The difference in Bm„^  varied from 2.8 to 17.6 %
m u  a
for ER (mean difference = 10.4±8.3 between groups) and 
-5.0 to 13.1 % for the PR (mean 1.1±4.5 %). A signifi­
cant difference (P<0.001) was observed for the values: 
17.0±13.8% for the ER and 108.3±11.3 % for the PR. Thus 
freezing and thawing tend to damage receptors and in the 
case of the PR a vast effects was observed on receptor 
affinity (K^). Corroboration for the fact that freezing 
and thawing physically affected the receptors could be 
seen in 10-35 % SDG profiles as depicted in Fig. 2.6.
Effect of temperature and duration of incubation of incuba­
tion on Scatchard plots and binding data:
(a) Experimental:
A batch of cytosol was prepared as described in Section 
2.10. Cytosol protein concentration was adjusted to ^ 2 
mg/mjZ and binding assays were executed employing several 
variations in incubation conditions:
(a) 0-4°C x 30 min.
(b) 0-4°C x 4 h
(c) 0-4°C x 18 h
(d) 10°C x 30 min.
(e) 20°C x 30 min.
(f) 37°C x 30 min.
(g) 50°C x 30 min.
(b) Results:
A temperature optimum graph is presented in Fig 2.7(A). 
A summary of the binding data is presented in Table 2.7 
while the effect of different incubation conditions is 
depicted in Fig. 2.7 (B)
At 37° C, receptors exhibited some denaturation and, al­
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though no vast effect on Bmax is noted, the receptor af­
finity (Kd) is influenced.At low temperatures, times had 
to be extended to more than 4 h in order to obtain suf­
ficient exchange of cold and radioligands for reliable 
Kj values. It would therefore seem appropriate to 
incubate for 30 min at 20°C or for 18 - 24 h at 0-4°C 
during the assay for the ER. Because the PR exhibited 
susceptibility to thermodynamic conditions, we prefer­
red to incubate at 0-4°C or at least 4 h.
2.12.4 Effect of different temperatures of incubation on the asso­
ciation and stability of VMU ER and PR:
(a) Experimental:
Cytosol (1 mSi) was incubated with 1 mSt 10 nM tritiated 
ligand (3H-E2 or 3 H-R5020) with and without a 250 fold 
excess level of the appropriate unlabelled competitor at 
either 0°C, 20°C or 37°C. Immediately, following the 
addition of the radioligands, aliquots (100) of the 
incubations mixtures were taken at regular time inter­
vals (2 min intervals for the first 10 min; 10 min in­
tervals for the next 60 min and 30 min interval for up 
to 3 h) and added to a DCC suspension ( 1 m£) on ice. 
Following thorough vortexing, the DCC suspensions were 
left on the ice for 15 min and then spun at 2000xg' . 
Aliquots (500p£) of the supernatants were monitored for 
radio-activity, following the addition of 2 m£ cocktail 
to the sample. Vials were counted in a Beckman LS 9000 
counter at an efficiency of 25 - 30 %.
(b) Results:
Association curves for both receptors are presented in 
Fig. 2.8. From these curves it is clear that the forma­
tion of the hormone-receptor complexes was completed 
within 15 min (ER) and 30 min (PR) at 0°C. At 20°C,
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however association proceeded much faster and plateaux 
were reached within 7 min (ER) at 15 min (PR) but a 
drastic inactivation could be observed, soon after maxi­
mum saturation was reached (< 5 min for both ER and PR). 
After 40 min at 37°C the PR was totally inactivated 
while the ER was still 50 % active.The ER was completely 
inactivated after 90 min at 37°C.
In .contrast to the rapid inactivation of both receptors 
at 37°C, they seemed to be very stable at 0°C and 20°C 
for at least 3 h and even after 24 h at 0°C there seemed 
to be no significant loss of activity.
From these observations and for practical purposes it 
was decided to incubate at 20°C for 30 min for the ER 
while a total of 4 h of incubation at 0°-4°C was employ­
ed for the PR assay.
2.12.5 Effect of Protein concentration of cytosol on the B and -------------------------------------- --------------- max----
(a) Experimental
Tissue was homogenized and cytosols were prepared as 
previously described. The protein concentration was 
found to be approximately 5.0 mg/m£.
Two variations of this experiment were executed:
(i) Binding assays were performed on cytosols serial­
ly diluted with plain Tris E O  buffer (TEDAG^) 
thus changing the total protein content as well as 
the specific binding protein for ER and PR.
(ii) binding assays were performed on cytosols serially 
diluted with a solution of 5 mg/mi? bovine serum 
albumin (BSA) in TEDAG.JQ buffer, keeping the total 
protein of the cytosol constant at ^ 5 mg/ml! while
58
the specific binding proteins were diluted as in 
(i) above.
(b) Results
Binding data for both experimental variations are depic­
ted in Fig. 2.9 and Table 2.8.
When, the cytosol was only diluted with buffer, a clear 
linear relationship could be established between cytosol 
protein concentration (0.29-5.0 mg/nue) and the amount of 
ligand specifically bound (Fig 2.9i. Dilution of cyto­
sols with the -v 5mg/mje BSA solution rendered a fairly 
linear graph with the non-1inearity ensuing at 1.1 mg/mji 
cytosolic protein (Fig. 2.9).
Although the concentration of receptors (Bmax in fmol/ 
m£) vary proportionally with the buffer dilution (assay 
1-5) and the actual receptor dilution (assay 1-5), the 
actual receptor content per mg cytosolic protein (BmflX 
in fmol/mg protein) is not affected. Also the 
seemed to be constant over a wide area of protein con­
centration. As soon as the ratio of non-specific bin­
ding proteins (BSA) relative to specific binding pro­
teins (ER) increased to between 4.5 and 8.2 the lineari­
ty of the Scatchard plots were significantly (p<0.001) 
affected.
2.12.6 Effect of the type of unlabelled competitors employed in 
competitive protein binding assays for ER:
(a) Experimental.
Cytosol (30m:e) was prepared from 2 VMU (5 g) in TEDAG^g 
buffer and stored in 1 mj2 aliquots at -70°C until needed. 
Aliquots (100m£) of cytosol were incubated with 100p^ of 
5 different concentrations (0.25-8nM) of labelled ligand
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for 30 min at 20°C.
Non-specific binding was assayed as described above, but
3
the H-ligand solutions also contained a 100 fold excess 
of either unlabelled E~, or DES. The reaction was 
terminated with the addition of 500p£ DCC. The suspen­
sions were vortexed, left on ice for 10 min and centri­
fuged at 2000g 1 for 15 min. Aliquots (500y£) of the 
supernatants were assayed for total and non-specific 
binding.
A range of 3H-E2 concentrations containing different ex­
cess levels (10'1, 1, 10, 102 , 103 , times of either un­
labelled DES, EE^ or relative to the radioligand 
concentrations was prepared. Multipointed competitive 
protein binding assays were performed on the cytosols, 
employing the different non-specific binding reagents 
prepared.
(b) Results:
Scatchard plots of titration analysis data revealed that 
at a 100 fold excess level no significant difference 
could be observed in both the binding capacity or 
dissociation constants (K^) when either DES, EE£ or E^  
were employed in assessing the level of non-specific 
binding in the cytosols (Fig. 2.10). Some differences 
could however be observed when the excess levels of the 
unlabelled competitors were varied (Fig 2.10-2.12 and 
Table 2.9.
2.12.7 Effect of a proteolytic enzyme (Trypsin) on affinity (K^) 
binding capacity (B m ) and SDG profiles for ER in VMU:
(a) Experimental:
Cytosol was prepared from a pool of 5 small VMU as
60
described in Section 2.10. The cytosol was divided into 
two parts. Multipoint titration assays and sucrose den­
sity gradient (10-35%) analyses (see description of 
methodology m  section 2.10 and 2.11) were performed on 
the one part or the cytosol which the same experiments 
were carried out on the other part of two cytosols 
except that a post-incutation step of partial trypsi- 
nization was included.
Partial trypsinization was based on a method published 
by Wrange et aj (304): Following the incubation of 
aliquots of the cytosols with the appropriate concentra­
tion of radic-ligand (specific and non-specific binding) 
at 20°C for 30 min, a trypsin solution (13.6 pg/mT was 
added and a second incubation at 10°C for 30 min follow­
ed. The reactions were terminated by the addition of 
soybean trypsin inhibitor (304) and DCC,the charcoal was 
pelleted at 2000xg' (40C) whereafter the supernatants 
were monitored for specific and non-specific binding or 
subjected to density gradient (10-35%) centrifugation.
(b) Results:
The effect of partial trypsinization on receptor ligand 
binding capacity and affinity is depicted in Fig. 2.14 
and 2.15 and Table 2.10.
2.13 OPTIMIZING C O N D I T I O N S  FOR QUALITATIVE DETERMINATION OF ER
AND PR BY SPG:
2.13.1 SDG centrifugation - experimental procedure
(a) Low ionic strength conditions
Freshly prepared cytosols ( 6 - 8  mg/rrud protein) were in­
cubated with 3H-t2 or M1-R5020 at a final concentration
of 5 nM with or without a 103 times excess of unlabel­
led DES or R 5020 respectively. Following a 30 min 
incubation at 20°C, the incubation mixture was added 
to a pellet of DCC, prepared by centrifuging 4 ml of 
DCC suspension at ZOOOxg' for 15 min. The suspension 
was vortexed and then centrifuged for 15 min at 2000xg' 
(0°-4°C). The supernatant was, immediately drawn off 
from the charcoal and stored in polypropylene tubes on 
ice prior to layering onto the gradients.
Gradients were prepared for centrifugation in a vertical 
rotor in either Quickseal or nitrocellulose tubes 
(Beckman Instruments) by handlayering of four different 
concentrations of sucrose in TEDAG^g buffer (10%, 18.3%, 
26.7% and 35% sucrose). A minimum of 2 h of conditioning 
at room temperature was necessary to create continuous 
linear gradients (10-35%). Gradients containing a final 
concentration of 10mM sodium molybdate, were prepared 
separately.
Linearity of gradients were checked regularly by refrac- 
tometry (Fig 2.16) and the gradients were calibrated 
using four unlabelled marker proteins myoglobin (2.OS), 
ovalbumin (3.65), bovine serum albumin (4.65) and aldo­
lase (7.35). The markers were run separately and in 
duplicate in continous gradients and not more than 1 mg 
of each marker was layered onto the gradients in 200p£ 
of TEDAG10 buffer. The marker gradients were frac­
tionated and the fractions scanned spectrophotometrical- 
ly at 280 nm. (Fig 2.17). With each experimental set of 
cytosols run on sucrose gradients a duplicate set con­
taining 14C-methylated bovine serum albumin (NEN) was 
also included.
Cytosols (200^j2) were run in duplicate for both total 
and non-specific binding at a maximum gravitational
force of between 365 OOOxg1 and 520 OOOxg1 for 2 to 20 h 
(2°C) depending on the rotor used. Rotors employed were 
either the VTi-80 SW 50.1 or SW 05 (Beckman Instruments) 
in a Beckman L8-80 ultracentrifuge. Following the 
completion of centrifugation, the gradients were 
fractionated from the top by displacement (Pharmacia P-3 
peristaltic pump) with a 50 % m/v of sucrose containing 
Trypan Blue. Five drop fractions were collected manually 
into mini vials (miniPoly-Q; Beckman Instruments), 2 iM 
of scintillation cocktail was added and the vials were 
than counted, using a fraction plot digital integration 
program.
(b) High ionic strength conditions:
The same methodology described in (a) above was employ­
ed. None of the gradients prepared, however contained 
molybdate. Prior to layering omo the gradients, tubes 
containing the incubation mixtures were cooled in crush­
ed ice and an ice cold solution of 2 M KC1 in TEDAG^ 
buffer was added to the solutions to a final concentra­
tion of 0.4 MKC1. The tubes were vortexed, their total 
contents transferred onto prepared DCC and vortexing re­
peated. Following centrifugation at 2000xg' (4°C) the 
supernatants (200p^) were immediately layered onto gra­
dients containing 0.4 M KC1 and processed as described 
in (a).
Before deciding on which optimal conditions for sucrose 
density gradient centrifugation to employ several dif­
ferent conditions of centrifugation were screened (Table 
2.11).
(c) Results
The linearity of a representative gradient is depicted 
in Fig. 2.16. A typical calibration curve appears in
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Fig. 2.17 and the calibration data is summarized in 
Table 2.12. Sucrose density gradient (SDG) profiles 
obtained with the various methods of centrifugation, 
outlined in Table 2.11 appear in Fig. 2.18.
It was subsequently decided to employ routinely the
vertical rotor (VTi-80) at maximum speed (80 000 r.p.m.)
for a duration of 120 min or to a constant w2t of 5.3 x 
11'10
TABLE 2.1
Summary of Receptor Data obtained for ER and PR in 21 VMU :
*(fm/mg
Bmax
protein) (x
Kd
-91 0 M)
Sedimentation coefficient 
(svedbergs)
Range Mean 
(± SD)
Range Mean 
(± SD)
Range Mean 
(± SD)
ER 151-822 327±1 65 0. 1 5-0.798 0.315±0.14 7.2-7.9 7.6±0.5
PR 444-2267 1285±511 2.3 -3.1 2.38 ±0.2 6.7-7.7 7.2 ±0 . 1
PR/ER 1.1-13.1 4.5±2.4 - -
p(*fm/mg protein = femtomoles per milligram cytosolic protein).
TABLE 2.2
Summary of binding data obtained, following the execution of assays on VMU tissue powders.
Group No. o f No . o f Binding  data
u t e r i Assays ER PR PR/ER
ER PR Bmax Kd Bmax Kd
(fmol /mg p r o t ) ( x 101 °M) (fmol /mg p r o t ) ( x10^M)
A 30 4 4 176±14 4 . 0 1 0 . 5 3 457118 .7 4 . 0 1 2 . 0 2 . 6 1 1 . 2
B 20 21 1 1 3 7 3 ±4 6 5 .0 12 .1 11681300 3 . 0 1 1 . 2 4 .312 .1
C 20 1 3 9 160±20 2 .611 .1 554140 .4 2 . 6 1 1 . 6 3 . 5 1 0 . 9
D 1 5 1 3 1 2 213±22 3 . 3 1 0 . 8 660136 2 . 8 1 2 . 0 3 . 0 1 0 . 8
E 1 0 26 8 300±29 3 . 9 1 1 . 5 871197 2 . 2 1 1 . 3 2 . 9 1 0 . 9
TOTAL 95 77 44
MEAN 224±61 3 . 8 1 0 . 9 7421283 2 . 9 1 0 . 7 3 .3 1 0 .9 5
B ,max K , are d the mean v a lu e s  f o r  the  group o f assays  e x e c u t e d on a p a r t i c u l a r  t i s s u e
p o w d e r ) .
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Figure 2. 1 : Standard c u r v e  f o r  the  d e t e r m i n a t i o n  o f  p r o t e i n  c o n ­
c e n t r a t i o n  i n  VMU c y t o s o l s  w i th  the m o d i f i e d  Lowry 
a s s a y  ( 2 4 0 ) .  Bovine serum albumin (BSA) was used as 
p r o t e i n  s ta n d a r d .
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Figure  2 . 2  . -Competi t i ve  p r o t e i n  b i n d i n g  a ss ay s  f o r  c y t o s o l i c  
VMU ER; s a t u r a t i o n  c u r v e s  and S c a tch ard  p l o t s .  
A l i q u o t s  (100 u£) o f  c y t o s o l  were i n c u b a t e d  with  
100 \x!L o f  3 H-Ea a t  5 d i f f e r e n t  were c o n c e n t r a ­
t i o n s  ( 0 . 25-8mM)( t o t a l  b i n d i n g ,  TB ) . N o n - s p e c i ­
f i c  b i n d i n g  NSB) was assayed  when the  3H - l i g a n d  
s o l u t i o n s  c o n t a i n e d  a 100 f o l d  e x c e s s  o f  u n l a ­
b e l l e d  DES. The r e a c t i o n  was t erm in ated  w i th  the 
a d d i t i o n  o f  500^1)  DCC s o l u t i o n .  A f t e r  c e n t r i ­
f u g a t i o n  ( 2 0 0 0 x g 'x 1 5  m in ) ,  a l i q u o t s  ( 5 0 0 p l )  o f  
the s u p e r n a t a n t s  were assayed  f o r  t o t a l  (TB) and 
n o n - s p e c i f i c  b i n d i n g  (NSB). S p e c i f i c  b i n d i n g  
(SB) was c a l c u l a t e d  by s u b t r a c t i n g  NSB from TB.
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Figure  2 .3  : C o m p e t i t i v e  p r o t e i n  b i n d i n g  a ss a y s  f o r  c y t o s o l i c  
VMU PR; s a t u r a t i o n  c u r v e s  and S catchard  p l o t s .  
A l i q u o t s  (100 u2 )  o f  c y t o s o l  were in c u b a t e d  with 
100 uJ o f  3 H-E2 a t  5 d i f f e r e n t  were c o n c e n t r a ­
t i o n s  ( 0 . 25-8mM)( t o t a l  b i n d i n g ,  TB) . N o n - s p e c i ­
f i c  b i n d i n g  NSB) was assayed  when the 3 H - l i g a n d  
s o l u t i o n s  c o n t a i n e d  a 100 f o l d  e x c e s s  o f  u n l a ­
b e l l e d  DES. The r e a c t i o n  was term in ated  w i t h  the 
a d d i t i o n  o f  5 0 0 p l )  DCC s o l u t i o n .  A f t e r  c e n t r i ­
f u g a t i o n  ( 2 0 0 0 x g 'x 1 5  m in ) ,  a l i q u o t s  ( 5 0 0 p l )  o f  
the  s u p e r n a t a n t s  were  assayed  f o r  t o t a l  (TB) and 
n o n - s p e c i f i c  b i n d i n g  (NSB). S p e c i f i c  b i n d i n g  
(SB) was c a l c u l a t e d  by s u b t r a c t i n g  NSB from TB.
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F igu re  2 . 4 : E f f e c t  o f  the  te m perature  on the r e c e p t o r  b i n d i n g  c a ­
p a c i t y  and a f f i n i t y  in  i n t a c t  VMU; (A) ER and (B) PR 
(•)  u t e r i  were im m edia te ly  p r o c e s s e d  f o l l o w i n g  h y s ­
t e r e c t o m y  and a n a ly s e d  f o r  ER and PR w h i l e  (A) u t e r i  
were l e f t  a t  room tem perature  i n  Medium 199 f o r  60 
min p r i o r  t o  a n a l y s i s .
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I ABLE 2.3
Binding data obtained for the ER following (a) immediate post­
hysterectomy assaying, (b) assaying following incubation of intact 
uteri at room temperature (60 min).
uterus
No Bmax Kd %A between a & b
( f mol /mg p r o t e i n ) s
ol
1 a 471 2 ,32
+ 26, 7
1 b 345 1 , 08
2a 395 1 , 28
+ 10 ,9
2b 352 2 ,17
3a 409 3 ,1 9
+33,2
3b 273 2 ,7
4a 277 3 ,0
+19 ,4
4b 304 2,75
Mean o f group a 388181 2 , 4 5 1 0 . 8 6
Mean o f  g roup  b 318±37 1 , 9 8 ± 0 .82
%A group  a v e r s u s  b 1 8±54 19 ± 4 . 6
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TABLE 2.4
Binding data obtained for the PR following (a) immediate post­
hysterectomy assaying, (b) assaying following incubation of intact 
uteri at room temperature (60 min).
u t e r u s
No Bmax Kd % A
( fmol /mg p r o t e i n )
_9( x1 0 M)
1 a 2491 0 ,8
+25
1 b 1 868 1 , 56
2a 1 625 1,95
+16
2b 1 350 1 , 73
3a 2638 2 ,77
+32
3b 1 003 4 ,6 3
4a 1 554 3 ,37
+35
4b 1003 2 ,53
Mean o f group a 2077±450 2 , 2  3 ± 1 ,1
Mean o f g roup  b 1306±408 2 , 6 1 ± 1 , 4
%A groupi a v e r s u s  b 37 ±16 .7 + 1 7 , 6±1 3 ,4
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Figure 2 .5  : E f f e c t  o f  f r e e z i n g  and thawing on VMU (A) ER and (B) 
PR r e c e p t o r s .
R e p r e s e n t a t i v e  S c a tch ard  p l o t s  o f  the  b i n d i n g  data  
o b t a i n e d  from a ss a y s  on two b a t c h e s  o f  c y t o s o l s ,  
where one ba tc h  (•)  o f  c y t o s o l  was im m ediate ly  a n a l y ­
sed f o r  ER and PR w h i l e  an oth er  (A) was s t o r e d  in  the 
d e e p f r e e z e  a t  -7 0 ° C  p r i o r  to  a n a l y s i s  24 hours l a t e r .
TABLE 2.5
Effect of freezing and thawing of cytosols on binding properties 
of the VMU ER.
Uterus
No Bmax Kd %A between a & b
( fm o l /m g  p r o t e i n ) ( x l 0 _ 1 °M)
1 a 1 079 3,10
17 ,6
1 b 889 3 ,26
2a 570 1,54
+2 ,8
2b 554 1,71
3a 847 3 ,8
+7 ,4
3b 784 2 ,44
5a 471 2 ,32
+ 1 3, 1
5b 409 3 ,19
6a 345 1 , 08
6 , 9
6b 321 1,51
7a 395 1 , 262
4 , 5
7b 377 3 ,02
8a 352 2 ,17
13 ,6
8b 304 2,75
Mean o f  g roup  a 579.9±281 2 . 1 8 1 1 . 0
Mean o f  group  b 5 1 9 . 7 1 2 . 3 3  2 . 5 5 1 0 . 7
% A g r o u p  a v e r s u s  b 1 0 . 4 1 8 . 3 1 7 , 0 1 1 3 . 8
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TABLE 2.6
Effect of freezing and thawing of cytosols on binding properties
of the VML) PR.
Uterus
No Bmax K _ %A between a & b a
( fm ol /m g  p r o t e i n ) -9( x10 M)
1 a 2491 0 ,9
- 5 , 0
2b 2638 2 ,775
3a 1868 1 , 56
+2,8
4b 1 781 4 ,6 3 8
5 a 1 625 1,95
+4 ,3
6b 1 554 3 ,378
5 a 471 2 ,32
+ 13,1
5b 409 3 ,1 9
Mean o f group a 1 6 1 3 . 8 ± 8 4 4 .6 1 .6810 .61
Mean o f g roup  b 1 5 9 5 .5 1 9 1 8 .5 3 . 5 0 1 0 .8 0
% A group  a v e r s u s  b 1 . 1 ±4.5 1 08.311 1 . 3
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F ig u r e  2 . 6  : E f f e c t  o f  f r e e z i n g  and thawing on VMU c y t o s o l s  SDG 
p r o f i l e s  f o r  VMU ER r e c e p t o r s .  C y t o s o l  p r e p a r e d  
from a b a tch  (15 )  o f  u t e r i  was s u b j e c t e d  and the p r o ­
c e s s  f o l l o w e d  by SDG c e n t r i f u g a t i o n  on 10-35% g r a ­
d i e n t s  (520000xg '  f o r  2 h in a VTi-80  r o t o r ) : ( A )  Con 
t r o l  c y t o s o l  was an a ly sed  im m ediate ly  by SDG; (B) Cy 
t o s o l  a n a l y s e d  on 10-35% SDG f o l l o w i n g  one c y c l e  o f  
f r e e z i n g  and thawing (24 h ) ; ( C )  c y t o s o l  a n a ly se d  f o l  
l o w in g  two c y c l e s  o f  f r e e z i n g  and thawing.
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F ig u r e  2 .7  : E f f e c t  o f  d i f f e r e n t  i n c u b a t i o n  c o n d i t i o n s  in  the a s ­
say o f  ER in  c y t o s o l s  p re p ar e d  from VMU. A b a t c h  o f  
o f  c y t o s o l  was p r e p a r e d  and b i n d i n g  a ss ay s  were e x e ­
c u t e d  em ploy in g  s e v e r a l  v a r i a t i o n s  in  i n c u b a t i o n  c o n ­
d i t i o n s  : (A) r e p r e s e n t a t i v e  S c a tc h a r d  p l o t s  o f  b i n ­
d i n g  d ata  o b t a i n e d  w ith  v a r y i n g  i n c u b a t i o n  c o n d i ­
t i o n s :  (a )  0 -4°C x30  min; (b)  0 -4°Cx4 h; ( c )  0 -4°Cx18  
h; (d )  10°Cx30 min; 20°Cx30 min; ( e )  37°Cx30 min; ( f )  
50°Cx30 m in . (B )  tem pera ture  optimum c u r v e  f o r  the  ER.
TABLE 2.7
Effect of different incubation conditions on binding parameters 
for cytosolic ER in VMU.
I n c u b a t i o n  I n c u b a t i o n  Bmax
Temp. (C°)  Time ( fm o l /m g  p r o t e i n )
K.a
(x10 - 1 °M)
0 30 min 586 3 .94
4 4 h 549 2 . 4
4 18 h 545 -
1 0 30 min 548 1 .53
20 30 min 467 0 . 8
37 30 min 539 3 .9
50 30 min ^20
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Figure  2 . 8  : R e c e p t o r - l i g a n d  k i n e t i c s  o f  the VMU ER(A) and PR(B) 
a s s o c i a t i o n .
C y t o s o l  (1 m£) was i n c u b a t e d  with  1 m£ o f  10nM t r i -  
t i a t e d  l i g a n d  ( ’ H-E? o r  J H-R5020 ) in  the p r e s e n c e  or  
abse nce  o f  a 250 f o l d  e x c e s s  o f  the a p p r o p r i a t e  u n l a ­
b e l l e d  c o m p e t i t o r  a t  e i t h e r  0 °C (a ) ,  20 °C ( « )  o r  37°C
( * ) .  Im m edia te ly ,  f o l l o w i n g  the a d d i t i o n  o f  the  r a ­
d i o l i g a n d s ,  a l i q u o t s  (100p£)  o f  the i n c u b a t i o n  mix­
t u r e s  were taken a t  de term in ed  time i n t e r v a l s  and ad­
ded t o  a DCC s u s p e n s io n  (1 mC) a t  0 ° - 4 ° C .  The DCC 
s u s p e n s i o n s  were l e f t  o f  the i c e  f o r  15 min and then 
spun at  2000xg '  f o r  an o th e r  15 min. A l i q u o t s  (500( j£) 
o f  the s u p e r n a t a n t s  were m on i tored  f o r  t o t a l  and non­
s p e c i f i c  b i n d i n g .
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F igu re  2 . 9  : The e f f e c t  o f  the  c y t o s o l i c  p r o t e i n  c o n c e n t r a t i o n  on 
S c a t c h a r d  p l o t s  d e r i v e d  from b i n d i n g  data  o b t a i n e d  on 
the  VMU ER : (A) Binding  a ss a y s  were per formed on c y ­
t o s o l s ,  s e r i a l l y  d i l u t e d  wi th  p l a i n  Tr is -H C l  b u f f e r  
(TEDAG^p): (B) b i n d i n g  a ss a y s  were per form ed on c y t o ­
s o l s  s e r i a l l y  d i l u t e d  wi th  a s o l u t i o n  o f  5mg/m1  b o v i ­
ne serum albumin (BSA) in  TEDAG^ b u f f e r .
80
TABLE 2.8
Effect of the protein concentration of the cytosol on binding 
parameters for ER in VMU
Means o f  
D i l u t i o n
Assay
No
C y t o s o l i c  
p r o t e i n  
C o n c e n t r a t i o n  
( mg/rrue)
T o t a l  p r o t e i n  
C o n c e n t r a t i o n  
(mg/ml )
Bmax
( fm o l /m £ )
Bmax 
( fmol /mg
p r o t e i n )
Kd
(xIO f °M)
1 4 . 9 4 . 9 980 200 2 .9 0
D i l u t i o n 2 3 . 9 3 . 9 775 1 99 2 .87
wi th 3 2 . 4 2 . 4 483 201 2 .9 6
b u f f e r 4 1 .1 1 .1 225 205 3 .00
5 0 . 6 0 . 6 1 1 5 192 3 .07
D i l u t i o n 6 4 . 9 4 . 9 990 200 2 .83
wi th 7 3 . 9 4 . 9 775 158 3.1 0
'V5mg/nu2 8 2 .4 4 . 9 477 97 3 .1 8
BSA in 9 1 . 1 4 . 9 285 58 4 . 3 8
buf  f e r 1 0 0 . 6 4 . 9 260 53 8 .6 7
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Figure  2 . 1 0 :  E f f e c t  o f  d i f f e r e n t  u n l a b e l l e d  c o m p e t i t o r s  employed 
in  the  assessm en t  o f  n o n - s p e c i f i c  b i n d i n g  on the 
g u a n t i t a t i v e  ass a y  o f  VMU ER. •
A l i q o u t s  (1 00pij2 ) o f  c y t o s o l  were i n c u b a t e d  w ith  100pf 
o f  5 H-E2  a t  5 d i f f e r e n t  c o n c e n t r a t i o n s  (0.25-8mM) f o r  
30 min a t  20°C.  N o n - s p e c i f i c  b i n d i n g  was assayed  wi th  
3 H - l i g a n d  s o l u t i o n s  c o n t a i n i n g  100 f o l d  e x c e s s  o f  
e i t h e r  u n l a b e l l e d  E2 , ( • ) ,  EE2  (■)  o r  DES (A) .  The
r e a c t i o n  was t e r m in a te d  with  the  a d d i t i o n  o f  500p5 
DCC. A f t e r  c e n t r i f u g a t i o n  a t  2000xg '  f o r  15 min, 
a l i q u o t s  (500pS)  o f  the  su p e r n a t a n t s  were assay e d  f o r  
t o t a l  and n o n - s p e c i f i c  b i n d i n g .
F ig u r e  2 . 1 1 :  E f f e c t  o f  d i f f e r e n t  e x c e s s  l e v e l s  o f  u n l a b e l l e d  com­
p e t i t o r s  on S c a tc h a r d  p l o t s  and s a t u r a t i o n  c u r v e s  d e ­
r i v e d  from t i t r a t i o n  a n a l y s i s  data  f o r  the c y t o s o l i c  
VMU ER em ploy ing  Ej as u n l a b e l l e d  c o m p e t i t o r s .
A range  o f  3 H-E2 c o n c e n t r a t i o n  c o n t a i n i n g  d i f f e r e n t  
e x c e s s  l e v e l s (  1 0 1 , 1 , 1 0, 1 02 , 1 03 t i m es )  o f  E2 r e ­
l a t i v e  t o  the  r a d i o l i g a n d  c o n c e n t r a t i o n s  was prep a ­
r e d .  M u l t i p o i n t  c o m p e t i t i v e  p r o t e i n  b i n d i n g  assay  was 
per form ed  on the  c y t o s o l s ,  em ploy ing  the d i f f e r e n t  
n o n - s p e c i f i c  b i n d i n g  r e a g e n t s  p r e p a r e d .
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Figure  2 . 1 2 :  E f f e c t  o f  d i f f e r e n t  e x c e s s  l e v e l s  o f  u n l a b e l l e d  com­
p e t i t o r s  on S c a t c h a r d  p l o t s  and s a t u r a t i o n  c u r v e s  d e ­
r i v e d  from t i t r a t i o n  a n a l y s i s  d ata  f o r  the  c y t o s o l i c  
VMU ER em ploy in g  EEj as u n l a b e l l e d  c o m p e t i t o r s .
A ran g e  o f  3 H-E2 c o n c e n t r a t i o n  c o n t a i n i n g  d i f f e r e n t  
e x c e s s  l e v e l s (  1 0 l , 1 , 1 0, 1 02 , 1 05 t imes)  o f  EEj r e ­
l a t i v e  t o  the  r a d i o l i g a n d  c o n c e n t r a t i o n s  was p r e p a ­
r e d .  M u l t i p o i n t  c o m p e t i t i v e  p r o t e i n  b i n d i n g  ass a y  was 
pe r fo r m e d  on the  c y t o s o l s ,  employ ing  the d i f f e r e n t  
n o n - s p e c i f i c  b i n d i n g  r e a g e n t s  p r e p are d .
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F ig u r e  2 . 1 3 :  E f f e c t  o f  d i f f e r e n t  e x c e s s  l e v e l s  o f  u n l a b e l l e d  com­
p e t i t o r s  on S c a t c h a r d  p l o t s  and s a t u r a t i o n  c u r v e s  d e ­
r i v e d  from t i t r a t i o n  a n a l y s i s  d ata  f o r  the c y t o s o l i c  
VMU ER em ploy ing  DES as u n l a b e l l e d  c o m p e t i t o r s .
A range  o f  3 H-E2 c o n c e n t r a t i o n  c o n t a i n i n g  d i f f e r e n t  
e x c e s s  l e v e l s (  1 0 1 , 1 , 1 0, 1 02 , 1 03 t im es)  o f  DES r e ­
l a t i v e  t o  the  r a d i o l i g a n d  c o n c e n t r a t i o n s  was p r e p a ­
r e d .  M u l t i p o i n t  c o m p e t i t i v e  p r o t e i n  b i n d i n g  assay  was 
pe r fo rm e d  on the c y t o s o l s ,  em ploy ing  the d i f f e r e n t  
n o n - s p e c i f i c  b i n d i n g  r e a g e n t s  p re p are d .
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TABLE 2.9
Effect of different excess levels of unlabelled competitors 
on Bmax (fmol/mg protein) and (x10- ’"M) for ER in VMU
cytosols.
Excess  l e v e l U n l a b e l l e d c o m p e t i t o r
(10X)
E2 ee2 DES
Bmax Kd Bmax Kd Bmax Kd
x = -1 1 22 9.1 8 1 99 9.  76 1 06 1 .7
x = 0 1 29 8 .5 1 33 1 . 09 1 05 6 .4 2
X  = 1 152 6 .4 149 7 .0 9 1 34 7.70
x = 2 1 70 4 . 5 1 71 4 .7 6 149 4 . 1 8
x = 3 1 75 4 . 1 9 1 77 4 .2 5 163 4.1 9
8 6
Figure  2 . 1 4 :  E f f e c t  o f  p a r t i a l  t r y p s i n i z a t i o n  o f  VMU c y t o s o l  on 
the  t i t r a t i o n  a n a l y s i s  o f  ER.
A l i q u o t s  o f  c y t o s o l ,  (100p£)  p re p ar e d  from a small  
p o o l  o f  3 -4  u t e r i ,  was i n c u b a t e d  w i th  3 H-Ez (0 .2 -8nM) 
f o r  30 min a t  20°C i n  the ab s e n c e  ( t o t a l  b i n d i n g )  o r  
p r e s e n c e  ( n o n - s p e c i f i c  b i n d i n g )  o f  a 100 f o l d  e x c e s s  
DES. F o l l o w i n g  i n c u b a t i o n  the tu bes were put on i c e ,  
500 p SL o f  a t r y p s i n  s o l u t i o n  added (1 mg/m£) t o  the 
i n c u b a t i o n  m ix tu re  and the r e a c t i o n  m ix tu r e  r e i n c u b a ­
ted  f o r  30 min a t  10°C t o  e f f e c t  p a r t i a l  p r o t e o l y s i s .  
This  r e a c t i o n  was s t o p p e d  by the a d d i t i o n  o f  soybean  
t r y p s i n  i n h i b i t o r  (2 mg/m£) , f o l l o w e d  by DCC (500p£)  
and the  2000xg '  s u p e r n a t a n t  m o n i to r e d  f o r  t o t a l  and 
n o n - s p e c i f i c  b i n d i n g .  A s e t  o f  c o n t r o l s  was run on 
the same c y t o s o l ,  e x c l u d i n g  the p o s t - i n c u b a t i o n  t r y p -  
s i n i z i t i o n .
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F igu re  2 . 1 5 :  E f f e c t  o f  p a r t i a l  t r y p s i n i z a t i o n  o f  VMH c y t o s o l s  on 
SDG p r o f i l e s .
A l i q u o t s  o f  c y t o s o l  ( 1 0 0 p £ ) ,  p r e p a r e d  from a p o o l  (15 
u t e r i )  o f  v e r v e t  monkey u t e r i  were i n c u b a t e d  (20°Cx30 
min) w ith  3 H-E2  ( f i n a l  c o n c e n t r a t i o n ,  5nM) in  the  ab ­
se n c e  ( t o t a l  b i n d i n g )  o r  p r e s e n c e  ( n o n - s p e c i f i c  b i n ­
d i n g )  o f  a 250 f o l d  e x c e s s  o f  DES. F o l l o w i n g  the t e r ­
m in a t i o n  o f  i n c u b a t i o n  the  tu bes  were a l l  t r a n s f e r r e d  
t o  i c e ,  500pj? t r y p s i n  (1mg/mf c y t o s o l  in  TEDAG  ^  ^ b u f ­
f e r )  added and r e i n c u b a t e d  a t  10°C f o r  30 min. Tryp­
s i n i z a t i o n  was t e rm in ate d  by  the  a d d i t i o n  o f  100pf 
soybean  t r y p s i n  i n h i b i t o r  (2 mg/m£ b u f f e r )  and the 
r e a c t i o n  m ix t u r e  then t r a n s f e r r e d  t o  tu bes c o n t a i n i n g  
DCC p e l l e t s .  The 2000xg '  s u p e r n a t a n t s  ( 2 0 0 p f )  were 
l a y e r e d  o n t o  10-35  % s u c r o s e  d e n s i t y  g r a d i e n t s ,  sub­
j e c t e d  t o  u l t r a - c e n t r i f u g a t i o n  (VTi -80  r o t o r , 520000 
x g ' x 1 2 0  min) and then f r a c t i o n a t e d  i n t o  40 f i v e  d r o p  
f r a c t i o n s .  The f r a c t i o n s  were m o n i to r e d  f o r  t o t a l  and 
n o n - s p e c i f i c  b i n d i n g  f o l l o w i n g  the a d d i t i o n  o f  s c i n ­
t i l l a t i o n  c o c k t a i l  (2  m£) and c o u n t i n g  in  a Beckman 
LS 5800 c o u n t e r  (2 5 -3 0  % e f f i c i e n c y ) .  In a c o n t r o l  
e x p e r im e n t ,  SDG p r o f i l e s  o f  n o n - t r y p s i n i z e d  c y t o s o l s  
were o b t a i n e d  in  the same way as d e s c r i b e d  abov e .
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TABLE 2.10
Effect of partial trypsinization on ligand binding capacity
(B ) and affinity (K.) of VMU ER . max J d
Assay T r y p s i n i z a t i o n  B K,max p
No ( fm o l /m g  p r o t e i n )  (xIO M)
T
2
3
+
+
138 2 .7 5  
133 2 .75  
125 2.91 
1 304 2 .6 5
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Figure  2 . 1 6 :  L i n e a r i t y  o f  c o n t i n u o u s  10 -35  % s u c r o s e  d e n s i t y  g r a ­
d i e n t s  (SDG) as m o n i t o r e d  by  r e f r a c t o m e t r y .
G r a d i e n t s  were p r e p a r e d  by the  hand l a y e r i n g  o f  1 .15  
each  o f  f o u r  d i f f e r e n t  c o n c e n t r a t i o n s  (10 % 18.3%, 
2 6 .7  % 35 %) o f  s u c r o s e  in  TEDAG  ^ b u f f e r ,  r a n g in g
from 10 t o  35 %. A minimum o f  2 h or  c o n d i t i o n i n g  a t  
room te m pe ra t ure  was r e g u i r e d  t o  c r e a t e  c o n t i n u o u s  
l i n e a r  g r a d i e n t s .  G r a d ie n t s  were then manually  f r a c ­
t i o n a t e d  i n t o  40,  f i v e  d r o p  f r a c t i o n s  and the  s u c r o s e  
c o n c e n t r a t i o n  m o n i t o r e d  in  a r e f r a c t o m e t e r  (Atago,  
J a p a n ) .
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F i g u r e  2 . 1 7 :  C a l i b r a t i o n  o f  s u c r o s e  d e n s i t y  g r a d i e n t s .
G r a d ie n t s  were p r e p a r e d  by t h e  hand l a y e r i n g  o f  f o u r  
d i f f e r e n t  c o n c e n t r a t i o n s  o f  s u c r o s e  (10 %, 18 .3  %, 
2 6 .7  % and 35 %) i n  TEDAG  ^ b u f f e r .  A f t e r  c o n d i t i o n ­
i n g  a t  room te m p e r a t u r e  f o r  2 h, 2 0 0 ■' samples o f  4 
d i f f e r e n t  s t a n d a r d  s o l u t i o n s  o f  1 mg/mf were l a y e r e d ,  
each  o f  them on a s e p a r a t e  g r a d i e n t .  The p r o t e i n s  
employed were m y o g lo b in  ( 2 . 0 4  S ) ,  ovalbumin ( 3 . 5  S ) ,
b o v i n e  serum albumin ( 4 . 6  S) and a l d o l a s e  ( 7 . 3 5  S ) . 
and c a t a l a s e  ( 7 . 5 - 7 . 8  S ) . C e n t r i f u g a t i o n  was e x e c u t e d  
as d e s c r i b e d  i n  the  l e g e n d s  o f  F i g .  2 .15  and 2 .1 6  
abov e .  F o l l o w i n g  the  c o m p l e t i o n  o f  c e n t r i f u g a t i o n  
(52 0 0 0 0 x g 'x 2  h ) ,  the  g r a d i e n t s  o f  the  s tan d ar d  p r o ­
t e i n s  were f r a c t i o n a t e d  i n t o  40,  f i v e  drop  f r a c t i o n s .  
A sm al l  volume o f  d i s t i l l e d  w ater  ( 200pjg) was added 
t o  each f r a c t i o n  and the  a b s o r b a n c e  a t  280 nm d e t e r ­
mined in  a s p e c t r o p h o t o m e t e r  (Beckman Model 3 5 ) .
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T a b le  2 . 1 8 : Comparison o f  t y p i c a l  SDG p r o f i l e s  o b t a i n e d  f o l l o w i n g  
d i f f e r e n t  c e n t r i f u g a t i o n  c o n d i t i o n s .  C y t o s o l s  were i n ­
c u b a t e d  a t  2 0 °C f o r  30 min and DCC t r e a t e d  a l i q u o t s  
( 2 0 0 p f )  l a y e r e d  on t o p  o f  10-35  % l i n e a r  SDG. C e n t r i ­
f u g a t i o n  was e x e c u t e d ,  em ploy in g  the f o l l o w i n g  c o n d i ­
t i o n s  : (A) SW 50.1 r o t o r  a t  45000 rpm f o r  16 h, (B)
SW 65 r o t o r  60000 rpm f o r  16 h, (C) VTi 80 r o t o r  a t  
75000 rpm f o r  3 h and (D) VTi 80 r o t o r  a t  80000 rpm 
f o r  2 h.
TABLE 2.11
Comparison of various conditions of ultracentrifugation for 
the qualitative analysis of VMU ER and PR on continuous su­
crose density gradients.
Type
R otor
Speed
RPMxg
D urati on  o f  
c e n t r i f u g a t i o n
D u rat io n  o f  
i n c u b a t i o n
I n c u b a t i o n
Temp.
1 . SW 50.1 45000 16 h 4 h 0 ° - 4 ° C
2 . SW.65 60000 16 h 4 h 0 ° - 4 ” C
3 . VTi80 65000 16 h 30 min 20 °C
4 . VTi80 65000 20 h 30 min 20 °C
5 . VTi80 75000 3 h 30 min 20 °C
6 . VTi80 80000 2 h 30 min 20 °C
93
TABLE 2.12
Calibration of 10-35 % continuous linear sucrose density 
gradients using unlabelled standard proteins.
PROTEIN MW
( d a l t o n s )
S-VALUE 
( S v e d b e rg s )
FRACTION NO
Myog lob in 17800 2 .0 4 9
Ovalbumin 43000 3 .55 14
Albumin 67500 4 . 6 18
A l d o l a s e 158000 7 .35 26
C a t a l a s e 232000 7 . 5  -  7 . 8 28
T h y r o g l o b u l i n  669000 1 9 .2 Bottom
CHAPTER 3.
MOLECULAR PROPERTIES OF THE VMU ER AND PR AND THE EFFECT OF 
SODIUM MOLYBDATE ON THE PROPERTIES OF THESE MACROMOLECULES.
HETEROGENEITY OF STEROID HORMONE RECEPTORS AND THE SODIUM 
MOLYBDATE EFFECT.
The oestrogen receptor from different tissues exhibits a 
complex variety of molecular forms depending on the mole­
cular environment (in vitro or in vivo) like the presence or 
absence of structural modifiers, and the type of isolation 
or separation methodology employed (212).
Human breast cancer cells were found to contain, in addition 
to the 8 S and 4 S forms, (discussed before in Chapter I), a 
high molecular weight species (9-10 S), a 2-3 S form
meroreceptor, as well as some other intermediate forms 
(223-214). Some of these have been demonstrated to have some 
functional significance: e.g. a 5.5 S species appears to 
interact with the nucleus (215). Bovine uterine oestrogen 
receptors, which is perhaps the best documented system, 
exhibit the greatest variety of molecular forms. Murayama's 
laboratory reported the presence of 2.9 S, 4 S, 5 S, 6 S, 
7 S and 8 S forms (216). The activation of uterine oestro­
gen receptors as investigated by Milgrom etaj_ (217) and by 
Notides et aj_ (63) led to a ^ 4 S - 5 S conformational shift 
demonstrating a distinct polymorphism. Milgrom demonstra­
ted that in the rat uterus, activation involved a conversion 
of the 4 S form to an altered 4 S form followed by the asso­
ciation of this altered 4 S with another moiety (itself, 
another form of itself, or a different macromolecule) to 
yield a 5 S form (218). Notides concluded that the activated 
5 S species is a homodimer (63). The multi piicity of 
receptor forms detected, so far, has led to the active 
pursuit of their origin and interrelationships. There are a 
number of mechanisms which could explain this diversity.
Puca et al (219) were the first to demonstrate a Ca+2-acti- 
vated factor in calf uterine cytosol, capable of transform­
ing a larger receptor moiety (8.6 S to 5.3 S), to a smaller 
species (4.5 S). This receptor transforming factor (RTF), 
exhibited protease activity, (not trypsin) and could not be 
inhibited by diisopropylfluorophosphate (DFP) or phenylme- 
thylsulfonyl fluoride (PMSF) (219). The protease activity 
was caseinolytic while N-benzoylarginine methyl ester seemed 
to inhibit RTF activity, N-benzoyltyrosinamide and L-leucyl- 
glycylglycine did not (216). Puca et a_1_ suggested that the 
RTF might be essential for nuclear translocation of the 
receptor (216).
Sherman et aj_ (220) investigated the Ca+2-activated, leupep- 
tin -sensitive, protease activity, capable of converting the 
large cytosolic receptor species (8.6-9.2 S) to the "mero- 
receptor". This would imply that receptor heterogeneity, as 
detected, could be the result of controlled or uncontrolled 
protease action during incubation, centrifugation or gel 
filtration. Murayama et aj_ (216) and Puca et al (218-219) 
also suggested a possibility of multiple 4 S species arising 
by protease action. They reported that the 4.5 S oestrogen 
receptor exists as two different forms, both sedimenting at
4.5 S, but differing in molecular weight (MW = 82,000 or 
65,000 daltons) and stokes radius (44 A and 35 A). Notides 
et al (244) was concerned about the possibility that multi­
ple proteases may act on the receptor. He reported that the 
general proteolytic activity of human, calf and rat uterine 
cytosol can vary considerably. Using the protease inhibitors 
DEP, EDTA and p-chloromercuribenzoate and hemoglobin as 
substrate, he determined that the proteases from the three 
tissues exhibited different biochemical properties. It would 
seem that the molecular heterogeneity of the receptors could 
be the result of the cell's own capacity to synthesize and 
modify the oestrogen receptor in controlled fashion.
Wittliff et al (212, 221-222) observed that patients bearing
tumours exhibiting predominantly the 4 5 form of the recep­
tor were less likely to respond to hormonal therapy, whereas 
those with tumours containing the 8 S or a combination of 4 
S and 8 S forms were more likely to give an objective 
response. They proposed that the "basic" subunits were hete­
rogeneous; that is that there were at least two different 
types of the 4 S receptor. This heterogeneity could arise in 
any of several ways: differences in either primary sequence 
of the protein, conformational changes, covalent or non­
covalent modifications of protein structures. The multiple 
isoforms could combine as homodimers or heterodimers to give 
rise to the "activated" or 5.5 S moiety. The 8 S form could 
represent a tetramer consisting of various combinations of 
heterogeneous 4 S subunits. The 5DG profiles of tumours with 
ER, exhibiting both 8 S and 4 S forms, may represent cases 
where there was an overproduction of one of the two 4 S 
species.
A number of exogeneous modifiers of receptor structure and 
function been studied recently (223-233). Sodium molybdate 
has been used in relatively low concentrations (5-20 mM) by 
many workers to "stabilize" the various steroid hormone 
receptors against inactivation and degradation (223-224). 
Molybdate was also found to prevent receptor "activation" 
(225-227). It has been suggested that the mechanism of 
action could involve : the inhibition of phosphatases 
(228-230) (implicating a phosphorylation-dephosphorylation 
mechanism), inhibition of proteases (151) or RNase activity 
(151) or by the direct interaction with the receptor protein 
(231,2 2 5).
Some of the most important effects of the molybdate anion, 
reported in theliterature seem to be rendering higher yields 
of receptors obtained in cytosols, prepared in the presence 
of sodium molybdate (232).Although a host of evidence would 
ascribe the effect of sodium molybdate to its possible 
inhibitive action on either proteases or phosphatases, the
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real physicochemical role of this compound remains unsolved. 
Some researchers claim the effect of molybdate to be 
completely reversible (230, 151).
In the light of the uncertainty as to what the molecular 
mechanism of the molybdate effect was, it was decided to 
investigate the effect of sodium molybdate on the molecular 
properties of the VMU ER and PR.
Chromatography has played a prominent role in the develop­
ment of biochemistry. The introduction of paper, thin-layer, 
gas, gel permeation, ion exchange and affinity chromato­
graphy into biochemical research enabled researchers to gain 
a lot of structural information on macromolecules like 
proteins and nucleic acids.
The rapid chromatographic separation of proteins require 
that mobile phases be forced through microparticulate 
columns under pressure. This requires mechanical stability 
at high mobile phase velocities which cannot be achieved 
with most classical gel type and resin like polymer support 
materials. Suitable column packing materials for HPLC 
columns must be semirigid to rigid. Additionally, the 
material must be macroporous to allow sufficient molecular 
penetration for molecular permeation and interaction with 
stationary phase functional groups and have adequate surface 
area to enable relatively high loading capacity in the case 
of ion exchange, reverse phase and affinity chromatography 
columns.
Theoretically, gel permeation chromatography (GPC) is the 
simplest and most predictable chromatographic method. 
Solutes are separated by size with the large excluded 
molecules eluting first and the small totally included 
molecules eluting last. In practice, however, many 
extraneous mechanisms such as adsorptive, hydropholic, and 
ionic effects may affect the retention of a solute. Since
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the physical and chemical properties of proteins vary so 
widely, it is inevitable that some will interact with any 
given support.
Isoelectric focussing differs from all the other separation 
methods in that it is an equilibrium method. A pH gradient 
is set up in the separation channel, and solutes migrate 
from any initial position in the channel to form a sharp 
Gausian zone at a pH corresponding to their isoelectric (or 
more strictly isoionic point) pi. Equilibrium methods 
possess two important advantages over the more usual kinetic 
methods. In the first place, after equilibrium has been 
attained, the process is time-independent, so that the zone 
definition does not deteriorate with the further passage of 
time. Secondly, since solutes migrate from all positions in 
the channel towards the final equilibrium position, no 
definite starting zone is required, and the initial solute 
mixture may indeed occupy the entire volume of the 
separation channel.The only notable disadvantage of the iso­
electric focussing method arises from the concentration of 
the solutes in very sharp zones. Under these conditions the 
solubilities of the solutes may be exceeded locally, and 
precipitation may occur, particularly as most ampholytes are 
least soluble in aqueous media near their isoelectric 
points.
There are five methods of separation using isoelectric 
focussing:
a) Free solution
b) Density gradients
c) Gels
d) Porous materials
e) Continuous flow methods
The potential advantages of agarose have prompted resear­
chers to investigate it as a medium for IEF. The gels are
easy to prepare, 
poses and it is 
relatively large 
focussing of large
it is optically clear for scanning pur- 
chemically inert. Also agarose has a 
pore size, making it suitable for the 
molecules.
The separation in ion exchange chromatography (anion or 
cation exchanges) is obtained by reversible adsorbion of 
ionic species onto an inert matrix (e.g. cellulose), 
containing defined covalently linked functional groups like 
-0CH2 CH2 N(C2 H5 )2 (diethylaminoethyl, DEAE) or -0CH2C00” 
(carboxymethyl,CM)-. Separation of macromolecules (proteins) 
is obtained on the basis of differences existing in the net 
ionic charge which affects the overall pKa values of the 
different protein molecules. Elution from the column can be 
effected by a variation in either the concentration of a 
competing ion (ionic strength) or the pH of the mobile 
phase. The differences in charge properties of biological 
compounds are considerable. Ion exchange chromatography is 
a powerful technique enabling researchers in separating 
macromolecular species with only minor differences in ionic 
properties (e.g. proteins differing by only one amino acid).
Recently, Pharmacia introduced the chromatofocussing tech­
nique for the separation of proteins based on differences in 
iso-electric points (pi). A pH-gradient is created over an 
anion exchange column with the aid of polybuffers, contain­
ing ampholytes within a particular pH-range. Proteins are 
then eluted in order of high to low pi values from the 
column, allowing separations within 0.01 pH unit. This 
principle was also recently introduced in HPLC (309).
MATERIALS AND METHODS
Reagents
Most of the reagents employed were the same as those descri­
bed in Chapter 2 (section 2.7.1). Other reagents used in
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the course of this investigation were:
16a- Q 2S I] Iodooestradiol (12S I-E2 ; specific activity > 1500 
Ci/mmol) was bought from Amersham International. The Blue 
Dextran 2000 was bought from Pharmacia. The polybuffers (96 
and 74) were bought from Pharmacia.
The following compounds were all purchased from Sigma 
Chemical Company : N-ethylmaleimide ('NEM), iodoacetic acid 
(IAA), 0-Phenanthroline (O-Phen), dithionitrobenzene (DTNB), 
leupeptin (Leu), phenylmethylsulfonyl fluoride (PMSF) and 
N-a-p-tosyl-L-chloromethylketone (TLCK).
Ultrogel AcA-22 gel was supplied by LKB. Other columns, 
employed in this investigation were the Waters 1-250 
(Mi 11ipore), as well as the AX-1000 and AX-500 (Synchropak).
The most important materials used in isoelectric focussing 
are the carrier ampholytes which provide the stable pH 
gradient. At the present time the synthetic materials 
supplied by LKB products under the trade name of Ampholines 
are quite satisfactory.
LKB Ampholines are currently available as one wide-range pH 
3-10 (LKB 8141), three medium-range, pH 3-6, 5-8 and 7-10 
(LKB 8142-8144) and six narrow-range grades. The later cover 
only 2 pH units and include the regions 3-5, 4-6, 5-7, 6-8, 
7-9 and 8-10.
3..2.2 Collection of Vervet monkey uteri (VMU) and preparation of 
cytosols:
Collection and storage of uteri have been described in 
detail in Section 2.9. Preparation of cytosols from either 
tissue slices, or tissue powders have been outlined in 
Section 2,10. All preparations were executed in the cold 
(0-4°C) unless stated otherwise.
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3.2.3 Binding capacity (B_ ) and dissociation constants (K.) of-------------------- m d x—------------------------------ vi----
ER and PR in VMU: Molybdate effect.
(a) Oestrogen receptors assay:
Aliquots (100u-2) of cytosol (CYT( + ) and CYT(—)) were tho­
roughly mixed and then incubated with 100ujZ of |3H|-oestra- 
diol at 5 different concentrations (0.25-8nM) for 30 min at 
20°C. Non-specific binding was assayed in parallel with 100 
fold excess of unlabeled DES. The reaction was terminated 
with the addition of 500pt DCC. The suspension was vortexed, 
left on ice for 15 min. Aliquots (500 p£) of the super­
natants were assayed for radioactivity following the addi­
tion of 4 ml scintillation cocktail.
(b) Progesterone receptor assay:
The assays were carried out simultaneously with the ER assay 
on aliquots of the same cytosols. Standard conditions used 
were the following: Cytosols (CYT(+) and CYT(—)) were incu­
bated on crushed ice for 2 h, following the addition of 
100pje of the radioligand. After the first 2 h, 1 0 0 of 
TEDAGgQ was added to the incubation mixture and thorough 
vortexing was followed by a reincubation in crushed ice for 
another 2 h. The reaction was stopped by the addition of DCC 
(500pJ2), the reaction mixture vortexed and then pelleted at 
2000xg for 15 min (0-4°C) and the supernatants monitored for 
radioactivity.
3.2.4 Effect of sodium molybdate on the association of VMU ER and 
PR with their respective ligands and the stability of the 
receptor-1igand complexes at 0°C, 20°C and 37°C:
Cytosols (CYT(+) and CYT(-)) were incubated with tritiated 
ligand ( H]-E2 or [3H]-R-5020 to a final concentration of 
5 nM, with and without a 250 fold excess level of the appro­
priate unlabelled competitor (DES or R5020) at either 0°C,
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20°C or 37°C. Immediately, following the addition of the 
radioligands, aliquots (100) of the incubation mixtures 
were taken at regular time intervals (2 min intervals for 
the first 10 min; 10 min intervals for the next 60 min and 
30 min intervals for up to 3 h) and added to a DCC suspen­
sion (1 ituZ) on ice. Following thorough vortexing, the DCC 
suspensions were left on the ice for 15 min after which they 
were centrifuged at 2000 xg1 for another 15 min. Aliquots 
(500 p£) of the supernatants were monitored for radioacti­
vity following the addition of 4 ml cocktail to the sample. 
Vials were counted in a Beckman LS 900 counter to an effi­
ciency of 25-30 %.
3.2.5 Ligand specificity of VMU ER and PR :
Aliquots (100p^} of freshly prepared uterine cytosols were 
incubated with 50pi of either labelled oestradiol or pro­
gesterone (8nM) in the presence of 50p^ of increasing con­
centrations (0.169nM-2.6p.f1) of a group of competitors (E2, 
E3 , Ev  EE2, DES, P, R 5020, NE, T, DHT, DHEA, HC) for 30 
min at 20°C. Reactions were terminated by the addition of 
cold DCC (500p£) and subsequent incubation on ice for 10 
min. Charcoal was pelleted by centrifugation (2000xg' x 15 
min) and aliquots (500 pJZ) of the resulting supernatants 
counted for radio-activity.
3.2.6 Effect of sodium molybdate on the dissociation of VMU ER and 
PR.
Cytosols (CYT(+) and CYT(—)) were equilibrated with 5nM 
[3H] oestradiol or [3H]R-5020 for 1 h at 0°C.
The [^H]-oestradiol and ["'H] R-5020 dissociation were assay­
ed at 20°C after the addition of 5nM (1000 fold excess) of 
unlabelled oestradiol. Receptors inactivation (control) was 
measured in a parallel incubation with the addition of 
buffer without the unlabelled oestradiol or promogestone.
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After time intervals at 20°C (1 min at the first 15 min and 
15-30 min for 130 min) 100p£ aliquots were vortexed with DCC 
solution (1 mj?) at 0°C and radioactivity was counted of 
500 m-2 of the 2000xg'x10 min supernatant. Each determination 
has been corrected for non-specific binding.
3.2.7 Reversibility of the effect of sodium molybdate on the VMU *10
ER and PR.
a. Cytosols (CYT(-) and CYT(+) were incubated at 20°C for 30 
min with either 3 H-E2 or 3H-R5020 (final ligand concentra­
tion of 5nM). Parallel incubation mixtures also contained a
100 fold excess of either DES or R5020 respectively. Incu­
bations were terminated by transfer of the incubation mix­
tures to DCC pel lets,vortexing and subsequent centrifugation 
at 2000xg' (15 min x 4°C). The resulting supernatants 
(200pl!) were then layered onto the sucrose density gra­
dients, prepared in Quickseal tubes (Beckman Instruments) by 
handlayering 4 different concentrations (10 %, 18.3 %, 26.7 
% and 35 %) of sucrose in TEDAG^ or TEDAG-M0 buffers. Prior 
to layering of the samples the gradients were left to con­
dition at room temperature for at least 2 h in order to ob­
tain continuous 10 - 35 % gradients. Centrifugation was then 
executed, employing the VTi-80 rotor in a Beckman L8-80 
ultra-centrifuge for 2 h at a maximum gravitational force of 
520000xg' (2°C) to a constant aft of 5.3 x 10".
Gradients were prepared, calibrated and processed as de­
scribed in section 2.13. Altogether four different combi­
nations of runs were executed : cytosols containing molyb­
date (CYT(+))) were either run on gradients containing 
(GRAD(+)) or not containing (GRAD(-)) molybdate and the same 
for cytosols not containing (CYT(-)) molybdate. Under the 
influence of the gravitational force the receptor molecules 
are being displaced from an environment containing molybdate 
to one not containing molybdate and vice versa. Therefor
this technique is excellent in studying the reversibility of
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the "molybdate effect".
(b) Dialysis studies monitored by SPG:
CYT(-) and CYT( + ) cytosols (2 ml!) were dialysed in cellulose 
bags against either TEDAG^g or TEUAG-MO buffer (500 mi) over 
a period of 4 h with a total of 4 buffer exchanges. Aliquots 
of the cytosols were taken before and after dialysis and 
then charged by incubating with the radio ligands (3H-E2 or 
3 H-R5020; 5nM) at 20°C for 30 min with or without an excess 
(250 fold) of either DES or R 5020 respectively. Following 
the incubation, unbound ligands were adsorbed on a DCC 
pellet and 200pl! of the resulting supernatants layered onto 
sucrose density gradients, prepared and calibrated as de­
scribed above. Aliquots (100pl!) of the supernatants were 
also assayed for radioactivity in order to calculate the 
specific binding for the different steps in the experiment. 
Gradient centrifugation was performed and the individual 
gradients processed as described in (a). The gradients were 
selected to have the same constitution irrelevant to molyb­
date content as that of the buffer against which dialysis 
was performed.
3_2.8 Influence of proteolytic inhibitors and thiol reactive 
agents on VMU ER and PR.
(a) Influence of Phenylmethylsulfonylfluoride (PMSF; Sigma):
Uteri were cut into thin slices and the slices thoroughly 
mixed, prior to homogenization. Aliquots (^00-500 mg) of 
uterine tissue then homogenized in TEDAG^ or TEDAG-M0 
buffers containing 1mM PMSF in order to "neutralize" the 
effect of proteolytic enzymes in the changes in the gradient 
profiles. Subsequent to incubation with the appropriate 
ligands (3H-E2 or 3H-R5020; 5nM) the charged cytosols were 
processed as described in section (a) of the previous 
experiment.
In another set of experiments aliquots of the tissue slices 
were homogenized in TEDAG^ buffer, containing 5mM of the 
PMSF. The 105000xg' cytosols were then incubated with the 
ligands (3 H-E2 or 3H-R5020, 8nM) in the absence (total 
binding) or presence (non-specific binding) of a 250 fold 
excess of either DES or R5020 respectively. Following DCC 
treatment, the 2000xg' supernatants were monitored for 
specific binding (single point saturation assay) and then 
subjected to SDG and IEF analysis (sections 2.13 and 
3.2.10).
(b) Influence of leupeptin (Sigma):
The experiments were performed exactly as described for the 
PMSF, except that homogenization buffers contained 2mM 
leupeptin.
(c) Effect of N-ethylmaleimide (NEM) on VMU ER and PR.
Vervet monkey uteri were sliced up and the thin tissue 
slices thoroughly mixed before portions of the batch (^00 
mg) were homogenised in a small volume (1.5 m£) of TEDAG,^ 
buffer containing the inhibitor at a specific concentration. 
The NEM was used in the buffer at a final concentration 
of 5mM. Cytosolic protein concentration was determined by 
the method of Lowry (240).
A single point saturation assay was conducted (8nM final 
concentration of 3H-E2 o r 3H-R5020) on the 105000xg1 cyto­
sol for both ER and PR, to assay total and non-specific 
binding in the presence or absence of the inhibitor. 
Ligand-charged, DCC treated, 2000xg' cytosolic supernatants 
were subjected to SDG and IEF analysis as described in 
Sections 2.13 and 3.2.10.
(d) Effect of iodoacetic acid (IAA) on VMU ER and PR:
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Experiments were executed exactly as described in Section
»
3.2.8.(c) above, except that the inhibitor IAA (20mM) was 
included in the homogenization buffer.
(e) Effect of O-phenanthroline (O-Phen) on VMU ER and PR :
Experiments were executed exactly as described in Section 
3.2.8(c) above, except that the inhibitor O-Phen (10mM) was 
included in the homogenization buffer.
(f) Effect of dithionitrobenzene (DTNB) on VMU ER and PR :
Experiments were executed exactly as described in Section 
3.2.8(c) above, except that the inhibitor DTNB (10mM) was 
included in the homogenization buffer.
(g) Effect of N-g-p-tosyl-L-lysine-chloromethylketone (TLCK) 
on VMU ER and PR :
Experiments were executed exactly as described in Section 
3.2.8(c) above, except that the inhibitor TLCK (5mM) was 
included in the homogenization buffer.
3.2.9 Chromatography of VMU ER and PR on size exclusion, ion 
exchange and chromatofocussing columns
3.2.9.1 Size exclusion chromotography of the VMU ER:
It was decided to investigate the effect of molybdate on 
receptor heterogeneity with the aid of gel permeation 
columns:
(a) Size exclusion chromatography on a Ultrogel AcA-22 
polyacrylamide gel :
All experiments were run in parallel on "identical" columns 
to obtain the results of total and non-specific binding at
the same time. Both columns were packed with LKB Ultrogel
AcA-22, at a flow rate of 9.6 m£/hour and 0.96 ml fractions
were collected. The wet bed diameter of the gel beads was
60-140 microns. The effective fractionation range for glo-
5 6bular proteins was between 10 and 10 daltons. The dimen­
tions of the packed columns were 16mmx570mm. Columns 
were equilibrated with Tris-EDTA containing dithiothreitol 
(1mM) at pH 7.4. Sodium azide (3mM) was added to all the 
buffers to prevent bacterial growth. The linear flow rate of 
the columns was 4.77cm/h for both of the columns.
Columns were calibrated prior to use. The total volume (V^ ) 
was determined with 3H-leucine (0.1yCi). Blue dextran 2000 
(Pharmacia) was employed to calculate the void volume (VQ) 
of the column: The following standard proteins were used :
(1) catalase (M.W.=232,000 daltons)
(2) Thyroglobulin (M.W.=669,000 daltons)
(3) aldolase (M.W.=158,000 daltons)
(4) ferritin (M.W.=444,000 daltons)
Elution of the standard proteins was monitored by measuring 
the optical densities at 280 nm. The distribution coeffi­
cient (Kp) of each binding component and standard was calcu­
lated from its elution volume (Ve):
The Kq was plotted against log molecular mass (M.W.) and 
(Kp)0,333 against the Stokes radius(Rs).
Cytosols were prepared in the presence or absence of 20mM 
sodium molybdate as described in Section 2.10. Columns were 
also run with TEDAG^q buffer containing 0.154 M or 0.4 M 
KC1. The incubation was executed at 20°C for 30 min during
which time the cytosol was incubated with 10nM 3H-EZ to a 
final incubation concentration of 5nM. Incubation with 250 
fold excess of unlabelled ligand (for NSB) was performed 
simultaneously. The incubation was terminated by mixing with 
a DCC pellet and 500^1 of the 2000xg' supernatant was layer­
ed on the column. Five hundred microliter fractions were 
collected (LKB 7000 Ultrarac fraction collector) directly 
into counting vials. All procedures were conducted at 0-4°C 
in a cold room. Four mi of Beckman Ready Solv CP cocktail 
was added and samples were monitored for radioactivity.
(b) Gel permeation chromatography on a Waters 1-250 gel 
column.
Cytosol was prepared and labelled with 3H-E* as previously 
described in Section 2.10 and protein assayed by the method 
of Lowry et al (240). Cytosol protein concentrations were 
usually in the range of 6-8 mq/mi. The column employed was 
a Waters 1-250 column containing a hydrophilic gel, linked 
to silicon beads of uniform size (5 ^m). The column length 
was 25 cm. and the flow rate was 1 mi/min. Total volume 
(Vt), determined with a mixture of polar and non-polar 
labelled amino acids was approximately 12.5 ml. The void 
volume (V ) of the column was determined with Blue Dextran 
(MW ^ 2x10® daltons) and it was found to be 5.91-6.71 mi 
(depending on the ionic strength). The column was eluted 
isocratically with 25 mM phosphate buffer containing 1.5 mM 
EDTA and 10 % glycerol (PEG buffer). The column was
calibrated by a set of marker proteins employing the fol­
lowing mobile phases:
(a) PEG buffer,
(b) PEG buffer containing 100 mM KCI (PEGK^g) or
(c) PEG buffer containing 400 mM KC1 (PEGK^gg).
Experiments were performed in the following way:
(1) Cytosols prepared without sodium molybdate, were 
run on columns eluted with PEG buffer.
(2) Cytosols, prepared without molybdate, were run on 
columns eluted with PEGK10Q buffer.
(3) Cytosols, prepared with or without molybdate, were
run on columns eluted with PEGK^gg buffer follow­
ing re-incubation by charged cytosols in 0.4 MKC1 
containing TEDAG^q at various time-intervals 
(t-zero and 30 min) at 0-4 °C.
In the first case the incubation was immediately stopped by 
the addition of the charged cytosols to a DCC pellet 
prepared from 2 ml. of DCC and the 2000xg' supernatants were 
then run on the column, employing PEGK^gg buffer as mobile 
phase. In the other experiment a second incubation was pro­
longed for 30 min at 0-4°C and the DCC treated cytosol then 
fractionated on the column employing PEGK^g buffer as the 
mobile phase.
3.2.9.2 HPLC chromatography of VMU ER and PR on an AX-1000 anion 
exchange column:
Cytsols were prepared in the presence and absence of sodium 
molybdate (CYT(+) and CYT(-)). The different cytsols were 
charged by incubation with 1^ I-Ez for 18-24 h at 0-4°C in 
the presence or absence of a 250 fold excess DES. Unbound 
ligand was removed by DCC pellet and the 2000xg' super­
natants applied to the columns. Columns were equilibrated 
with 25 mM Tris buffer (pH 8.2 prior to sample application 
and developed with a limiting buffer containing 500 mM 
disodium hydrogen phosphate (Na2 HPO^) at a flow rate of 1 
rM/min. Fractions of 1 ml were collected straight into 
counting vials.
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3.2.9.3 Chromatofocussing of VMU ER and PR on an AX-500 polyamine
column:
Cytosols were either prepared in the presence (CYT(+)) or
absence (CYT C-)) of sodium molybdate (10mM).
125Aliquots of cytosols were incubated with I-E2 with or 
without unlabelled DES (250 fold excess) for 18-24 h at 
0-4°C. Reactions were terminated by DCC treatment and the 
2000xg' supernatants injected onto the AX-500 column. Prior 
to sample application, the columns were equilibrated with a 
25mM Tris buffer (pH 8.4) until the column was pH 8.4. It 
was then eluated with a 30:70 mixture of Polybuffers 96 and 
74 (Pharmacia) respectively (dilution 1:15 with 20% 
glycerol). The pH of the polybuffer mixture was adjusted to 
4.5. The flow rate was 1 m£/min and 1 mi fractions were 
collected straight into counting vials. The radioactivity 
of the fractions was monitored in each fraction and the pH 
was determined for every second fraction.
3.2.10 Isoelectric focussing (IEF) of VMU ER and PR on agarose
gels:
3.2.10.1 Experimental procedure:
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a. Gel preparation:
Agarose gels were prepared containing a concentration of 1 % 
agarose, 12 % sorbitol and the appropriate pharmalyte range 
at a final dilution of 1 to 16. A typical gel contained :
(1) 0.35 g agarose
(2) 4.2 g sorbitol
(3) 31.5 ml water
(4) 2.2 ml pharmalyte
Gels were handled by casting the gel upon a hydrophilic 
plastic sheet (Gel Bond - Pharmacia). The agarose and the 
sorbitol were first dissolved in boiling water, the solution 
cooled down to 75°C and the Pharmalyte carrier ampholyte 
added prior to casting of the gel. Gels were left overnight 
at 0-4°C to set. As the anode solution, 0.05 M h^SO^, was 
used, while the cathode solution consisted of 1 M NaOH.
A Pharmacia, Constant Power Supply (ECPS 3000/150) was used 
for the focussing at the following settings :
Mode:
Set Voltage: 
Set current: 
Set power: 
Time:
Temperature:
Constant power. 
1500 V 
maximum 
15 watts 
2 hours 
10°C approx.
Gels were generally prefocussed for 30 min prior to the 
application of the cytosols. Once the gels were focussed, 
they were fixed, (5 % sulfosalicylic acid plus 10 % tri­
chloroacetic acid) washed and then dried before staining and 
destaining. Gels were then cut into slices of 1-3 mm width 
and the slices dissolved in 2 ml of scintillation cocktail, 
prior to counting radioactivity.
The pH gradient of each individual gel was calibrated, 
employing the standard proteins : lactoglobulin (pi = 5.5), 
horse myoglobin (pi = 7.4 and 7.0), carbonic anhydrase (pi =
6.1) and whale myoglobin (pi = 7.7 and 8.2).
(b) Preparation and incubation of cytosols :
Cytosols were prepared as described before in section 2.10. 
Incubations were conducted in parallel with CYT(-) and
CYT(+) cytosols. Aliquots (100pJZ) of cytosol were incubated
125with 100 \il of ' I-E2 (final ligand concentration of 5 nM) 
at 20°C for 30 min without (total binding) or with_(non- 
specific binding) a 100 fold excess of DES. Incubations were 
terminated by transfering the incubation mixtures to DCC 
pellets, vortexing and subsequent centrifugation at 2000 x 
g 1 for 15 min at 4°C.The resulting supernatants (40u£) were 
applied to the gels on small rectangles of filter paper, or 
in a specially designed plastic sample applicator.
RESULTS :
Table 3.1 shows the values for B and K. for VMU ER and PR 
receptors. The results represent mean values for about 30 
VMU, which were carried out in groups of 7-8 uteri at a 
time. There was a significant difference between Bmax values 
obtained for cytosols, homogenized in the presence (CYT(+)) 
or absence (CYT(-)) of sodium molybdate. In the presence of 
sodium molybdate the Bm  ^ values were found to be consis­
tently higher (20-30 %) for both ER and PR. No difference in 
the binding affinity (K^) could, however, be illustrated for 
both receptors, either in the presence or absence of sodium 
molybdate. Representative Scatchard and saturation plots 
appear in Fig. 3.1. The effect of molybdate appeared to be 
very specifically directed towards the high affinity binding 
sites (Fig 3.1 panel inserts) while the non-specific binding 
levels were not significantly different.
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Association curves for both ER and PR (CYT(+) and CYT(-) 
cytosols) are represented in Fig. 3.2. It is clear that the 
formation of the hormone receptor complexes was complete 
within 15 min (ER) to 30 min (PR) at 0°C. At 20°C, however, 
association proceeded much faster and plateaus were reached 
within 7 min (ER) to 16 min (PR) for both CYT(+) and CYT(-) 
cytosolic receptors. At 37°C the receptors were rapidly 
inactivated, while molybdate provided some protection 
against . the process of inactivation and denaturation. At 
this temperature, without molybdate, a very rapid associa­
tion occurred at 37°C (<2 min), but in the presence of 
molybdate the receptors remained stable for 15 min (ER) and 
12 min (PR) respectively, before being inactivated. After 40 
min at 37°C the PR was totally inactivated in both CYT(+) 
and CYT(-) cytosols while the ER appeared to be more stable 
without molybdate : 30 % active in the absence of sodium 
molybdate and 40 % active in the presence of molybdate. 
After 90 min at 37 °C the ER was totally inactivated, even 
in the presence of sodium molybdate. Both receptors appeared 
to be very stable at 20°C for up to 3h,at 0°C for up to 24h.
Ligand specificity for the two receptors is represented in 
Fig 3.3 and 3.4. Relative binding affinities (RBA) and 
apparent values for the ligands (mean of 2 to 4 assays) 
have been calculated according to Rodbard et aj_ (233) and 
the data are summarized in Table 3.2.
These results indicated a much narrower specificity for the 
ER as compared to the PR. For the ER the ligand preference 
was of the order : DES > EE2 > E2 > E^  > E^  while no affi­
nity was observed for any of the other steroid hormone 
categories. The result also seemed largely in agreement with 
literature reports (305-306). The PR, on the other hand, 
exhibited a much lower level of ligand specificity, a 
finding partially in agreement with other investigators 
(224,307). The most remarkable characteristic was the high 
affinity of the PR for EE2 (91.2 %) and the relative high
affinity for other oestrogens : E2 > (see Table
3.2). It would seem that the VMU progesterone receptor 
displays a unique property in comparison with other proges­
terone binding proteins. Published values for the relative 
binding affinities of oestrogens for the PR were found to be 
much lower than our values (221,308).
The dissociation of receptor-1igand complexes exhibited a 
biphasic. pattern (Fig 3.5) for both ER and PR. Molybdate 
increased the rate of dissociation of the fast dissociating 
complexes (FDC), but slowed down the dissociation of the 
slow dissociating complexes (SDC) (see Table 3.3). The half 
lives of the ER and PR complexes at 20°C was found to be 35 
min for CYT(+) and 43 min for CYT(-) for ER and 22 min for 
CYT(+) and 25 min for PR.
The most marked effect of the molybdate on the receptor 
yield and stability can be appreciated in Fig. 3.6 - 3.8 and 
Table 3.4. Once the receptors are "protected" during 
homogenization (CYTuo), they appear to be more stable, even 
under conditions where no molybdate is present (GRAD(—)). 
Receptors, not "protected" during the homogenization process 
can only be partially regenerated to a higher binding 
capacity by molybdate, present in the gradient solution 
(GRAD(+)). This sedimentation dialysis experiment (Fig. 3.7 
and 3.8) implies that the "protective" effect of molybdate 
is not fully reversible, an observation which applies to 
both ER and PR in the VMU.
The sucrose density gradient profiles appearing in Fig. 3.9 
depict the results obtained, when CYT(+) and CYT(-) cyto­
sols were dialysed in cellulose tubing against different 
compinations of TEDAG^q or TEDAG-MO buffers, over a period 
of 4 h in the cold prior to labelling and centrifugation. 
Much better reversibility has been obtained for both ER and 
PR in this experiment. The partial loss in ligand binding 
capacity obtained cannot be attributed to receptor inacti-
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vation during the experiment, since low temperatures (0-4°C) 
prevailed and no significant changes in the binding capaci­
ties were observed in control cytosols (CYT(+) or CYT(-i) 
subjected to the same conditions. A quantitative analysis of 
the binding data appear in Table 3.5.
The effect of the proteolytic inhibitors Leu (2mM) and PMSF 
(1mM) in the presence or absence of molybdate is depicted in 
Fig. 3..10 and 3.11, while the relevant binding data appear 
in Table 3.6. The action of molybdate does not seem to be 
affected by the presence of Leu or PMSF. Receptor inacti­
vation still occurs in molybdate deficient media, varying 
between 14 % for the PR and 61.4 % for the ER in the 
presence of Leu. In molybdate containing cytosols (CYT(+)) a 
higher yield of receptors (ER and PR) was found when these 
cytosols were prepared in the presence of Leu when compared 
to that found in control conditions (CYT(+) and GRAD(+i). 
The ER proved to be exceptiona1ly prone to inactivation in 
the absence of molybdate even though Leu was present in the 
homogenization buffer (61.4 % inactivation). No stabilizing 
effect on ER and PR was observed when molybdate and PMSF 
were present in the homogenization buffer.
Sedimentation coefficients for both ER and PR did not change 
significantly. Only in the case of the PR, another specific 
binding component, sedimenting at 5.2 S was observed.
At a higher concentration of PMSF (5mM) and in the absence 
of molybdate (CYT(-)) ligand binding capacity of the recep­
tors was inhibited by 86.1 % (PR) to 89.2 % (ER) (Table 3.7) 
and this result was strongly corroborated by the SDG 
profiles and IEF patterns obtained (Fig. 3.12 and to Fig. 
3.15).
A loss in the ligand binding capacity of the ER (44.1 %) and 
PR (22.5 %) was observed in this batch of experiments in the 
presence of 2mM Leu, a result which is somewhat contradic­
tory to that, illustrated in Fig, 3.10 and 3.11. However we 
found that differences in the apparent stability of the 
receptors did exist between individual uteri, a finding 
which might relate to the levels of endogenous receptor 
inactivating factors (e.g. proteolytic enzymes) existing in 
the uterine tissue at different stages of development or the 
hormonal status of the female, prior to removal of the 
uterus. For this reason, most of the experiments were 
executed, on batches of uteri. Curiously enough, the ER 
appeared to be more labile in the presence or absence of 
Leu relative to the PR (Table 3.7) and this was also obser­
ved in the first batch of experiments (Fig. 3.10-3.11).
Ligand binding capacity of both receptors (Table 3.7) was 
severely inhibited in the presence of the sulfhydryl 
reactive agents NEM (77.0-81.5 %), IAA (93.8-94.9 %) and 
DTNB (94.1 - 95.4 %). These results were all corroborated by 
the SDG profiles and IEF patterns (Fig. 3.12 to Fig. 3.14).
0-Phen did not cause such a great loss in receptor ligand 
capacity (ER : 29.2 %; PR : 51.4 %) than TLCK (ER : 82.1 ; 
PR : 66.7 %) or the other inhibitors (Fig 3.12 to Fig. 3.14 
and Table 3.7). IEF patterns and SDG profiles, however, 
indicated a much greater effect of this compound on the 
integrity of the ER and PR. As for TLCK, although SDG 
profiles confirmed the finding that the binding capacities 
of both ER and PR were severely inhibited, some specific 
binding components could still be observed in IEF gels. 
Whereas TLCK tended to effect a shift in pi values to a 
higher pH range (6.5 - 7.2 : ER ; 6.5 - 7.0 : PR), 0-Phen 
had the opposite effect, shifting the peaks to lower pH 
ranges (Table 3.8). Only Leu caused significant shifts in 
the sedimentation coefficients of ER (8.2 - 9.9) and PR (8.4 
-  9. 5 ) .
The calibration curve for the Ultrogel AcA-22 column appears 
in Fig.3.16. A representative column elution profile of the
size exclusion chromatography of VMU ER Is depicted In Fig. 
3 . 17.
To facilitate the description of the various forms of the 
VMU oestrogen receptor, it was decided to use the nomencla­
ture proposed by Sherman et £l_ (213) and to number the forms 
from class I to class V in order of decreasing molecular 
size as measured by gel filtration. Table 3. 9 summarizes thp 
results obtained for the molecular masses and Stokes radii(r*) 
calculated from the column data while Fig. 3.17 depicts 
typical column elution profiles obtained for the VMU ER.. A 
highly aggregated complex (MW = 3.9 -4.7 x10S daltons) 
appeared in the void volume of the column, when the 
cytosols, prepared in hypotonic buffers (TEDAG10) were frac­
tionated on Ultrogei AcA-22 employing hypotonic buffer as 
the mobile phase.
Receptor aggregation tended to be slightly more prominent
when fractionation was executed in the absence of sodium
F o
molybdate (MW = 4.68xlO'daltons; r*= 63.2 A) as compared to 
that obtained in the presence of sodium molybdate (MW = 
3.87x10s daltons; r *= 61.8 A). Only Class I receptors were 
noticed under these conditions. Fractionation of cytosols 
(CYT(-j) on the same column, employing a hypertonic mobile 
phase (0.4 MKC1) yielded a Class III type of receptor (MW = 
9.2x10^  daltons; r *= 42.3 A), while an isotonic mobile phase 
(0.15 MKC1) yielded a similar type of receptor molecule (MW 
= 8.6x104 daltons, r ^  41.8 A). A summary of the molecular 
masses and Stokes radii appears in Table 3.9.
Calibration curves of the Waters 1-250 gel exclusion columns 
are depicted in Fig 3.18. The ionic strength of the mobile 
phase affected the elution volumes of the standard proteins 
and molecular masses were subsequently calculated, employing 
the proper calibration curves. Typical, representative 
column elution profiles for VMU ER on the Waters 1-250 gel 
column appear in Fig. 3.19, while the calculated molecular
size data are summarized in Table 3.10. The molecular size 
for the ER, as determined with a hypotonic mobile phase 
(PEG, PEGM) was 2.006x10^ daltons, both in the presence or 
absence of sodium molybdate (Table 3.10). Extensive receptor
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aggregation (MW = 7.2-8.6x10 daltons) was observed in the 
absence of molybdate, following an extended incubation in
0.4 MKC1, prior to size exclusion chromatography (hypertonic 
mobile phase). However, this aggregation effect was not 
observed with cytosols prepared in the presence of sodium 
molybdate (MW = 1.1 - 1.5x10^ daltons).
The effect of sodium molybdate on the subunit integrity of
the VMU ER is obvious when Fig. 3.20 and Fig. 3.21 are
compared. In the case of CYT(-) cytosols (Fig. 3.20) two
well resolved high affinity ligand binding molecular species
were obtained. One species eluted at 90mM and the other at
230mM salt (HPO^). There appeared to be a 1:1 ratio (51 %
: 49 %) for the surface areas representing the two subunit
peaks. When molybdate was present, only one peak was
_2
observed, eluting at 189 mM HPO^ . Receptor yields for 
CYT(-) cytosols were only 30-50 % of the values obtained 
with CYT(+) cytosols.
Data obtained with the AX-500 column, following HPLC 
chromatofocussing is depicted in Fig. 3.22 and 3.23 as well 
as in Table 3.11. The apparent receptor heterogeneity 
observed with isoelectric focussing on Agarol gels was 
underlined with the results of this experiment. At least 7 
high affinity binding components were observed (Table 3.11) 
spanning the pH range 8.0 to 4.0 in cytosols not prepared in 
the presence of sodium molybdate (CYT(-)), while only 3 
components were detected in (CYT(+) cytosols. It would 
appear that the molybdate oxyanion affected the ionic 
properties of the high affinity bindings components to such 
an extent, that they eluted at lower pi values. In a way 
this finding was also corroborated by data obtained on anion 
exchange columns, as well as isoelectric focussing.
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Typical, representative iso-electric profiles for the VMU ER 
appear in Fig. 3.24 and 3.25. More than 90x1 mm fractions 
were derived from each gel, with the result that well 
resolved peaks were obtained. Iso-electric points and 
receptor yields in individual peaks are summarised in Table 
3.12.
The effect of molybdate on the receptor species was clearly 
observed upon inspection of the iso-electric focussing 
pattern : In the absence of molybdate (CYT(—)) the pattern 
revealed clearly defined peaks with pi's of 5.9 (28.9 %),
6.2 (30.3 %) and 6.8 (40.7 %) respectively. Molybdate con­
taining cytosols (CYT(+)) yielded one major high affinity 
binding species at pi = 5.9 (39.9 %), with two minor enti­
ties, appearing at pi = 5.6 (13 %) and 6.8 (16.6 %). A 
broad, undefined area, containing some specific binding 
components appeared in the pH region 5.0-5.5 (30.5 %).
As a rule, receptor yield was much lower in the absence of 
molybdate, yielding between 30 % and 50 %, (>10 assays) 
lower specific binding, compared to IEF assays on CYT(+) 
cytosols.
TABLE 3.1
The effect of molybdate on the binding capacity and affinity of
ER and PR in the VMU.
Receptor Bmax
(fmol /mg protein)
Kd 
(x 10
y M)
%I*
CYT(+) CYT(-) CYT(+) CYT(-) %I*
ER 191 ± 51 135 ±62 0.32 ± 0.1 0.3 ± 0.1 29.3
PR 566 ±184 356 ± 57 7.7 ±1.5 7.4 ± 1.5 37.1
*%I = % inactivation of ligand binding capacity; CYT(+) = 100
% value)
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Figure 3.1 : Scatchard and saturation curves for VMU ER and PR.
Cytosols were prepared in buffer containing (A) or 
not containing (■) 20mM sodium molybdate. Aliquots 
(1 0 0piJ0) of cytosols were incubated with the appro­
priate ligand (3 H-Ej or 3M-R5020) in the absence 
(total binding) or presence (non-specific binding) 
of a 100 fold excess of DES or R5020 respectively, 
at 5 different concentrations (0.25-8nM) : 30 min at 
20°C for the ER and 4 h on ice for PR. The reac­
tions were terminated with the addition of DCC 
(500pf) and aliguots (500p£) of the 2000xg' super­
natants monitored for total and non-specific binding 
: (A) oestrogen receptor; (B) progesterone receptor.
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Figure 3.2 : Receptor ligand association as a function of time 
and temperature : the effect of sodium molybdate. 
Cytosols were prepared in the presence (•) or absen­
ce (■) of sodium molybdate, and incubated with tri- 
tiated ligand ( |3 H | — or 3H-R5020 ) to a final con­
centration of 5 nM with and without a 250 fold ex­
cess level of the appropriate unlabelled competitor 
(DES or R5020) at three different temperatures (C’C, 
20°C and 37°C). Following the addition of the radio­
ligands, aliquots (10OpiJe) of the incubation mixtures 
were taken at determined time intervals and added to 
a DCC suspension (1 m£) on ice. Aliquots of 500p£ of 
the supernatant of 20 0 0xg'x103 were monitored for 
total and non-specific binding : (A,B,C) association
of the VMU ER with 3 H-E2 in the presence (CYT(+),*) 
or absence (CYT(-),*) of 10 mM sodium molybdate at 
0°C(A), 20°C(B) and 37°C(C); (D,E,F) association of
the VMU PR with 3H-R5020 in the presence ((CYT(+),*) 
or absence ((CYT(-),>) of 1OmM sodium molybdate at 
0 °C(D), 20 °(E) and 37°C(F).
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Figure 3.3 : Competition of various ligands for binding to the VMU 
ER. Aliguots (100p£) of freshly prepared cytosols 
were incubated with 50p£ of labelled oestradiol (fi­
nal concentration, 8 nM) in the presence of 50p£ of a 
range of 8 different concentrations (0.169 nM -2.6pM) 
of a group of competitors : oestradiol (E2 jd ), 
oestriol (£31 ■ )» oestrone (E-| ) ethynyloestradiol
(EE2 ,0 ), diethylstilbestrol (DES,<0, progesterone 
(P, + ), promogestone(R5020,A), norethindrone (NE,A), 
testosterone (T,0), dehydrotestosterone (DHT,*), 
dehydroepiandrosterone (DHEA),*) and hydrocortisone 
(HC,*) for 30 min at 20°C. Reactions were terminated 
by the addition of cold DCC (500p^) and subseguent 
incubation on ice for 10 min. Charcoal was pelleted 
by centrifugation (2000xg'x15 min) and aliguots 
(500p{) of the resulting supernatants counted for 
radio-activity.
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Figure 3.4 : Competition of various ligands for binding to the VMU 
PR. Aliguots (100pf) of freshly prepared cytosols 
were incubated with 50p£ of labelled progesterone 
(final concentration, 8 nM) in the presence of 50pf 
of a increasing concentrations (0.169 nM -2.6pM) of a 
group of competitors : oestradiol (E2 ,d), oestriol 
(Ej ,b ), oestrone ( E ,ethynyloestradiol  (EEjjO)* 
diethylstilbestrol (DES,^, progesterone (P, + ), pro- 
mogestone 85020,^), norethindrone (NE,i), testoste­
rone (T,0), dehydrotestosterone (DHT,«), dehydro- 
epiandrosterone (DHEA),*) and hydrocortisone (HC,») 
for 30 min at 20°C. Reactions were terminated by 
the addition of cold DCC (500p£) and subsequent incu­
bation on ice for 10 min. Charcoal was pelleted by 
centrifugation ( 2000xg'x15 min) and aliquots (500vi£) 
of the resulting supernatants counted for radio­
activity.
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TABLE 3.2
Relative Binding Affinities and Apparent Dissociation 
Constants^) of various Ligands for ER and PR:
ER PR
Ligand RBA
(%)
Kd
(M)
RBA
(%)
Kd
(M)
DES 174.2 1 .8x 10-  ^° < 0.1 _
ee2 133.3 2.4x10“1° 99.4 2 .6x 10-9
E 2
1 0 0 .0 3.2x10-  ^° 15.9 2 .0x10-^
F 3 7.2 7.4x10-9 0.7 4.0x10~7
E t 3.4 1 .1x 10-8 13.0 1 .5x10 -8
NE 0 .1 2 .6x 10 " 6 623.0 4.2x 10-1°
P < 0.1 — 1 0 0 . 0 2 .4x1O-9
R5020 < 0.1 596.2 4.0x10_1°
T < 0.1 1 .9 1 .6x10 ^
DHT < 0.1 - 0 . 6 4.7x10-7
DHEA < 0.1 - < 0.1 -
HC < 0.1 _ < 0.1 _
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Figure 3.5 : Effect of sodium molybdate on the dissociation of VMU *20
ER and PR.
Cytosols (cYT(+) and CYT(-)) were equilibrated with 
5nM of the proper radioligand (3 H-E^ or 3H-5020). 
The dissociation was assayed at 20°C following the 
addition of 5nM(1000 fold excess) of unlabelled oes- 
tradiol or progesterone!*). Receptor inactivation was 
checked in a parallel incubation at 10°C with the 
addition of buffer containing no unlabelled oestra- 
diol or progesteronef*). At determined time intervals at
20 °C, 100p£ aliquots were removed and added to a DCC
suspension (1 m£) on ice. Aliquots (500vi£) of the
resulting 20 0 0xg' min supernatants were monitored for 
radioactivity. Each determination has been correc­
ted for non-specific binding : dissociation of ER and 
PR in molybdate-free cytosols (panels A and B) or in 
cytosols prepared in the presence of 20mM molybdate 
(panels C and D).
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TABLE 3.3 :
Effect of sodium molybdate on the dissociation of VMU ER and PR
at 20°C.
Receptor Rate constants 
( x 10“ 3
of dissociation 
min )
CYT(-) CYT(+)
FDC SDC FDC SDC
ER 7.02 2.08 8.55 1 .41
PR 10.31 5.39 12.91 2.24
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Figure 3.6 : Effect of sodium molybdate on the VMU ER (A) and 
PR(B) SDG profiles.
Cytosols containing (•) and non containing (A) sodium 
molybdate were incubated at 20°C for 30 min with 
either 3 H-E2 of 3H-R5020.Parallel incubation mixtures 
also contained a 100 fold excess of either DES or 
R5020 respectively. Reactions were terminated by 
transferring the incubation mixtures to DCC pellets. 
The 20(J'0xgl supernatants (200y£) were then layered 
onto hypotonic 10-35% sucrose density gradients. The 
cytosols containing molybdate were layered onto gra­
dients containing molybdate ((GRAD(+)) while cytosols 
free of molybdate were layered onto gradients not 
containing sodium molybdate ((GRAD(-)).The gradients 
were subjected to ultracentrifugation (VTi-80 rotor, 
520000xg■x120 min x 2°C), fractionated (40x5drop 
fractions) and the fractions counted in a scintilla­
tion counter, following the addition of 4 m£ cock­
tail. Positions of the marker proteins are indicated 
by arrows : myoglobin (M, 2.03S), ovalbumin (Ov, 
3.6S), bovine serum albumin (BSA,4.oS) and aldolase 
(Aid 7.3S).
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Figure 3.7 : Reversibility of the effect of sodium molybdate on
the VMU ER as studied by sedimentation-dialysis 
experiments, monitored by SDG. Cytosols were homo­
genized in the presence (CYT(+)) (A) or absence 
(cYT(-)) (B) of sodium molybdate. The gradients
were prepared containing (g r a d (+)) or not con­
taining ((GRAD (-)) sodium molybdate. Aliquots of 
(200p£) incubation mixture were analysed on hypo­
tonic 10-35% SDG gradients and were processed as 
described in section 3.2.7. Different combina­
tions of conditions relative to the sodium molyb­
date status were employed: SDG profiles of the VMU 
ER analysed in (A)CYT(+) GRAD(+) ( —  ), CYT(+) 
GRAD(-) conditions and (B) CYT(-) GRAD(+) or 
CYT(-) GRAD(-) conditions.
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F igu re  3 . 8
FRACTION
R e v e r s i b i l i t y  o f  the  e f f e c t  o f  sodium molybdate  on 
the VMU PR as s t u d i e d  by s e d i m e n t a t i o n - d i a l y s i s  
e x p e r i m e n t s ,  m o n i t o r e d  by SDG. C y t o s o l s  were homo­
g e n i z e d  i n  the  p r e s e n c e  (CYT(+) )  (A) o r  absence  
( CYT( - ) )  (B) o f  sodium m olyb date .  The g r a d i e n t s  
were  p r e p a r e d  c o n t a i n i n g  ( gRAD(+))  o r  n o t  co n ­
t a i n i n g  ((GRAD ( - ) )  sodium m olybdate .  A l i g u o t s  o f  
(200p£)  i n c u b a t i o n  m ix tu r e  were an a ly sed  on hypo­
t o n i c  10-35% SDG g r a d i e n t s  and were p r o c e s s e d  as 
d e s c r i b e d  in  s e c t i o n  3 . 2 . 7 .  D i f f e r e n t  combina­
t i o n s  o f  c o n d i t i o n s  r e l a t i v e  t o  the sodium molyb­
d a t e  s t a t u s  were employed :  SDG p r o f i l e s  o f  the VMU 
ER a n a ly s e d  i n  (A)CYT(+)  GRAD(+) ( —  ) ,  CYT(+) 
GRAD( - )  c o n d i t i o n s  and (B) CYT(-)  GRAD(+) o r  
CYT( -)  GRAD(-) c o n d i t i o n s .
TABLE 3.4
Quantitative analysis of the effect of sodium molybdate on the stabilization of VMU LB and PR in
typical sedimentation-dialysis experiment
RECEPTOR SPECIFIC BINDING IN ^ 8  S 
( d p m / m g / p r o t e i n )
%  I n a c t i v a t i o n
CYT( + ) /GRAD(+)  CYT( + ) /GRAD( - )  CYT( - ) /GRAD(+) CYT( - ) /GRAD( - )  
(1 )  (2 )  (3 )  (4)
1 - 2  3 - 4  1 - 3  1 - 4
ER
PR
6249 6465 4401 3069 
17718 16429 11439 10221
- 3 . 5  3 0 .3  2 0 .6  5 ( 1 . 9  
7 . 3  10 .7  27 .4  35 .2
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F ig u r e  3 . 9  : R e v e r s i b i l i t y  o f  the  e f f e c t  o f  sodium m olybdate  on
the  VM(J ER and PR as s t u d i e d  by d i a l y s i s  m o n i to r e d  
in  h y p o t o n i c  10-35%. C y t o s o l s  were homogenized in 
the  p r e s e n c e  (CYT(+) )  o r  abse nce  ( c Y T ( - ) )  o f  s o ­
dium m o lyb d ate .T h e  c y t o s o l s  were d i a l y s e d  in  c e l ­
l u l o s e  tu b in g  ( 1 . 5  cm d ia m e t e r )  a g a i n s t  a b u f f e r  
w ith  the same c o n s t i t u t i o n ,  r e l a t i v e  t o  sodium 
m olybdate  c o n t e n t  as the  h o m o g e n iz a t i o n  b u f f e r ,  o r  
a g a i n s t  a b u f f e r  w ith  the  o p p o s i t e  c o n s t i t u t i o n .  
F o l l o w i n g  d i a l y s i s  (4hxO-4°C)  c y t o s o l s  were l a b e l ­
l e d  and p r o c e s s e d  as p r e v i o u s l y  d e s c r i b e d  and then 
f i n a l l y  an a ly se d  on h y p o t o n i c  10-35 % SDG, with 
the same m olybdate  s t a t u s  as the d i a l y s i s  b u f f e r  : 
( A,B)  h y p o t o n i c  SDG p r o f i l e s  o f  the  VMUER o b t a i ­
ned under the f o l l o w i n g  c o n d i t i o n s  : (CYT(+)GRAD(+) 
( A ) ,  CYT ( + )GRAD( -  ) ( • ) ,  and CYT(-)GRAD( + ) ( ■ )  
and C Y T ( - ) GRAD(- ) ( O ) ;  (C,D)  h y p o t o n i c  SDG p r o f i ­
l e s  o f  the  VMU PR o b t a i n e d  under the f o l l o w i n g  
c o n d i t i o n s  : CYT( + ) GRAD( + ) ( A ) , CYT(+ ) GRAD(- ) (  • ) ,
CYT ( -  ) GRAD ( +) ( ■ )  and CYT( - )  GRAD( -  ) ( O ) .
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TABLE 3.5
Effect of molybdate on receptor inactivation during the dialysis 
of cytosols ( c y t (+)  and c y t ( - ) )  against buffers (TEDAG^ and 
TEDAG-MO) and subsequent SDG.
R e c e p t o r Molybdate  s t a t u s  
C y t o s o l  B u f f e r
S p e c i f i c  b i n d i n g  in  
^ 8 S peak 
(dpm/mg p r o t e i n )
I n a c t i v a t i o n
(%)
ER + + 3788 -
+ - 301 7 20 .4
- - 2475 34 .7
- + 301 0 20 .5
PR + + 10257 -
+ - 7992 22.1
- - 3947 61 .5
- + 7390 28 .0
1 34
Figure 3. 10: I n f l u e n c e  o f  PMSF and Leu on s e d im e n t a t i o n  p r o f i l e s  
o f  ER i n  CYT(+)  and CYT(-)  c y t o s o l s .  C y t o s o l s  were 
p r e p a r e d  in  the p r e s e n c e  ( • ) o r  a b s e n c e  ( A ) o f  2mM 
Leupept in  (A,B)  and in  the  p r e s e n c e  ( • ) o r  absence  
( A )  o f  1 mM PMSF (C ,D ) .  CYT(-)  c y t o s o l s  an a ly se d  on 
g r a d i e n t s  n o t  c o n t a i n i n g  m olybdate  (GRAD(-) whereas 
CYT(+) c y t o s o l s  were run on g r a d i e n t s  c o n t a i n i n g  
m olybdate  GRAD( + ) .  The p o s i t i o n  o f  the  1 * C - l a b e l l e d  
marker p r o t e i n  (BSA, 4 .6 S )  i s  i n d i c a t e d  by an arrow.
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Figure 3.11 : I n f l u e n c e  o f  PMSF and Leupeptin  on s e d im e n t a t io n
p r o f i l e s  o f  PR in  CYT(+) and CYT(-)  c y t o s o l s .  
C y t o s o l s  were p r e p a r e d  in  the  p r e s e n c e  ( • ) o r  
a b s e n c e  ( A  ) o f  2mM Leupeptin  (A,B) and in  the 
p r e s e n c e  ( •  ) o r  a b s e n c e  ( A )  o f  1 mM PMSF (C ,D ) .  
CYT(-)  c y t o s o l s  an a ly se d  on g r a d i e n t s  n o t  c o n t a i n i n g  
m olybdate  (GRAD(-) )  whereas CYT(+) c y t o s o l s  were run 
on g r a d i e n t s  c o n t a i n i n g  m olybdate  ( gRAD(+)) .
Marker p o s i t i o n  (1£,C-BSA; 4 . 6 5 )  i s  i n d i c a t e d  by BSA.
TABLE 3.6
Effect of proteolytic inhibitors
during
Leu and PMSF 
preparation
on the molybdate stabilization of 
of cytosols and SDG analysis.
VMU ER and PR
R e c e p to r Molybdate s t a t u s P r o t e o l y t i i c i n h i b i t o r
C y t o s o l G r ad ie n t Leu 
( 2mM)
PMSF 
( 1mM)
S p e c i f i c - b i n d i n g  
in  8 S peak 
(dpm/mg p r o t )
I n a c t i v a t i o n
{ % )
ER + + _ 1 6455 0
- - - - 9314 4 3 .4
+ + + - 19677 -  19 .6
- - + - 9582 41 .8
+ + - + 13292 19.2
+ 8506 4 8 .3
PR + + - - 16006 0
- - - - 9861 38 .4
+ + + - 19919 -  24.4
- - + - 17667 -  10.4
+ + - + 12765 20 .2
- - + 7961 50 .3
O J
cr>
13 7
Figure  3 .1 2  : E f f e c t  o f  p r o t e o l y t i c  i n h i b i t o r s  and t h i o l  r e a c t i v e  
a g e n t s  on VMU ER SDG p r o f i l e s .
VMU were s l i c e d  up and th in  s l i c e s  were homogenized 
in  1 .5  m£ o f  TEDAG1 b u f f e r  c o n t a i n i n g  the  i n h i b i t o r  
a t  the  f o l l o w i n g  f i n a l  c o n c e n t r a t i o n s  : panel  A: 
DTNB ( * ) 1 OmM, NEM (■)  5 mM and IAA (•)  1OmM. Panel  
B : Leu pept in  (•)  2mM and TLCK (■)  5mM. Panel  C : 
PMSF (■ )  5mM and O-Phen (•)  5mM. The c y t o s o l s  were 
s u b j e c t e d  t o  SDG a n a l y s i s .  C y t o s o l s  were i n c u b a t e d  
w i th  3 H-E* in  the  p r e s e n c e  o r  absence  o f  250 f o l d  
e x c e s s  o f  c o l d  l i g a n d .  The DCC t r e a t e d  s u p e r n a t a n t  
( 2 0 0 0 x g 'x 1 0  min) was l a y e r e d  (200pj(!) on top  o f  
l i n e a r  10-35% h y p o t o n i c  SDG, and c e n t r i f u g a t i o n  was 
e x e c u t e d  a t  VTi -80  (520000 xg '  f o r  2 h. F ive  d r o p  
f r a c t i o n s  were c o l l e c t e d  and the f r a c t i o n s  were 
m o n i t o r e d  f o r  r a d i o a c t i v i t y .
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Figure 3 .1 3  : E f f e c t  o f  p r o t e o l y t i c  i n h i b i t o r s  and t h i o l  r e a c t i v e  
a g e n ts  on VMU EP. IEF p r o f i l e s .
VMU were s l i c e d  up and th in  s l i c e s  were homogenized 
in  1 .5  m£ o f  TEDAG^ b u f f e r  c o n t a i n i n g  the i n h i b i t o r  
a t  the  f o l l o w i n g  f i n a l  c o n c e n t r a t i o n s  : pan e l  A: 
DTNB ( • ) 1 OmM, NEM (■ )  5 mM and IAA (* )  10mM. Panel  
B : L eu pep t in  (• )  2mM and TLCK (■ )  5mM. Panel  C : 
PMSF (•) 5mM and O-Phen (■)  5mM. The c y t o s o l s  were 
s u b j e c t e d  t o  IEF a n a l y s i s .  C y t o s o l s  were in c u b a t e d  
w i th  1 H-E2  in  the  p r e s e n c e  o r  absence  o f  250 f o l d  
e x c e s s  o f  c o l d  l i g a n d .  The DCC t r e a t e d  su p e r n a t a n t  
(2 0 0 0 x g 'x 1 0  min) was a p p l i e d  (40p£)  t o  the  g e l s  on 
sm al l  r e c t a n g l e s  o f  f i l t e r  paper  and ran f o r  2 hou rs 
in  the  c o n d i t i o n s  d e s c r i b e d  in  S e c t i o n  3 . 2 . 1 0 .
CtntroJs are indicated by a ,
139
Figure  3 .1 4  : E f f e c t  o f  p r o t e o l y t i c  i n h i b i t o r s  and t h i o l  r e a c t i v e  
a g e n t s  on VMU PR SDG p r o f i l e s .
VMU were s l i c e d  up and t h in  s l i c e s  were homogenized 
i n  1 .5  mj? o f  TEDAG  ^ b u f f e r  c o n t a i n i n g  the  i n h i b i t o r  
a t  the f o l l o w i n g  f i n a l  c o n c e n t r a t i o n s  : pan e l  A: 
DTNB ( • ) 1 OmM, NEM (■)  5 mM and IAA ( * )  1OmM. Panel  
B : Leu pept in  (•)  2mM and TLCK (■)  5mM. Panel  C : 
PMSF (•)  5mM and O-Phen (■)  5mM. The c y t o s o l s  were 
s u b j e c t e d  t o  SDG a n a l y s i s .  C y t o s o l s  were i n c u b a t e d  
with  R-5020 in  the  p r e s e n c e  o r  absence  o f  250 f o l d  
e x c e s s  o f  c o l d  l i g a n d .  The DCC t r e a t e d  s u p e r n a t a n t  
( 2 0 0 0 x g 'x 1 0  min) was l a y e r e d  (200pj?) on t o p  o f  
l i n e a r  10-35% h y p o t o n i c  SDG, and c e n t r i f u g a t i o n  was 
e x e c u t e d  a t  VTi-80  (520000xg '  f o r  2 h. F iv e  drop  
f r a c t i o n s  were c o l l e c t e d  and the f r a c t i o n s  were 
m o n i t o r e d  f o r  r a d i o a c t i v i t y .
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Figure  3 .1 5  : E f f e c t  o f  p r o t e o l y t i c  i n h i b i t o r s  and t h i o l  r e a c t i v e  *19
a g e n t s  on VMU PR IEF p r o f i l e s .
VMU were s l i c e d  up and t h in  s l i c e s  were homogenized
in  1.5  m S .  o f  TEDAG „ b u f f e r  c o n t a i n i n g  the i n h i b i t o r19a t  the f o l l o w i n g  f i n a l  c o n c e n t r a t i o n s  : pane l  A: 
DTNB ( • ) 1 OmM, NEM (■)  5 mM and IAA ( * )  10mM. Panel  
B : Leu pept in  (•)  2mM and TLCK (■)  5mM. Panel  C : 
PMSF (•)  5mM and O-Phen ( a ) 5mM. The c y t o s o l s  were 
s u b j e c t e d  t o  IEF a n a l y s i s .  C y t o s o l s  were in c u b a t e d  
w i th  3 H-Ej in  the p r e s e n c e  o r  abse nce  o f  250 f o l d  
e x c e s s  o f  c o l d  l i g a n d .  The DCC t r e a t e d  su p e r n a t a n t  
( 2 0 0 0 x g ' x10 min) was a p p l i e d  ( 4 0 M£) t o  the  g e l s  on 
sm al l  r e c t a n g l e s  o f  f i l t e r  paper  and ran f o r  2 hours 
in  the c o n d i t i o n s  d e s c r i b e d  i n  S e c t i o n  3 . 2 . 1 0 .
TABLE 3.7
Effect of proteolytic inhibitors and thiol reactive agents 
on the ligand binding capacity of VMU ER and PR.
I n h i b i t o r Binding c a p a c i t y % i n a c t i v a t i o n
( fmol /mg p r o t e i n )
ER PR ER PR
None 195 387 0 0
O-Phen 1 38 1 88 29 .2 51 .4
PMSF 21 54 8 9 .2 86.1
DTNB 9 23 95 .4 94.1
IAA 1 0 24 9 4 .9 9 3 .8
Leu 1 09 300 44.1 22 .5
NEM 36 89 81 .5 77 .0
TLCK 35 1 29 82.1 6 6 . 7
TABLE 3.8
iffect of p r o t e o l y t i c a n d  t h i o l  i n h i b i t o r s  o n t h e  pi v a l u e s  a n d S D G  p r o f i l e s  o f
V M U  E R  a n d PR
ihibitor ER PR
I s o e l e c t r i c  
( p i )
p o i n t s  Se d im e n ta t io n  
c o e f f i c i e n t s  
(S v e d b e r g s )
I s o e l e c t r i c  p o i n t s  
( p i )
Sed im en ta t ion  
c o e f f i c i e n t s  
( S v e d b e r g s )
one 6. 6, 5 . 8 8 . 2 6.5, 5. 0 8 . 4
-Phen 6 . 5 8 . 4 5.2, 4 . 6 8 . 7
MSF 5.1 8 . 4 n . p . 8 . 2
TNB 4 . 5 n . p . 6 . 5 n . p .
AA n . p . n . p. n . p . n . p .
eu 6. 1, 7. 0 6. 1, 9 . 9 6.1 9. 5
EM 7 . 2 n . p . n . p . n . p .
LCK 7 . 2 n . p . 7.0. 8 . 9
n.p. = no p e ak s ;  peak s u r f a c e  a r e a  s e v e r e l y  re d u c e d )
AB
143
' i g u r e  3 .1 6  (A) A c a l i b r a t i o n  c u r v e  f o r  the m o l e c u la r  mass d e t e r ­
m in a t i o n  o f  the VMU ER on u l t r o g e l  AcA-22 co lumns.  
The s tan d ard  p r o t e i n s  used were : C a t a la se  
(MW=232000 d a l  t o n s )  t h y r o g l o b u l i n  (MW=669000), 
a l d o l a s e  (MW=158000 d a l t o n s )  and f e r r i t i n  MW=440000 
d a l  t o n s ) .
(B) A c a l i b r a t i o n  c u r v e  f o r  the d e t e r m i n a t i o n  o f  the 
S to k e s  r a d i u s  ( r * )  o f  the VMU ER on an U l t r o g e l  
AcA-22 column. Standard  p r o t e i n s  employed were 
c a t a l a s e  ( r * = 5 2 . 2 A ) ,  t h y r o g l o b u l i n  ( r * = 8 5 . 0 A ) ,  
a l d o l a s e  ( r * = . ! A )  and f e r r i t i n  ( r * = 6 1 . 0 A ) .
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Figure 3 .1 7  : A r e p r e s e n t a t i v e  column e l u t i o n  p r o f i l e  o b t a i n e d  
with  s i z e  e x c l u s i o n  chromatography on an u l t r o g e l  
AcA-22 column. C y t o s o l s  were i n c u b a t e d  in  the 
p r e s e n c e  o f  20mM sodium m olybdate  (cYT(+)).
I n c u b a t i o n  with  3 H-E  ^ was e x e c u t e d  a t  20°Cx30min. 
I n c u b a t i o n  wi th  250 f o l d  e x c e s s  o f  u n l a b e l l e d  
l i g a n d  ( f o r  NSB) was per form ed  s i m u l t a n e o u s l y .  The 
su p e r n a t a n t  ( 500 jj1) o f  2000xg 'x10  min was l a y e r e d  
on the  column. The m o b i l e  phase was TEDAG b u f f e r  
and the  f l o w  r a t e  was 4 . 9  m£/cm. Marker p r o t e i n s  
used were c a t a l a s e  (C) and a l d o l a s e  ( A) .
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Figure 3 . 18 R e p r e s e n t a t i v e  c a l i b r a t i o n  cu rve  f o r  the Waters 
1 -250 HPLC g e l  column. The d i f f e r e n t  marker p r o t e i n s  
used were : r i b o n u c l e a s e  ( 1 ) ,  chym otryps in  ( 2 ) ,  
albumin ( 3 ) ,  a l d o l a s e  ( 4 ) ,  c a t a l a s e  ( 5 ) ,  f e r r i t i n  
(6)  and t h y r o g l o b u l i n  ( 7 ) .  The column was e l u t e d  
w ith  d i f f e r e n t  m o b i l e  phases : PEG b u f f e r  ( A) ,
PEGK , b u f f e r  (B) and PEGK.,,,, b u f f e r  (C) 100 400
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Figure 3 . 1 9  : R e p r e s e n t a t i v e  s i z e  e x c l u s i o n  chromatography p r o f i l e  
o f  VMU ER on Waters 1-250 column. C y t o s o l s  were 
p r e p a r e d  in  the p r e s e n c e  o f  sodium molybdate and 
l a b e l l e d  w i th  3H-E2 (30 minx20°C).  The DCC t r e a t e d  
su p e r n a t a n t  was i n j e c t e d  o n t o  the column. A run was 
a l s o  e x e c u t e d  em ploy in g  a 250 f o l d  e x c e s s  u n l a b e l l e d  
DES. Columns were c a l i b r a t e d  with a s e t  o f  
u n l a b e l l e d  marker p r o t e i n s  (as  i n d i c a t e d  in F ig .  
3 . 1 8 ) .  The m o b i l e  phase was PECK b u f f e r  and the f l o w  
r a t e  was 1ml/min.
TABLE 3.9
Molecular weights and Stokes radii of VMU ER calculated from column
data:
Cytosol M o b i l e  phase MW
( x 1 0 ^ d a l t o n s )
r *
O
(A)
R e c e p t o r  c l a s s  
(Sherman e t  a l  
( 213 ) )
CYT(-) TEDAG1q+ 0 .4  MKC1 * 0 .9210 .21 4 2 . 1 1 1 . 3 I I I
CYT(-) TEDAG +0 .1 5  MKCl 0 . 8 6 1 0 . 3 41 . 8 1 1 . 5 I I I
CYT (+) TEDAG., „+20mM Na_MoO, 10 2 4 3 . 8 3 1 0 . 4 6 6 0 . 5 1 2 . 6 I
CYT(-) TEDAG1 4 .6 8 1 0 . 3 5 6 3 . 2 1 2 . 5 I
(* r=Stokes r a d i u s ;  ± S.E.M. = s tan d ard  e r r o r  o f  the  mean; mean o f  3 
assays)
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TABLE 3.10
Summary of data on molecular weight of ER using different conditions
on Waters 1-250 HPLC gel column.
Cytoso l M o b i le  phase M o le c u la r  mass C a l i b r a t i o n
(x 105 d a l t o n s ) cu rve
Peak 1 Peak 2
CYT(+) MPEG - 2 .0 06 1
CYT( - ) PEG 4 .8 2 2 .0 0 6 i
CYT( - ) PEGKioo - 2 . 113 i
CYT( - ) PEGKioo - 1 .204 2
CYT( - ) PEGK°400 7 .196 - 1
CYT( - ) PEGK°400 8 .5 5 6 - 3
CYT(+) PEGK°400 - 1 . 252 1
CYT (+) PEGK“aoo
PEGK400
- 1 . 1 04 3
CYT( - ) 7 .1 96 - 1
CYT( - ) PEGK^400 3 .5 56 - 3
CYT(+)
PEGK400
- 1 . 526 1
CYT(+) - 1 .1 04 3
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Figure  3 . 20  : HPLC Ion exchange  chromatography o f  V e r v e t  monkey
u t e r i n e  ER on an AX-1000 column. C y t o s o l s  f r e e  
o f  sodium m olybdate  CYT(- )  were ch arged  by i n c u b a ­
t i o n  w i th  1 2 5 I-Ez f o r  18-24h  a t  0 -4 ° C  in  the p r e ­
se n c e  o r  a b s e n c e  o f  a 250 f o l d  e x c e s s  DES. Unbound 
l i g a n d  was removed by DCC and the 2000xg '  su perna ­
t a n t s  a p p l i e d  t o  the  columns.  Columns were e q u i l i ­
b r a t e d  w i t h  25 mM T r i s  b u f f e r  (pH 8 . 2 )  and d e v e l o ­
ped with  a l i m i t i n g  b u f f e r  c o n t a i n i n g  500 mM p h os ­
p h ate .  Flow r a t e  was 1 m£/min and 1 mf f r a c t i o n s  
were c o l l e c t e d .
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F ig u r e  3.21 : HPLC Ion  exchange  chromatography o f  v e r v e t  monkey
u t e r i n e  ER on an AX-1000 column. The e f f e c t  o f  
sodium m o lyb date  on the i o n i c  p r o p e r t i e s  i s  d e p i c t e d  
in  the  chromatograms above .  C y t o s o l s  c o n t a i n i n g  
sodium m olyb date  CYT(+) were charged  by i n c u b a t i o n  
w i th  1 2 5 I -E 2 f o r  18-24h  a t  0 -4 °C  i n  the  p r e s e n c e  o r  
a b s e n c e  o f  a 250 f o l d  e x c e s s  DES. Unbound l i g a n d  was 
removed by DCC and the  2000xg '  s u p e r n a ta n ts  a p p l i e d  
t o  the  co lumns.  Columns were e q u i l i b r a t e d  wi th  25 mM 
T r i s  b u f f e r  (pH 8 . 2 )  and d e v e l o p e d  wi th  a l i m i t i n g  
b u f f e r  c o n t a i n i n g  500 mM ph osph ate .  Flow r a t e  was 
1 mf /min  and 1 ml f r a c t i o n s  were c o l l e c t e d .
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F ig u r e  3 .2 2  : HPLC c h r o m a t o f o c u s s i n g  o f  V e r v e t  monkey ER on an *125
Ax-500 column. The ab s e n c e  o f  m olybdate  on the  i o n i c  
p r o p e r t i e s  o f  the  r e c e p t o r  m o l e c u l e s  i s  i l l u s t r a t e d .  
C y t o s o l s  were p r e p a r e d  in  the absence o f  sodium 
m o ly b d a te .  A l i g u o t s  o f  c y t o s o l s  were in c u b a t e d  with
125 I-E 2  w i th  o r  w i t h o u t  u n l a b e l l e d  DES (250 f o l d  
e x c e s s )  f o r  18 -24h  a t  0 -4 °C ,  t r e a t e d  with DCC and 
the  2000xg '  su p e r n a t a n t s  i n j e c t e d  o n to  the column. 
P r i o r  t o  sample a p p l i c a t i o n  the columns were
e g u i l i b r a t e d  wi th  a 25 mM T r i s  b u f f e r  (pH) 8 . 4 )  
u n t i l  the column e l u a t e  had a pH o f  8 . 2  t o
8 . 4 . Columns were d e v e l o p e d  by e l u t i n g  wi th  a 30 :70  
m ix tu re  o f  P o l y b u f f e r s  (Pharmacia)  96 and 74 r e s p e c ­
t i v e l y  ( d i l u t i o n  1 : 15  wi th  20% g l y c e r o l ) .  The pH o f  
the  P o l y b u f f e r  m ixture  was a d j u s t e d  t o  4 . 5 .  Flow 
r a t e  was 1 mf/min and the pH o f  e v e r y  secon d  f r a c ­
t i o n  d e te rm in e d .
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Figure 3 .2 3  : HPLC c h r o m a t o f o c u s s i n g  o f  V e r v e t  monkey ER on an *12
Ax-500 column. The e f f e c t  o f  m olybdate  on the i o n i c  
p r o p e r t i e s  o f  the r e c e p t o r  m o l e c u l e s  i s  i l l u s t r a t e d .  
C y t o s o l s  were p r e p a r e d  in  the  p r e s e n c e  o f  sodium 
m olyb date .  A l i q u o t s  o f  c y t o s o l s  were in c u b a t e d  with
12 5 1-Ez w ith  o r  w i t h o u t  u n l a b e l l e d  DES (250 f o l d  
e x c e s s )  f o r  18-24h a t  0 -4 °C ,  t r e a t e d  w ith  DCC and 
the  2000xg'  su p e r n a t a n t s  i n j e c t e d  o n to  the column. 
P r i o r  t o  sample a p p l i c a t i o n  the columns were 
e q u i l i b r a t e d  with  a 25 mM T r i s  b u f f e r  (pH) 8 . 4 )  
u n t i l  the  column e l u a t e  had a pH o f  8 . 2  t o
8 . 4 . Columns were d e v e l o p e d  by e l u t i n g  with  a 30 :70  
m ix tu r e  o f  P o l y b u f f e r s  (Pharmacia)  96 and 74 r e s p e c ­
t i v e l y  ( d i l u t i o n  1: 15 w i th  20% g l y c e r o l ) .  The pH o f  
the P o l y b u f f e r  m ix tu r e  was a d j u s t e d  t o  4 . 5 .  Flow 
r a t e  was 1 m£/min and the  pH o f  e v e r y  secon d  f r a c ­
t i o n  d e te rm in e d .
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TABLE 3.11
A summary of ER species obtained, following HPLC chromato­
focussing of CYT(-) and CYT(+) cytosols on an AX-500 
polyamine column
Isoelectric points
Peak CYT(-) CYT(+)
1 8.2 -
2 8.0 -
3 7.4 -
4 7.1 -
5 6.5 6.1
6 5.8 5.5
7 4.5-5.4 -
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Figure 3.24 : Iso-electric focussing on Agarose gels of the Vervet 
monkey uterine ER. Ampholine range employed, was pH 
5-8.Cytosols prepared in the absence of molybdate 
(CYT(-)) were incubated with 125 I-E^ with or without 
unlabelled DES (250 fold excess) for 18-24h at 
0-4°C. Reactions were stopped by treatment with DCC 
and the 2000xg' supernatants applied to the gels 
(power, 15W) the gels were cut manually into 1 mm 
slices and the slices placed into counting vials and 
the radio-activity monitored. The pH gradient of the 
gels was calibrated employing standard proteins : 
lactoglobulin (pi 5.5-5.5), myoglobin (horse, pi 
7.4,7.0), carbonic anhydrase (pi 6.1), myoglobin 
(sperm whale, pi 7.7, 8.2).
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Figure 3.25 : Iso-electric focussing on Agarose gels of the Vervet 
monkey uterine ER. Ampholine range employed, was pH 
5-8. The effect of sodium molybdate on the molecular 
properties of the ER is depicted in the figures 
above. Cytosols prepared in molybdate (CYT(+) were 
incubated with 125I-E2 with or without unlabelled 
DES (250 fold excess) for 18-24h at 0-4°C. Reactions 
were stopped by treatment with DCC and the 2000xg' 
supernatants applied to the gels. Following the 
development of the gels (power, 15W) the gels were 
cut manually into 1 mm slices and the slices placed 
into counting vials and the radio-activity monito­
red. The pH gradient of the gels was calibrated 
employing standard proteins : lactoglobulin (pi 5.5­
5.5), myoglobin (horse, pi 7.4,7.0), carbonic anhy- 
drase (pi 6.1), myoglobin (sperm whale, pi 7.7,
8 . 2 ) .
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TABLE 3.12
A sunmmary of ER species obtained, following iso-electric 
focussing on agarose gels (pH range : 5-8) in the absence 
and presence of sodium molybdate.
CYT(-) CYT(+)
Peak Pi *%B Pi %B
1 6.8 4.07 6.8 16.6
2 6.2 30.3 - -
3 5.9 28.9 5.9 39.9
4 - - 5.6 13.0
5 - - 5.0-5.5 30.5
(*%B = % specific binding in peak)
CHAPTER 4
EFFECT OF KC1 ON SEDIMENTATION PROPERTIES OF THE VERVET MON­
KEY UTERINE OESTROGEN AND PROGESTERONE RECEPTORS.
INTRODUCTION:
Apart from general characteristies of the process of hormone 
receptor interaction as discussed in Chapters 1 and 3, there 
are several features that the different hormone receptor 
systems have in common. First, many of the receptors studied 
seem to possess a highly similar molecular architecture 
(243). Secondly, there seems to be remarkable similarity in 
the effects of certain chemical agents (e.g.) sodium molyb­
date, proteolytic inhibitors, sulfhydryl active chemicals on 
steroid receptor structure and function (232,235-237). 
Thirdly, the receptors appear to dissociate into smaller 
subunits in hypertonic media (25,238).
These common effects, would seem to imply that, apart from 
the obvious similarities in overall size and shape, there 
exists some common architecture in the subunit organization. 
The effect of 0.4 m KC1 on the mechanism of action of female 
sex hormones was first studied in detail by Jensen & De 
Sombre (239). These workers demonstrated that the radio­
active oestradiol taken up by the immature rat uteri, was 
associated with a different form of the receptor entity in 
the cytosol than in the nucleus. Upon ultracentrifugation 
in low ionic strength sucrose density gradients, the cyto­
solic complex sediments as a discrete band displaying a 
sedimentation coefficient originally believed to be 9,5 S 
(23), but later proved to be ^ 8 S (241).
In the presence of sodium or potassium chloride, at concen­
trations of 0.2 M or higher,the v 8 S complex is transformed 
into a more slowly sedimenting entity, with a sedimentation
coefficient close to that of bovine serum albumin (215). 
This "transformation" was thought to consist of a process of 
dissociation from the ^ 8 S to a ^ 4 S entity and was claim­
ed to be fully reversible.
The effect of hypertonic media on the receptors was studied 
in more detail by Stanley and Korenmann (242), who demon­
strated that oestrogen binding activity in the cytosolic 
fraction of rabbit and rat uteri underwent a reversible 
dissociation in 0.3 M KC1. Erdos (27) studied the state 
of aggregation of the receptor-oestradiol-complex as a func­
tion of the ionic strength. The labelled cytosol was incuba­
ted overnight in the presence of different concentrations of 
KC1 and analysed on sucrose gradients containing the corres­
ponding amounts of KC1. Up to 0.05 M the position and pat­
tern of the radioactive peak remains unchanged, i.e. the 
sedimentation constant is still ^ 8 S. Between 0.3 - 1.0 M 
KC1 the radio-active complex displayed a sedimentation con­
stant of 5 S. Incubation with KC1 does not change the amount 
of 3H-oestradiol bound by the receptor, and in fact the 
results are identical whether the extract is labelled 
before, simultaneously or after addition of KC1. NaCl was 
found to have the same effect as KC1.
Wittliff et aj_ (13) reported that specific oestrogen binding 
components in cytosols of lactating rat mammary gland sedi­
mented at 8.6S under conditions of low ionic strength and at 
4.6S on sucrose gradients containing 0.4 M KC1 (238). No 
loss in bound radioactivity under these conditions occurred, 
indicating that conversion of protein-associated steroid was 
involved. According to Jensen & De Sombre (243) both the 
'v 8 and % 4 S complexes sediment at ^ 8 S in low sait su­
crose gradients, but they can be readily distinguished in 
the presence of 0.3 M KC1 which reversibly dissociates the ^ 
8 S complexes into steroid-binding subunits. The cytosol 
complex sediments at 3.8 S and the nuclear complex sediments 
at 5.2 S. These two subunit complexes are usually referred
i by
to as the 4 5 and 5 S complexes,respectively. In their clas­
sical twostep model for steroid hormone action, presented in 
Fig. 4.a Jensen and De Sombre (243 j gave an explana­
tion for' the different roles, played by various hormone 
receptor species, observed in low and high ionic strength 
buffers.
In this model the predominant oestradiol-receptor complex is 
not derived from a nuclear receptor protein, but originated 
from an extranuclear complex, which was translocated to the 
nuclear compartment, following a "temperature-dependent 
transformation" of the initial ^ 8 S cytosolic hormone- 
receptor complex.
In the light of the importance of understanding the nature 
of receptor-subunit organisation, it was deemed necessary to 
investigate the effect of KC1 on the sedimentation proper­
ties of the VMU ER and PR.
4.2 MATERIALS AND METHODS:
4.2.1 Preparation of cytosols and gradients:
A pool of uteri were sliced up into small, thin sections, 
the pieces thoroughly mixed and divided into two equal parts 
(by weight). One part was homogenized in 10 mM Tris-HCl 
buffer (pH=7.4) containing 20mM sodium molybdate while the 
other part was homogenized in a similar buffer not contain­
ing sodium molybdate. Cytosols were either used immediately, 
or stored at -70°C in 1 ml aliquots, prior to the experi­
ment.
Gradients containing 0.4 M KC1 but no sodium molybdate were 
prepared as described in Section 2.9.2.
4.2.2 Expermimental Procedure:
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Figure 4,a: Schematic representation of interaction pathway of 
oestradiol in uterine cell (E). (From Jensen and 
DeSombre) (243).
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4.2.2.1 Dissociation (in situ) of ER and PR on hypertonic (0.4 M 
KC1) sucrose density gradients during centrifugation : ef­
fect of sodium molybdate in cytosols on gradient profiles :
The cytosols contained (CYT(+)) or did not contain (CYT(-)) 
sodium molybdate (20mM). Cytosols (200 , 6-8 mg/rrul
cytosolic protein) were incubated with 3H-E2 or 3H-R5020 to 
a final ligand concentration of 5nM at 20°C for 30 min, with 
(non-specific binding) or without (total binding) a 250 fold 
excess of either DES or R5020. The reaction was terminated 
by transferring the incubation solution to a DCC pellet. The 
slurry was thoroughly vortexed and the DCC spun down at 
2000xg' (15 min). An aliquot (200ul) of the resulting 
supernatant was layered onto sucrose density gradient 
containing 0.4 M KC1. Following centrifugation (VTi-80 
rotor; 520000xg1x2hx2-4°C) the gradients were fractionated 
and processed as described in Section 2.9.2.
4.2.2.2 Dissociation of ER and PR, following reincubation in hyper­
tonic buffer (0.4M KC1) for various times, prior to centri­
fugation on hypertonic gradients :
The cytosols contained (CYT(+)) or did not contain (CYT(-)) 
sodium molybdate (20mM). Cytosols (200^4; 6-8 mg/rM cyto­
solic protein) were charged by incubation with an equal 
volume of the proper radioligand (final concentration : 5 
nM; 3H-E2 or 3H-R5020 with (non-specific binding) or without 
an excess (250 fold) of the proper unlabelled competitor 
(DES or R5020) for 30 min. at 20°C. Labelled cytosols were 
then reincubated at 0-4°C for various periods (0, 5, 10, 20 
min), following the addition of a small volume (100pJZ) of 
concentrated KC1 (2M) in TEDAG^ buffer to render a final 
concentration of 0.4 M KC1.
The second incubation was terminated by transferring the 
cytosolic solutions to a DCC pellet, followed by vortexing 
and centrifugation at 2000xg' for 15 min in the cold
(0-4°C). The clear supernatants were then layered onto 
precooled gradients, prepared as described before and cen­
trifugation usually commenced ten minutes later. Following 
completion of centrifugation (VTi 80 rotor; 520000xg'x2h) 
gradients were processed as before.
4.2.2.3 Reversibility of the dissociation of ER and PR : sedimenta­
tion dialysis.
The experiment was executed as described in Section 4.2.2 
above except that the second incubation was followed by 
centrifugation (VTi-80; 52000xg1x2hx2°C) of the resultant
0.4M KC1 cytosols on low ionic strength sucrose density 
gradients. Gradients either contained (GRAD(+)) or did not 
contain (GRAD(-)) 20mM sodium molybdate.
4.3 RESULTS AND DISCUSSION :
Typical SDG profiles, obtained when VMU receptors were 
allowed to dissociate _i_n situ in the high ionic strength 
gradient solutions (0.4 M KC1) during centrifugation, are 
depicted in Fig. 4.1 and Fig. 4.2. As a rule these profiles 
seemed to be more complex than those reported by the majo­
rity of workers in the field (221,238 ). Sodium molybdate 
only seems to effect higher yields of all the different 
molecular species and exerted no selective protection for a 
particular molecular entity after a slight shift towards 
lower S-values occurred. Flowever it is doubtful whether 
these shifts are at all significant. A distinct difference 
can be observed between the ER and PR with reference to the 
ratio of the different peaks in the profile. For the ER the 
6.9 S peak seems to be more prominent than the 5.6 S entity. 
The PR displayed the opposite of what is observed for the ER 
: here the 6.2 S species is the minor component, while the 
4.6 S is the dominant molecular entity.
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When cytosols were reincubated with 0.4 M KCI, prior to cen­
trifugation on the 0.4 M KCI containing SDG (10-35% sucrose) 
a progressive loss of the faster sedimenting 6-7 S) en­
tity, with a resultant increase in the slower sedimenting 
components 4-6 S) could be observed. Again, sodium 
molybdate only affected the yield, but not the relative pro­
portions of the different molecular entities. The progeste­
rone receptor seems to dissociate at a faster rate, compared 
to the ER as judged from the SDG profiles, but qualitatively 
it is following the same pattern. The faster sedimenting PR 
entity, however, seems to shift to lower S values for cyto­
sols prepared in the presence of sodium molybdate (CYT(+i), 
while the shift for the ER in the presence of sodium molyb­
date is towards slightly higher S-values.
Reversibility of the dissociation of the ER seems to be af­
fected by the length of time it is exposed to 0.4 M KCI du­
ring a second incubation at 0 - 4°C. The dissociation at 
zero time exposure (pre-centrifugation) is practically 
totally reversible, while a swift decrease in reversibility 
is observed at longer pre-centrifugation exposure to hyper­
tonic buffers. A remarkable feature observed in this re­
versibility study, is that sodium molybdate tends to cause 
severe aggregation of the % 8 S of molecules, which is ag- 
grevated the longer the second incubation in 0.4 M KCI. 
Quantitatively (Table 4.1) it can be seen that in the absen­
ce of sodium molybdate (CYT(-)) the longer KCI incubation
r
renders a linear decrease in the surface area of the ^ 8 S 
peaks, while a directly proportional increase in the surface 
area of the 4 S peaks can be observed (Fig. 4.8). For molyb­
date containing cytosols (CYT( + )), the loss in the ^ 8  S 
entity can be attributed to the formation of aggregates. The 
rate of increase in the ^ 4  S area seems to be the same for 
both (CYT(+) and CYT(-i), while the rate of decrease in the 
^ 8 S peak is 82 % greater for CYT(+) than for CYT(-) cyto­
sols.
U T E R I N E  TI S S U E  (-70°)
r-buffer +
homogen i ze-
Na2Mo04
L- buffer - Na^MoO^ 
,,105 OOOxg' x 30 min 
CYT(+) and CYT(-) cytosols
+ 3 El-ligand ± unlabeljed competitor 
incubation (1) : 20°C x 30 min.
labelled CYT( + ) and CYT(-)
+ KC1 (final concentration 0.4M) 
incubation (2) : 0-4°C x t ■
(i = 0,5,10,20 min)
,,DCC pellet
CYT(±) 10 CYT(±)
layer onto 0.4MKC1 SDG 
centrifugation 
(520000xg'x2hx2°C) 
fractionate
layer onto low p SDG 
(l) SDG+Na2Mo04 
(ii) SDG-Na2Mo04 
centrifugation 
(520000xg'x2hx2°C)
0.4MKC1 SDG profiles fractionate
▼
hypertonic CYT( + ) SDG 
profiles
hypotonic CYT(-) SDG 
proflles
FLOW DIAGRAM 4.1 : Methodology for investigating the
dissociation of VMU ER and PR in 
hypertonic media.
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Figure 4.1: Dissociation of the VMU ER and PR on . 10-35 % sucrose *3
density gradients containing 0.4 M KC1. Comparison of 
ER with PR : (A) dissociation of VMU ER : (A) CYT(+)
and (•) CYT (-) cytosols; (B) dissociation of VMU PR : 
Cytosols were prepared in the presence (CYT(+)) or 
absence (CYT(-)) of 20mM sodium molybdate. Following 
incubation with the appropriate ligands ( 5nM 5 H-Ei, or
3H-5020) for 30 min at 20°C, the charged cytosols were 
treated with DCC and the 2000xg' supernatants (200pP) 
applied to precooled hypertonic (0.4M KC1) SDG (10-35°s 
sucrose). Centrifugation was executed at 520000xg' for 
2h at 2-4°C and the gradients fractionated into 5 drop 
fractions.
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Figure 4.2: Effect of sodium molybdate on the dissociation of the 
VMU receptors on 10-35 % SDG containing 0.4 M KCl.
Comparison of the dissocation of ER and PR receptors 
in C YT(+) and CYT(-) cytosols : (A) dissociation of ER
and PR in CYT(+) cytosols : (■) ER, (•) PR; (B) disso­
ciation of ER and PR in CYT(-) cytosols : (■) ER and
(•) PR. Cytosols were prepared in the presence or 
absence of 20 mM sodium molybdate. After incubation 
with the appropriate ligand ('H-E, or 3H-R5020) for 30 
min at 20°C in the absence (total binding) or presence 
(non-specific binding) of 250 fold excess of either 
DES or R 5020. The DCC treated supernatants (2000xg' 
x10 min) were layered onto hypertonic (0.4 M KCl) IQ- 
35 % SDG,following ultra-centrifugation (VTi-80 rotor, 
520000g'x120 minx2°C). The gradients were fractionated 
into 5 drop fractions and the fractions monitored for 
total and non-specific bindings.
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Figure 4.3: Dissociation of VMU ER, following different pre-cen­
trifugation exposure times to 0.4 M KC1. Cytosols were 
prepared in the absence of sodium molybdate (CYT(-)). 
Cytosolic receptors were charged (20°Cx30 min) with 
radioligand (3H-Ej ; final concentration, 5 nM) in the 
absence (total binding) or presence (non-specific bin­
ding) of a 250 fold excess of the unlabelled ligand 
(DES). Prior to DCC treatment, a solution of KC1 (2M) 
was added to the reaction mixture (final concentration 
of KC1, 0.4 M) and the resulting solution reincubated 
on ice (0°C) for varying time intervals : (A) zero
time incubation : following the addition of the KCl, 
the reaction was immediately stopped by the addition 
of DCC, (B) 5 minutes; (C) 10 minutes and (D) 20 minu­
tes. The resulting 2000xg' supernatants of the DCC 
treated incubation mixtures were then subjected to ul­
tra-centrifugation of 10-35 % SDG (VTi rotor; 520000 
x g'x120 min) at low temperature (2°C) after which the
gradients were fractionated (40x5 drop fractions) and 
counted for radioactivity.
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F R A C T I O N
Figure 4.4: Dissociation of VMU FR, following different precentri­
fugation exposure times to 0.4 M KC1. Cytosols were 
prepared in the presence of 20 mM sodium molybdate 
(CYT (+)). Cytosolic receptors were charged (20°Cx30 
min) with radioligand (3H-E2 ; final concentration, 5 
nM) in the absence (total binding) or presence (non­
specific binding) of a 250 fold excess of the unlabel­
led ligand (DES). Prior to DCC treatment, a solution 
of KC1 (2M) was added to the reaction mixture (final
concentration of KC1, 0.4 M) and the resulting solu­
tion reincubated on ice (0°C) for varying time inter­
vals : (A) zero time incubation : following the addi­
tion of the KCl, the reaction was immediately stopped 
by the addition of DCC, (B) 5 minutes; (C) 10 minutes 
and (D)20 minutes. The resulting 2000xg' supernatants 
of the DCC treated incubation mixtures were then s 
jected to ultra-centrifugation of 10-35 % S D G  
tor; 520000 x g'x120 min) at low temperatur .. _
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Figure  4.
#
5: Dissociation of VMU PR following precentrifugation ex­
posure to 0.4 M KCl. Cytosols were prepared either in 
the presence (CYT(+)) or absence (CYT(-)) of 20mM so­
dium molybdate. Following the first incubation (20°C 
x30 min) with 3H-R 5020 (final concentration, 5nM> in 
the absence (total binding) for presence (non-specific 
binding) of a 250-fold excess if R 5020, the incuba­
tion mixture were reincubated (0°C for varying time 
intervals, following the addition of KCl : (A) zero
time exposure (•) CYT(+), (A) CYT(-) (B) 10 min expo­
sure (•) CYT (+), (A) CYT(+). After completion of the
second incubation the incubation mixtures were treated 
with DCC and the 2000xg' supernatants (200pf) layered 
onto hypertonic 10-35 % SDG. The SDG profiles were
obtained following ultracentrifugation (VTi-80 rotor, 
520000xg1x120 minx2°C) and fractionation (40x5 drop 
fractions).
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Figure 4.6: Effect of the duration of pre-centrifugation exposure 
of cytosolic receptors to 0.4 M KCl on the reversible 
dissociation of the VMU ER on low ionic strength SDG. 
Cytosols were prepared in the absence ((CYT(-)) of 
sodium molybdate. Gradients also did not contain 
((Grad(-)) any sodium molybdate or 0.4 M KCl. Follow­
ing the first incubation (20°Cx30 min) with 3H-Ez 
(final concentration, 5 iiM ) in the absence (total 
binding) or presence (non-specific binding) of a 250 
fold excess of DES the incubation mixture were reincu­
bated (O'C) for varying time intervals, following the 
addition of KCl to a final concentration of 0.4 M KCl 
: (A) zero time incubation; (B) 5 min, (C) 10 min and
(D) 20 min. After completion of the second incubation
the incubation mixtures were treated with DCC and the 
2000xg’ supernatants (200pf) layered onto hypotonic 
10-35 % SDG. The SDG profiles were obtained following 
ultra-centrifugation (VTi-80 rotor, 520000xg’x120 minx 
2°C) and fractionation (40x5 drop fractions).
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Figure 4.7: Effect of the duration of pre-centrifugation exposure 
of cytosolic receptors to 0.4 M KCl on the reversible 
dissociation of the VMU ER on low ionic strength SDG. 
Cytosols were prepared in the presence (CYT(+)) of 
20mM sodium molybdate. Gradients also contained 
(GRAD(+)) molybdate but no KCl. Following the first 
incubation (20°Cx30 min) with 3H-E2 (final concen­
tration, 5 nM) in the absence (total binding) or 
presence (non-specific binding) of a 250 fold excess 
of DES the incubation mixture were reincubated (0°C) 
for varying time intervals, following the addition of 
KCl to a final concentration of 0.4 M KCl : (A) zero
time incubation; (D) 5 min, (C) 10 min and (D) 20 min. 
After completion of the second incubation the incuba­
tion mixtures were treated with DCC and the 2000xg' 
supernatants (200yP) layered onto hypotonic 10-35 % 
SDG. The SDG profiles were obtained following ultra­
centrifugation (VTi-80 rotor, 520000xg1xl20 minx 2°C) 
and fractionation (40x5 drop fractions).
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Figure 4. 8: Rates of disappearance of the 8 S high affinity bin­
ding component and the simultaneous formation of smal­
ler specific binding species in the 3 - 5 S area : (A) 
effect as seen with CYT(+) cytosols : (A) disappearan­
ce of 8 S peak (•) formation of 3 5 S specific binding 
components; (B) effect as seen with CYT(-) cytosols 
: ( a ) disappearance of 8 S and (+) formation of 3 - 5
S species. This figure represents an analysis of the 
reversibitlity experiments depicted in Fig 4.6 and 4.7
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TABLE 4.1
Effect of sodium molybdate on the dissociation of VMU ER in 
hypertonic (0.4M KC1) gradients, when cytosols were incuba­
ted at different times in hypertonic buffers (0.4M KC1), 
prior to centrifugation.
Time incubated 
in hypertonic 
buffer (second 
incubation) 
(min)
% Activity
CYT(+) CYT(-)
4 S 8 S *A A+8S 4 S 8 S A A+8S
0 22.0 46.2 17.1 63.3 23.8 62.2
5 28.7 28.0 26.0 54.0 27.7 56.1 - -
10 31.1 20.6 29.0 49.6 26.9 52.6 - -
20 38.4 12.8 20.1 32.9 42.0 47.8 - -
(*A = aggregate)
CHAPTER 5
ACTIVATION, TRANSFORMATION AND TRANSLOCATION OF VMU ER AND 
PR.
INTRODUCTION
According to the classical, two-step model for steroid hor­
mone action, proposed by Jensen et aj_ (215) and Gorski et al 
(245), in the early 1960's, the initial cytoplasmic steroid 
receptor complex must be converted ("activated") into a 
form, exhibiting a high affinity for nuclear elements (245­
246). Binding of this "activated" complex to the chromatin, 
initiates transcription and the subsequent synthesis of spe­
cific hormone-induced proteins (246). A lot of uncertainty, 
concerning the actual nature of the "activated" species 
still exists. Several investigators made some interesting 
observations on the molecular and kinetic properties of the 
"activated" complex in recent years (248-249). These obser­
vations seem to support a model for ligand-induced receptor 
dimerization or association of dissimilar subunits, convert­
ing the non-activated ^ 4  S (MW ^ 7.5x104 daltons) to a 'v 5 
S "activated" (MW ^ 1.4x10^ daltons).
Receptor transformation seems to be hormone and tempera­
ture-dependent, and only the "activated" % 5 S receptor form 
exhibits a high affinity for target cell nuclei. An immedia­
te effect of this binding of the activated complex to the 
chromatin is the increase in RNA polymerase activity (247). 
Other studies (248) have also concluded that the ^ 5 S oes­
trogen binding protein consists of the ^ 4  S oestrogen re­
ceptor plus an additional protein. This additional protein 
was found to be present (248) in target, as well as non­
target, tissues. Notides (244) on the other hand, suggested 
that in the absence of hormone, the % 4  S binding protein is 
associated with a macromolecular inhibitor from which it 
must dissociate before it can form the activated % 5 S
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complex.
Evidence has also been presented for a dialyzable, low mole­
cular weight, heat stable inhibitory molecule or molecules 
in the cytosols of murine Leydig cell tumours (249) and rat 
uteri (250), which seemed to inhibit oestrogen receptor ac­
tivation. A similar low molecular weight inhibitor of gluco­
corticoid receptor activation has also been reported (251­
252). In the glucocorticoid receptor system, activation is 
associated with a change in isoelectric point of the recep­
tor without any significant change in sedimentation beha­
viour, as is observed for the oestrogen receptor (253, 254).
In the case of the oestrogen receptor it was observed that 
the activation of cytosols by dialysis did not require the 
presence of hormone (250) an observation which tend to ren­
der the process of receptor activation even more intriguing. 
The progesterone receptor of chick oviduct can be transform­
ed by heating (temperature activation), as well as by high 
salt treatment (salt activation), to acquire the capacity to 
bind to nuclei ATP-Sepharose, DNA-cellulose, or to phospho- 
cellulose (255).
Recent studies have shown that sodium molybdate, which is a 
potent phosphatase inhibitor (271), stabilizes the glucocor­
ticoid receptor (256) as well as the androgen and progeste­
rone receptors (257). The molybdate oxyanion appears to 
interfere with the transformation of the progesterone recep­
tor (257) and it is thought that receptor transformation may 
involve a dephosphorylation process (231-232).
It is still unsolved whether receptor transformation normal­
ly occurs in vivo in the cell cytoplasm or in the nucleus. 
In the light of the recently proposed nuclear model for 
steroid hormone action (46,45,258), it seems even more 
important to clear up uncertainties about the process of 
receptor activation and transformation (259). Although
temperature dependent receptor transformation can occur in 
the cytoplasm _i_n vitro, Yamamoto(248) recently reported that 
the 'v 4 S to ^ 5 S conversion occurs much more rapidly in 
the presence of DNA. In addition, Siiteri et al (259) repor­
ted finding a ^ 4 S receptor in target cell nuclei; a fin­
ding which seems to support the new model. Pulse-chase expe­
riments revealed that the level of the nuclear % 4 S form 
decreases with a concomitant increase in the level of the 
% 5 S form, suggesting that the ^ 4 S oestrogen binding pro­
tein is transformed within the nuclear compartment. This ^ 4 
S to "*> 5 S conversion within the nucleus has already been 
reported for several target tissues e.g. hypothalamus, pitu­
itary and uterus. The rates of receptor activation, however, 
were found to differ considerably among the three types of 
tissues (260).
It has recently been reported that the steroid binding 
portion of the receptor molecule is distinguishable from 
that portion of the receptor molecule required for nuclear 
binding. Mild proteolysis of cytoplasmic receptors for a 
variety of steroid classes generated a small (MkK 2-4x10^ 
daltons) fragment of the receptor ("meroreceptor") and which 
seem to retain the high affinity steroid binding properties, 
but lacks the capacity to bind to target cell nuclei(65).
More accurate information on the relation between nuclear 
and cytoplasmic forms of the oestrogen receptor has been 
derived from immunological investigations. Jensen and co­
workers (208) recently succeeded in generating antibodies to 
highly purified, nuclear oestradiol-receptor complexes from 
calf uteri. These antibodies cross reacted with both the 
nuclear and cytoplasmic oestrogen receptors from a variety 
of mammalian species (calf, rat, mouse, guinea pig and 
human). However, they did not seem to cross react with 
androgen or progesterone receptor complexes, indicating that 
definite immunogenic differences exist among the receptor 
proteins for different classes of steroid hormones (208).
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These monoclonal antibody preparations to the nuclear oes- 
tradiol receptor have been provided a novel tool in the 
study of receptor structure and function, as well as for the 
quantitation of the steroid hormone receptors in target tis- 
sues(261).
Studies on human breast cancer cells in culture (56, 262) 
indicated that approximately 75 % of the total oestrogen re­
ceptors .in these cells are contained in the nucleus even in 
the apparent absence of hormones. Many human breast tumours 
have also been found to contain substantial levels of 
"free," or unoccupied, nuclear receptors (196, 263), a fact 
which might indicate that this unusual distribution is not 
an artifact of j_n vitro assay conditions.
It has been suggested that phosphorylation affects the bin­
ding of steroid receptors to hormones and to nuclei (266). 
However, so far only limited evidence has been found to pro­
ve that steroid receptors are indeed phosphorylated (269). A 
nuclear phosphatase, inactivating the oestradiol receptor 
in vitro (267,268) as well as in vivo (269) and a Ca^depen- 
dent kinase which reacts with the receptors (270), have been 
reported to be present in oestrogen target tissues. These 
enzymes were partially purified and characterized by 
Auricchio et aj (271) and in so doing these researchers 
provided first direct evidence that the oestradiol receptor 
must be a phosphoprotein and that the "_in vitro" phosphory­
lation-dephosphorylation process could regulate its hormone 
binding activity (270).
The process by which the hormone receptor complex becomes 
"activated" would appear to differ for different hormone 
classes (264). This process might involve the dissociation 
of certain inhibitory factors or some changes in conforma­
tion, resulting from macromolecular (homologous or heterolo­
gous) associations (265). No single model, as yet, could 
explain the complex relationship between receptor-ligand
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interaction, transformation of the complexes, the nuclear 
binding of the hormone receptor complex and the resultant 
induction of various molecular responses. These dynamic 
features of steroid hormone-receptor interactions provide 
numerous key points at which hormone action may be regulated 
in order to provide the fine physiological control seen in 
diverse target tissues (246). It may also be an important 
level where differences in normal and abnormal tissues may 
occur.
We subsequently decided to investigate these processes as 
they occur in the VMU. Since we could not obtain abnormal 
(malignant or benign) uterine tissues for our experimental 
model, we decided to do some parallel studies on the dyna­
mics of activation-transformation and translocation in 
normal and abnormal human uterine tissues.
5.2 MATERIALS AND METHODS
5.2.1 Reagents
Reagents were the same as those described in Chapter 2. 
Calf thymus DNA was bought from Sigma. The cellulose em­
ployed in the synthesis of DNA cellulose was Munktell 410 
Cellulose (Bio-Rad, Richmond, California).
The diphenylamine reagent was prepared as follows : 0.3 g 
diphenylamine, 0.3nu2 concentrated E^SO^ . and 20 ml acetic 
acid: just before use, 0.1 ml of diluted acetaldehyde 
(1.6/lOOmje H20) was added to the diphenylamine reagent.
5.2.2 Preparation of cytosols and nuclei for binding studies
Uteri were cut into small pieces while still frozen and 
homogenized by one of 2 different methods :
(a) a Ultra Turrax (Janke & Kunkel) homogenizer
(b) a Dounce glass homogenizer
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The homogenates were first centrifuged at 800xg' for 10 min 
(0-4°C), after which the 800xg' supernatants were decanted 
and then recentrifuged at 105000xg1 for 30 min (0-4°C). The 
crude nuclear fraction was washed (3 times) with Tris-HCl 
buffer (pH=7.4) and approximately 2 ml of the final nuclear 
suspension were layered onto a 1.2 M sucrose pad (2 mJZ) in a 
5 mi! centrifuge tube. Following centrifugation at 6900xg' 
for 45 min (0-4°C), the washed and resuspended pellets were 
assayed . for DNA prior to the execution of the nuclear 
binding experiments. Cytosols (105000xg1 fraction) were 
processed at the same time. A comprehensive description of 
the procedure is shown in Flow diagram 5.1.
5.2.3 Protein and DNA determination
Protein concentration was assessed, employing the procedure 
of Lowry et aj_(273 ). described in Section 2.8, while the DNA 
content was assayed by a slightly modified method, developed 
by Burton(274).
To every 1 ml of either standard DNA solution or sample, 
0.22 ml perchloric acid (PCA, 2.5 N) was added. After 10-30 
min on ice and 5 min centrifugation at 2000 x g 1, the pellet 
was resuspended in 1 ml 0.3 N PCA. This suspension was 
subsequently hydrolysed for 30 min at 90°C, followed by 
rapid cooling and recentrifugation for 5 min at 2000 x g' . 
Two hundred and fifty \\l of this hydrolysate was added to 
500p£ of diphenylamine reagent, the reaction mixture was 
allowed to stand for 16 hours at room temperature and the 
absorbance measured at 600 nm.
Standard curve for DNA determination: 30mg of calf thymus 
DNA were dissolved in 100m£ of 5 mM NaOH. 7 different DNA 
dilutions were prepared ranging from 25 to 300 pg/mjl DNA.
The standard curve is depicted in Fig 5.1.
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5.2.4 Preparation of DNA-cellulose
DNA-cellulose was prepared according to Albert and Herrick 
(272) with only minor modifications : Fifty grams of cellu­
lose were washed several times with boiling ethanol to 
remove adsorbed pyridine. The ethanol was removed by suction 
and the cellulose susequently washed repeatedly with 0.1 M 
NaOH 1 mM trisodium EDTA (Tris-EDTA) and 10mM HC1 solutions 
at room, temperature. After washing the cellulose with water 
to neutrality, it was lyophylized to dryness and then 
employed in the preparation of DNA-cellulose.
A solution of DNA (1-3 mg/mji in 10 mM Tris-HCl containing 1 
mM Na^ at pH 7.4) was transferred to a glass beaker. Clean, 
dry cellulose was added with occasional stirring, until the 
paste thickened (approximately 1 g cellulose per 3 ml). The 
lumpy mixture was spread out in an evaporating dish and left 
at room temperature and then covered with gauze until it was 
dry. After grinding the lumps to a powder with a glass rod, 
any remaining water was removed by overnight lyophi1ization. 
The thoroughly dry powder was then suspended in approximate­
ly 20 volumes of Tris-EDTA and left at 4°C for one day. 
After two quick washes, to remove any free DNA, the DNA-cel- 
lulose was stored as a frozen slurry in Tris-EDTA,containing 
0.15 M sodium chloride.The DNA content of the DNA-cellulose 
was assayed as described in section 5.2.3.
5.2.5 Correlation of DNA content with number of uterine nuclei
In order to express nuclear binding as a function of DNA 
content and to correlate this way of expressing binding data 
with the total binding capacity per target cell nucleus, we 
endeavoured to employ the Coulter counter in the quantita­
tion of nuclei and subsequent calculation of the binding of 
receptor-complexes to nuclei.
Nuclei were prepared by the method described in section
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5.2.2. The washed nuclei were diluted serially and 
subsequently counted in Coulter counter. Results are 
depicted in Fig. 5.2.
5.3 ANALYSIS OF NUCLEAR RECEPTORS FOR VMU ER
5.3.1 Quantitative assay of nuclear receptors : the ligand exchan­
ge technique
5.3.3.1 Current methods:
The [J H|-oestradiol exchange assay has proven useful for 
measuring nuclear oestrogen receptor complexes in the uterus 
(252) pituitary glands and hypothalami (281) lactating 
mammary gland (238), corpi lutei (246), chicken oviducts 
(288) and in Leydig cell tumours (249). Clark et aj_ (278, 
280) employed a modified method for the measurement of pro­
gesterone and glucocorticoid receptors in the nuclear and 
cytoplasmic compartments of rat uteri as well as in rat and 
chicken liver nuclei. Other workers have reported the use of 
the exchange method to measure androgen receptors in the 
nuclei of the testis cells (277). Clark also used the same 
method to assay oestrogen receptor complexes bound to 
chromatin (278).
In this section we wish to present the method currently in 
use in our laboratory. This method was derived and modified 
from most of the techniques mentioned above, but with a bit 
more emphasis on Clark's method (278,280).
5.3.1.2 Experimental Procedure:
Uterine tissues were homogenized in a ground-glass (Dounce) 
homogenizer or an Ultra Turrax PT10 homogenizer in TEDAG^
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buffer to the pellet (1 mi/50mg) followed by thorough vortex- 
ing and subsequent recentrifugation at 800xg for 10 min. The 
crude washed nuclear pellet was resuspended by vortexing in 
TEDAG^g buffer (same ratio as above) and 100pl! homogeneous 
aliquots of the nuclear suspension dispensed into disposable 
culture tubes, which contained 5 different concentrations of 
3H-oestradiol or 3H-oestradiol plus a 100 fold excess of 
diethylstiIbestrol(DES) and 100p£ of buffer.
Assay tubes were placed in a 37°C shaking water bath for 30 
min. Exchange was terminated by the addition of 1 mH ice- 
cold TEDAG10 buffer to each tube, followed by centrifugation 
at 800xg' for 10 min (0-4°C). The nuclear pellet was washed 
(3 times) by resuspension in 1.5 ml ice-cold TEDAG^g buffer, 
vortexing and centrifugation described above. Subsequent­
ly, 1.0 ml 100 % ethanol was added to the washed nuclear
pellets and assay tubes were placed in a 30°C water bath for
10-20 minutes. The tubes were thoroughly vortexed and 
centrifuged at 800xg' for 10 minutes. The total ethanolic 
extract was added to 4 ml of scintillation cocktail and sam­
ples were counted in a Beckman LS 1800 scintillation coulter 
to an efficiency of 25-30 %.
5 3 2  Qualitative assay of nuclear receptors: : SPG analysis :
5.3.2.1 Introduction : extraction procedures for the nuclear
receptors :
In studies of specific hormone binding in the nucleus salt 
extraction of receptors and subsequent analysis on sucrose 
density gradients are probably the most common method of 
qualitative analysis (234). However this technique does not 
seem to be ideal, since only a fraction (7 %) of the nuclear 
receptors can be re-extracted (285). Another disadvantage of 
this method is the fact that the oestradiol receptor 
complexes normally undergo dissociation during extraction 
with high concentrations (0.3-0.6 M KC1) of salt (279-283).
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These problems have been found to be greatly magnified in 
human uterine tissue(284). Salt extraction of nuclear recep­
tors in this tissue appear to be highly inefficient. Rat et 
al (285) reported that mild trypsinization of calf uterine 
cytosol produced a stable form of the cytoplasmic receptor. 
Mild proteolysis not only effectively released nuclear 
receptors from high affinity chromatin "acceptor" sites, but 
also did not cause any impairment in oestradiol binding 
activity.(286).
5.3.2.2 Experimental procedure
The mild trypsinization procedure was slightly modified for 
the extraction of vervet monkey uterine nuclear receptors 
and was compared to the salt extraction method and DNAse I 
treatment. VMU tissue slices were incubated ^ 25 mg per 
incubation) with a final concentration of 5 nM [3H]-oestra- 
diol without (total binding) or with a 250 fold concentra­
tion DES (non-specific binding). Incubations were conducted 
at 27°C for 30 min in a C02 incubator (5% C02 : 92 % air). 
The uterine tissue slices were then thoroughly rinsed with 
ice cold TEDAG^q buffer and homogenized in a Dounce glass 
homogenizer or with an Ultra Turrax PT10 (Janke and Kunkel) 
at 3x10 second bursts (50 second cooling periods in ice 
inbetween). The homogenate was centrifuged at 800xg' for 20 
min. The 800xg' pellet was washed three times with ^  mi of 
TEDAG^q buffer, by resuspension (vortexing) and recentrifu­
gation at 800xg' for 10 min (0-4°C). The washed nuclear 
pellet was subsequently extracted by a number of procedures 
for one hour at 0°C, followed by centrifugation at 180000xg' 
for 15 min in a Beckman Ti50 rotor. The resulting super­
natant was assayed for radioactivity following removal of 
unbound ligand by treatment with a DCC pellet:
The following treatment and extraction procedures were 
employed:
(a) Trypsinize nuclear pellet for 15 min at 0°C, fol-
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lowed by extraction with 0.4 M KC1 for 15 min at 
0°C (trypsin-KCl method);
(b) extract nuclear pellet with 0.4M KC1 for 15 min at 
0°C (0.4 M KC1 method);
(c) hydrolysis with deoxyribonuclease I (DNAse 1) for
30 min at 0°C (DNAse method).
(a) Trypsin KC1 method:
In the case of the trypsin-KCl extraction, the nuclear 
pellet was first treated with trypsin: a nuclear pellet 
obtained from 150 mg monkey uterine tissue ('vSSOpg D N A )  was 
suspended and in 0.5 mSi T E D A G . g  buffer and incubated with 
50ng of trypsin(Sigma) for 15 min at 0°C, followed by the 
addition of 0.5mjZ of 0.8 M KC1 in T E D A G „ n  buffer (final 
concentration was 0.4M KC1) and incubation continued for 15 
min at 0°C. Excess trypsin inhibitor (100^g) was added to 
terminate proteolysis, prior to centrifugation at 80000xg' 
for 2 hours.
(b) 0.4 M KC1 method :
For the 0.4 M KC1 treatment the nuclear pellet was incubated 
for 15 min at 0°C with 0.4 M KC1 solution in TEDAG^.
Linear (10-35 %) sucrose density gradients were prepared as 
described in section 2.13. The nuclear extracts (200pje) were 
layered on 0.4 M KC1 sucrose gradients and the cytosols were 
layered on low salt gradients.
(c) DNAse method:
Nuclear pellets were also prepared in TEDAG1Q buffer 
(pH=7.4) and allowed to react with DNase 1 for 30 min at 
0°C. Optimal DNase 1 concentration was found to be 50pg per
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350pg of DNA in 0.5 mi! of TEDAG10 buffer (pH7.4).
5.3.2.3 Results
Fig. 5.1 represents a standard curve for the DNA assay.
A linear correlation could be illustrated between the amount 
of DNA present in the solution and the absorbance at 600nm 
(r=0.9998) for the range of 25-300 pg DNA per ml.
When nuclei were diluted with buffer, a linear correlation 
(r -0.964) was found to exist between the number of nuclei 
counted with the aid of the Coulter Counter and the dilution 
factor (Fig. 5.2). Furthermore, the DNA concentration also 
proved to be directly proportional (r = 0.969) to the number 
of nuclei (Coulter Counter) (Fig. 5.2). Although this method 
appeared to be quite reliable, visual inspection of the 
nuclear suspension with the light microscope (400 x 
magnification) revealed that a fairly large proportion of 
the nuclei (> 80 %) were broken and consequently it was
decided that it would be more accurate to perform DNA assays 
rather than to count number of nuclei.
Fig. 5.3 represents a typical Scatchard plot for nuclear 
binding while Table 5.1 represents a summary of binding data 
obtained for ER in approximately 53 VMU. The mean value for
ER was 1483±1236 fmol/mg DNA and the mean K . was 4.02±1.8x
-9 a
10 yM.
Fig (5.4) compares SDG profiles of cytosolic and nuclear 
oestrogen receptors isolated from tissue slices. The 
cytosolic receptors in tissue slices rendered one main peak 
at 7.6 S in hypotonic gradients, while the 0.4 M KC1 extract 
of the nuclear pellets (methods b) yielded one main peak at 
4.6 S and a minor peak at 3.8 S in hypertonic gradients. A 
comparison between SDG profiles obtained in hypertonic 
gradients following the other two methods of treatment and
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extraction of the nuclear pellets (method a and c) revealed 
peaks at 2.5 S and 4.5 S respectively (Fig. 5.5).
These results indicated that the molecular species extracted 
with DNase 1 (method c) had the same sedimentation coeffi­
cients as the 0.4m KC1 extracted entity (method b).
When a quantitative assessment for the different extraction 
procedures was made, it was observed that the best extrac­
tion could be obtained with the trypsin-KCl procedure (me­
thod b) a finding which agrees favourably with results re­
ported by other workers(282) (see Table 5.2).
5.4 DYNAMICS OF ACTIVATION, TRANSFORMATION AND NUCLEAR BINDING 
OF THE ER AND PR IN THE VMU:
5.4.1 Aim of investigation:
The problems surrounding the question of activation and 
transformation of "cytosolic" receptors as necessary prere­
quisites for the creation of specific binding species dis­
playing a high affinity for nuclear components have been 
discussed in Chapter 1 and in the introduction to this chap­
ter. It seems however necessary to explain that the main aim 
behind the experiments described in Chapter 5 is to produce 
creating a model system for studying the dynamics of the 
processes of activation and transformation of the steroid 
receptor species (ER and PR) in the vervet monkey uterus.
A decision was made to employ temperature induced activa­
tion-transformation in a cell free system and to follow the 
time course of events on high ionic strength sucrose density 
gradients. The sedimentation shift (% 4 S - ^ 5 S) could 
then be directly related to the increased affinity of the 
activated (^ 4 S) species for isolated uterine nuclei and
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binding to DNA-cellulose. Since sodium molybdate has been 
reported to inhibit transformation, it was employed as an 
activation inhibition control for the sedimentation shift 
and the nuclear and DNA-cellulose binding studies.
Since all the molecular processes-, involved in the activa­
tion-transformation-translocation occur in vivo in the 
intact cell it seemed logical to employ a tissue slice ap­
proach in parallel with a cell free system. In the next sec­
tions of this chapter the development of a model system for 
the study of the activation-transformation and subsequent 
binding of the activated (transformed) species to target 
cell nuclei and DNA-cellulose will be described. A need was 
also felt to employ the model in an investigation into the 
possibility that differences might exist in the processes of 
activation-transformation-translocation between normal, 
benign and malignant uterine tissues. Since abnormal monkey 
tissues are a rarity it was also decided to employ the model 
system employing normal, benign and malignant human uterine 
tissues.
5.4.2 Experimental procedure:
(a) Tissue slice technique:
Tissue slices were prepared from a pool of 10 vervet monkey 
uteri. Exactly 100 mg of tissue per assay, were incubated in
3
a final concentration of 5 nM of [ H]-oestradiol for varying 
periods at 3 different temperatures (0°C, 20°C and 37°C) in 
a C02 : air (5:95) atmosphere. In exactly the same fashion, 
a duplicate set of 100 mg tissue was incubated with a 250­
fold excess of D E S .
At 15-30 min intervals pairs of tubes for the different in­
cubation conditions were processed as follows:Incubation was 
terminated by the addition of a relatively large volume(5m£) 
chilled T E D A G ^ g  buffer, followed by thorough vortexing and
centrifugation (800xg'x10 min) to remove free ligand. This 
process was repeated three times. The washed tissue slices 
were then homogenized manually in a Dounce homogenizer 
(0-4°C). The 800xg' nuclear pellets were washed (3x) with 
TEDAG^q buffer and then extracted with 1 mji of absolute 
ethanol. Radio-activity was assayed, following the addition 
of 4 ml of scintillation cocktail and counting in a Beckman 
LS 1800 counter at an efficiency of 25-30 %.
(b) Cell Free System :
A batch of 10-15 VMU were cut into small pieces, which were 
thoroughly mixed and then divided (by weight) into 2 equal 
parts. One part was homogenized in TEDAG^ buffer con­
taining 20mM sodium molybdate (TEDAG-MO) and the other part 
in buffer not containing sodium molybdate(TEDAG^Q). The 
homogenates were centrifuged at 800xg'x10 min and the 
resulting cytosols were separated from the crude nuclear 
preparation. The cytosols were then centrifuged at 105000xg1 2
for 30 min (0-4°C). The crude nuclear sediments were washed 
(3x) with the appropriate buffer (with or without sodium 
molybdate). Cytosols were then incubated for 16 hr at 0°C
3
with a final concentration of 5nM of H-oestradiol or
3
H-R5020 in the presence (non-specific binding) or absence 
(total binding) of a 250 fold excess of the appropriate cold 
ligand (DES or R5020 respectively). The first incubation was 
then followed up by a second incubation at 30°C (activation) 
for varying times (0, 5,15 and 30 min).
Incubation was terminated by the addition of the "activated" 
cytosol to a DCC pellet, followed by vortexing and centri­
fugation (2000xg'x15 min). The activated cytosol was subse­
quently divided into 4 different parts which were employed 
to assay:
(1) total and non-specific cytosolic binding,
(2) sucrose density gradient profiles,
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(3) binding to uterine nuclei and
(4) binding to DNA-cellulose
5.4.3 Results
The time course of ligand distribution between the cytosolic 
and nuclear compartments at different incubation conditions 
is depicted in Fig. 5.6. As expected, the different tempe­
ratures, prevailing during incubations, affected the rate of 
uptake and distribution of the ligand receptor complexes 
between the cytosolic and nuclear compartments.
A quantitative analysis of the uptake and distribution of 
ligand-receptor complexes as a function of both time and 
temperature of incubation is summarised in Table 5.3 and 
Fig. 5.6. At 0°C nuclear uptake is suppressed and reaches a 
plateau at 30 min (29.6 %). Nuclear uptake increases with 
the duration of incubation and also with temperature. At 
37°C a distinct shift of complexes is observed from the 
cytosolic (71.3 % at 30 min) to the nuclear compartment (65 
% at 75 min) as a function of time. This shift also takes 
place at 20°C but at a reduced rate. This observation fits 
in with the view, that cellular uptake of the steroid 
hormone '(17-e-oestradiol) is followed by an intracellular 
redistribution of the ligand, resulting in maximum nuclear 
accumulation.
At physiological temperatures (37°C) a rapid depletion is 
noted in the cytosolic complexes with a concomitant increase 
in nuclear uptake. Because the cytosolic maximum (71.3 % at 
30 min) is reached prior to the nuclear maximum (65 % at 75 
min) it could imply that some processing of the cytosolic 
complexes (activation-transformation) is needed to speed up 
nuclear uptake. Because of several difficulties in the 
execution of the tissue slices study, it was decided to 
concentrate on the cell free system. This system consisted 
of an isolated cytosolic fraction, which is charged with
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radioligand, prior to activation (30°C x ti) and binding to 
nuclei and DNA-cellulose.
The temperature dependent activation of the ER and PR in 
CYT(+) and CYT(-) cytosols as a function of the duration of 
the second incubation at 30°C (assessed by SDG centrifuga­
tion) is depicted in Fig. 5.7-5.8 for ER and Fig. 5.9-5.10 
for PR. The first panel in the figures always serves as a 
control profile against which the activation transformation 
process depicted by the profiles in the other panels must be 
judged.
As a rule at zero time activation for the ER and PR, a main 
component, sedimenting at 4.3 S was observed in CYT(+) and 
CYT(-) for both ER and PR. A gradual shift from 4.3 S to 
3.98 S and 5.75 S could be demonstrated (Fig. 5.8 and 5.10). 
At 15 min activation-transformation, the major species is a
5.5 S component. This shift is not observed when sodium 
molybdate was employed in the preparation of the cytosols 
(CYT(+)) Fig 5.7.
Even at 30 min activation -transformation the CYT(+) ER 
sediments as a 4.0 S species a relatively large 8.2 S peak 
persists. Cytosols employed in the SDG analysis of 
activation-transformation were simultaneously used in 
binding assays to uterine nuclei and DNA-cellulose and the 
results are shown in Fig. 5.11 below.
A gradual increase in nuclear binding (and binding to DNA 
cellulose) was observed, following activation in the absence 
of molybdate (CYT(—)). Maximum binding (36.5 % for ER 
and 51.2 % for PR) occurred after 15 min of activation. 
Simultaneously, the maximum sedimentation shift could be 
seen in the hypertonic SDG profits (4.3 S to 5.52 S for ER 
and 3.7 S to 4.6 for PR). In the presence of molybdate
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(CYK+-)) .nuclear binding was inhibited (maximum binding 12.5 
% for ER and 15.5 % for PR) while the SDG profiles revealed 
an absence of the sedimentation shift for both ER and PR.
5.5 DYNAMICS OF ACTIVATION - TRANSFORMATION AND NUCLEAR BINDING
OF ER AND PR IN NORMAL HUMAN UTERINE TISSUES:
5.5.1 A comparison between the distribution and levels of ER and 
PR in normal Vervet monkey and human uterine tissues:
Individual Vervet monkey uteri were separated into the 
anatomically different parts e.g. myometrium, endometrium 
and cervix. Pools of the various parts were prepared (6-7 
uteri) and homogenised in TEDAG^-MO buffers as described 
before. Binding assays for both ER and PR were conducted in 
parallel with low ionic strength SDG analyses in gradients 
containing 20 mM sodium molybdate (GRAD(+)) for the pools of 
individual parts of the uteri.
Human uteri were collected, following clinical hysterectomy 
for non-pathological (sterilization) or pathological
(benign or malignant tumours) reasons. Each uterus was 
treated in the following manner postoperatively: in the 
theatre the whole uterus was placed in ice and transported 
to the laboratory. Blocks of tissue were removed from the 
fundus, corpus and cervix while the endometrium was scraped 
off with a curette. A representative sample was obtained 
from benign or malignant tumours. These "normal" as well as 
"abnormal" uterine tissues were obtained for every patient. 
Histological data were obtained for all representative sam­
ples collected and used in assays. Binding assays as well as 
SDG analyses for both ER and PR were done on all the diffe­
rent uterine samples.
5.5.2 Activation, transformation and nuclear binding of PR in 
normal and abnormal human uterine tissue :
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Experimental procedure:
A cell free system was employed as described in Section 5.4. 
Following overnight incubation of cytosols (CYT(+) and 
CYT(-)) at 0-4°C with H-R5020 (5nm) the receptors were
"activated" by reincubation at 30°C for various time inter­
vals (0- 30 min).
SDG gradients were developed on high salt (0.4 M KC1) while 
nuclear and DNA-cellulose binding studies were performed on 
the same cytosols. This procedure was repeated for both 
normal, benign leiomyomatous uterine tissues, as well as 
malignant cervical carcinomas.
5.5.3 Results :
Binding and SDG data for the different parts of the Vervet 
monkey uterus is depicted in Table 5.4 and Fig. 5.12 and 
5.13.
Similar data for normal and abnormal human uterine tissues 
is summarised in Table 5.8 while SDG profiles are presented 
in Fig. 5.14 to Fig. 5.19.
Low ionic strength sucrose density gradients (10-35%) 
clearly reveal a 7.1 - 7.7 S specific binding peak for both 
ER and PR present in the different parts of the VMU (Fig. 
5.12 and 5.13). Differences in sedimentation values seem to 
be insignificant, while the total activity within the main 
peaks differed for the different parts of the uteri. In rare 
cases cervix tissues exhibited a clearly defined % 4  - 5 S 
entity (Fig. 5.12 panel A). Levels of PR were always found 
to be higher than ER levels. Quantitatively (binding assays) 
the endometrium contains the highest concentration of ER and 
PR receptors. No significant differences in dissociation 
constants (K^) were found (Table 5.4).
In the case of human uterine tissues (Fig. 5.14 to 5.19) low 
ionic strength SDG profiles showed mainly the faster sedi­
menting 7.2 - 8.45 component for the different parts of the 
uterus and also for benign and malignant uterine tumours. 
This component was observed for both ER and PR. However, SDG 
profiles for cervix and leimyoma tissues also simultaneously 
display bands for slower sedimenting, specific binding mole­
cule^) in the 4-5 S region.
Quantitatively it would seem that receptor levels in normal 
human uterine tissues were comparable to that found in the 
VMU. Endometrial tissues generally contained the highest 
levels of receptors, while cervix tissue appeared to contain 
very low levels of ER and PR. As for the VMU practically all 
tissues displayed a PR/ER ratio higher than one. The wide 
variation observed in receptor levels can be related to the 
different stages in the menstrual cycle at the time of the 
hysterectomy. Such a variation is also obvious within 
different parts of the same uterus.
Binding data of activated cytosol to nuclei are shown in 
Fig. 5.20 while 0.4 M KC1 SDG sedimentation profiles of a 
selected experiment are depicted in Fig. 5.21.
From the binding data it is again clear that maximum acti­
vation (re-incubation at 30°C) was obtained after 15 min. In 
the absence of sodium molybdate, a 4.6 to 5.5 S shift for ER 
and a 3.7 to 4.6 S shift for PR were observed. This result 
agreed with that demonstrated for the normal VMU. Again no 
shift was observed in the sodium molybdate controls a 
finding which agreed with the fact that nuclear binding was 
severely suppressed in these cytosols.
In the case of normal human myometrial tissue (Patient 
38/83) nuclear binding of PR-ligand complexes was also found 
to be maximal (80 %) after 15 min of activation at 30°C and 
also showed a normal 3.7 S to 4.6 S sedimentation shift
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in the absence of molybdate. Abnormal myometrical tissue 
(leiomyoma, Patient 12/83), however, exhibited subnormal 
nuclear binding, while at the same time totally lacked the 
ability to yield a 4 S to 5 S sedimentation shift. This same 
tendency was observed (Fig. 5.20) in 3 samples of abnormal 
cervical tissue (carcinoma in situ) : subnormal nuclear 
binding accompanied by the lack of the sedimentation shift 
(Fig. 5.21). Due to difficulties in obtaining human 
uterine tissue, experienced at the time of this investi­
gation only a small number (3) of abnormal gradient samples 
were investigated. Thus, this finding can not be genera­
lised. Flowever, we hope to be in a position to continue with 
the investigation as soon as sufficient patient material can 
be obtained.
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FLOW DIAGRAM 5.1 : Preparation of cytosols and nuclei from
vervet monkey and human uterine tissue 
for the investigation of the dynamics 
of activation-transformation and trans­
location of receptor-ligand complexes 
to the nuclear compartment.
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F ig u r e  5.1 : A r e p r e s e n t a t i v e  standard  c u r v e  f o r  the  DNA assay .
A m o d i f i c a t i o n  o f  B u r t o n ' s  method (274 )  was employed 
( S e c t i o n  5 . 2 . 3 . )  D i f f e r e n t  d i l u t i o n s  o f  c a l f  thymus 
DNA were p r e p are d  in  5 mM NaOH, v a r y i n g  from 25 to  
300 pg /mf DNA. Absorbance  o f  the r e a c t i o n  m ixture  
was measured a t  600 nm and the DNA c o n c e n t r a t i o n  
was p l o t t e d  a g a i n s t  a b s o rb a n ce .
D
ilu
ti
on
Figure  5 . 2  : C o r r e l a t i o n  between the  t o t a l  number o f  n u c l e i  and 
the  c o n c e n t r a t i o n  o f  DNA. N u c le i  were prep ared  as 
d e s c r i b e d  in  S e c t i o n  5 . 2 . 2  and s e r i a l  d i l u t i o n s  made 
: (A) the number o f  n u c l e i  was d e term in ed  f o r  each o f
the  d i l u t i o n s  by means o f  the  C o u l t e r  c o u n t e r  (B) the 
DNA c o n t e n t  o f  each d i l u t i o n  was a l s o  e s t i m a t e d ,  em­
p l o y i n g  the  method o f  Burton (274 )  d e s c r i b e d  in  Sec ­
t i o n  5 . 2 . 3 .
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F ig u r e  5 . 3  : R e p r e s e n t a t i v e  S c a tc h a r d  p l o t  f o r  the  e s t i m a t i o n  o f  
n u c l e a r  VMU ER. N u c le i  were pre p ar e d  as d e s c r i b e d  in  
S e c t i o n  5 . 3 . 1 . 2 .  A l i q u o t s  (100 p£) o f  the  homogenous 
n u c l e a r  s u s p e n s i o n  were added t o  tu bes  c o n t a i n i n g  
1 00p£ o f  5 d i f f e r e n t  3 H-E2 c o n c e n t r a t i o n  (0 .5 -8nM) in  
the  abse nce  ( t o t a l  b i n d i n g  ) and p r e s e n c e  ( n o n - s p e c i ­
f i c  b i n d i n g )  o f  a 100 f o l d  e x c e s s  o f  DES. In c u b a t i o n  
was e x e c u t e d  a t  37°C f o r  30 min. The r e a c t i o n s  were 
te r m in ate d  by the  a d d i t i o n  o f  a l a r g e  volume (5 m£) 
o f  c o l d  TEDAG^p b u f f e r  and n u c l e i  spun down a t  800xg '  
x15 min. Fu r th er  washings (3x )  were per form ed  t o  
remove a l l  the  unbound l i g a n d  and the 800xg '  su perna ­
t a n t s  d e c a n t e d .  Ethanol  ( 1 . 0  m£) was added t o  the
n u c l e a r  p e l l e t  and the s u s p e n s i o n  t h o r o u g h l y  v o r t e x e d  
f o r  1 min a f t e r  which the e t h a n o l i c  e x t r a c t s  were mo­
n i t o r e d  f o r  t o t a l  and n o n - s p e c i f i c  b i n d i n g .
TABLE 5.1
Summary of binding data obtained for the oestrogen receptors
in VMU nuclei:
no o f  u t e r i fmol /mg  DNA k xi o ;a
3 31 52 5 .35
2 4032 4.1 6
1 782 5 .2
'V 15 ( powder ) 1818 2.1 5
^  15 1474 2 .3
1 433 3 .2
1 365 7 . 2
3 848 1 .9
14 429 2 .0 8
T i s s u e  powder 1 498 6 .7 5
Mean 1483±1236 4 . 02±1 .
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F ig u r e  5 . 4  : A com par ison  o f  the  c y t o s o l i c  and n u c l e a r  VMU ER on 
s u c r o s e  d e n s i t y  g r a d i e n t s .  U t e r in e  s l i c e s  were 
i n c u b a t e d  (20°Cx30 min) w i t h  r a d i o l i g a n d  (3 H-E2 ; 5nM) 
in  the  a bsence  ( t o t a l  b i n d i n g )  o r  p r e s e n c e  ( n o n - s p e ­
c i f i c  b i n d i n g )  o f  a 250 f o l d  e x c e s s  DES. Upon co m ple ­
t i o n  o f  the  i n c u b a t i o n ,  a l a r g e  volume o f  TEDAG1 
b u f f e r  was added t o  the r e a c t i o n  s u s p e n s i o n .  The 
t i s s u e  s l i c e s  were spun down a t  800 x g 'x 1 0  min, r e s u s ­
pended i n  f r e s h  c o l d  TEDAG._ b u f f e r  and the washing 
sequence  r e p e a t e d  3 t imes  t o  remove unbound and non­
s p e c i f i c a l l y  t i s s u e  adsorbed  l i g a n d  m o l e c u l e s .  The 
t i s s u e  s l i c e s  were then manual ly  homogenized in  a 
Dounce ground g l a s s  hom ogen izer  with  a l o o s e  f i t t i n g  
p e s t l e  a t  0 -4 °C .  The homogenate was spun a t  8 0 0 x g ‘ 
f o r  15 min and the n u c l e a r  m y o f i b r i l l a r  p e l l e t  t h o ­
r o u g h l y  washed,  p r i o r  t o  e x t r a c t i o n  with  0 .4  M KC1 
(15 min a t  0 - 4 ° C ) .  The 800xg '  su p e r n a t a n t  ( c r u d e  
c y t o s o l )  was r e c e n t r i f u g e d  at  105000xg'  f o r  30 min, 
t r e a t e d  w ith  DCC and then s u b j e c t e d  to  e i t h e r  hypo-  
o r  h y p e r t o n i c  SDG a n a l y s i s  : (A) 105000xg'  c y t o s o l i c  
r e c e p t o r  in  h y p o t o n i c  SDG ( • ) ;  10500 0xg ’ c y t o s o l i c
r e c e p t o r  in  h y p e r t o n i c  SDG (A) ;  ( B) 0 .4  M KC1 n u c l e a r
e x t r a c t  on h y p e r t o n i c  SDG.
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F ig u r e  5.5 : A com par ison  o f  VMU n u c l e a r  ER s p e c i e s  o b t a i n e d  wi th  
v a r i o u s  e x t r a c t i o n  p r o c e d u r e s  : n u c l e a r  m y o f i b r i l l a r  
p e l l e t s  were p r e p a r e d  and p r o c e s s e d  as d e s c r i b e d  in 
the l e g e n d  o f  F i g .  5 . 4  and in  S e c t i o n  5. Three d i f ­
f e r e n t  p r o c e d u r e s  were employed t o  e x t r a c t  the nu­
c l e a r  ER from the  n u c l e a r  p e l l e t s  : (A) b u f f e r  s u s ­
p e n s i o n s  o f  the  n u c l e a r  sed im ents  were t r e a t e d  w ith  
t r y p s i n  (50pg)  f o r  15 min a t  0°C and then e x t r a c t e d  
w i t h  0 . 4  M KC1 a t  0 -4 ° C  f o r  15 min; (B) n u c l e a r  p e l ­
l e t s  were t r e a t e d  with  DNase I f o r  15 min a t  0 - 4 °C; 
(C) n u c l e a r  p e l l e t s  were e x t r a c t e d  w ith  0 .4  M KCl;
204
TABLE 5.2
Summary of S-values for ER obtained by different treatments
of nuclei
No. o f  
a s s a y s
Method o f  
t re a tm e n t
Mean
S e d im e n ta t io n
E f f i c i e n c y  o f  
t r e a tm e n t  and 
e x t r a c t i o n
1 0 0 . 4  M KCl 3 . 8 ;  4 . 6 12 .5  %
(1 5 minxO °C)
1 0 t r y p s i n  KCl 2 . 5 ; 47 %
(15 minxO°C;15 minxO°C)
1 0 DNase 3 . 6 ;  4 . 6 2 6 .7  %
(30 minxO°C)
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F igu re  5 . 6  : A c t i v a t i o n ,  t r a n s f o r m a t i o n  and t r a n s l o c a t i o n  o f  V e r -  
v e t  monkey u t e r i n e  ER in  t i s s u e  s l i c e s  as f u n c t i o n s  
o f  t ime and t e m pe ra t u re :  T i s s u e  s l i c e s  were i n c u b a t e d  
w i th  3 H - o e s t r a d i o l  ( f i n a l  c o n c e n t r a t i o n ,  5nM) w i t h o u t  
( t o t a l  b i n d i n g )  o r  w i t h  ( n o n - s p e c i f i c  b i n d i n g )  a 250 
f o l d  e x c e s s  o f  DES a t  the tem peratures  i n d i c a t e d  
abov e .  Upon c o m p l e t i o n  o f  i n c u b a t i o n  the  r e a c t i o n  was 
t e r m in a t e d  by  the  a d d i t i o n  o f  a l a r g e  volume (5 m f ) 
o f  c o l d  TEDAG^g b u f f e r .  The t i s s u e  s l i c e s  were 
t h o r o u g h l y  washed in  TEDAG^ b u f f e r  (3x with  5 mi 
b u f f e r )  t o  remove unbound and n o n - s p e c i f i c a l l y  t i s s u e  
adsorbed  l i g a n d  and then homogenized in  a Dounce 
ground g l a s s  h om ogen izer .  The homogenate were 
c e n t r i f u g e d  a t  800xg '  f o r  10 min (0 - 4 ° C )  and the  
c r u d e  n u c l e a r  p e l l e t s ,  as w e l l  as the 800xg c y t o s o l s ,  
a ssay e d  f o r  (A) i n c u b a t i o n  a t  37°C in  a CQ> i n c u b a t o r  
(5% C02 , 95 % a i r ;  (B) i n c u b a t i o n  a t  20°C in  wate r
bath  and (C) i n c u b a t i o n  on i c e  ( 0 ° C ) .
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TABLE 5.3
Distribution of 1igand-receptor complexes at different 
incubation temperatures in a time course study, employing
tissue slices:
D i s t r i b u t i o n  o f  ER between 
n u c le a r ( N )  and c y t o s o l i c ( C )  
compartments
30 min 75 min 1 35 min
N C N c N c
(%) (%) (%) (%) (%) (%)
0 29 .6 70 .4 2 9 .6 7 0 .4 2 9 .6 7 0 .4
20 35 .6 6 4 .4 4 6 .9 53.1 51 .9 42.1
37 28 .7 71 . 3 6 5 .0 35 .0 5 1 .6 4 8 .4
Temp o f  i n c u b a t i o n  
(°.C)
20 7
F r a c t io n  IMo
F ig u r e  5 . 7  : E f f e c t  o f  sodium m olybdate  (10mM) on the  t im e - d e p e n ­
d e n t  t r a n s f o r m a t i o n  o f  V e r v e t  monkey u t e r i n e  ER, as 
f o l l o w e d  by SDG a n a l y s i s .  C y t o s o l s  c o n t a i n i n g
sodium m olybdate  (CYT(+) )  were in c u b a t e d  on i c e  (0°C)  
f o r  10 h w i t h  3 H-Ez (5nM) in  the abse nce  ( t o t a l  b i n ­
d i n g )  o r  p r e s e n c e  ( n o n - s p e c i f i c  b i n d i n g )  o f  a 250 
f o l d  e x c e s s  DES. At the end o f  the  i n c u b a t i o n  the 
r e a c t i o n  tubes  were t r a n s f e r r e d  t o  a 3 0 °C wate r  ba th  
f o r  d i f f e r e n t  t ime i n t e r v a l s  (5 min, 10 min and 15 
m in ) .  Temperature in duced  a c t i v a t i o n  was t e rm in ate d  
by DCC t rea tm en t  on i c e  (0°C)  and the r e s u l t i n g  2000 
x g 1 su p e r n a t a n t s  (200pj2) were s u b j e c t e d  t o  u l t r a - c e n ­
t r i f u g a t i o n  (V Ti -80  r o t o r ,  520000xg1x 1 20 minx2°C) on 
10-35% s u c r o s e  d e n s i t y  g r a d i e n t s .  G r a d ie n t s  were then 
f r a c t i o n a t e d  ( 4 0 x 5 - d r o p  f r a c t i o n s )  and the  f r a c t i o n s  
m o n i to r e d  f o r  r a d i o - a c t i v i t y .  P o s i t i o n  o f  the marker 
p r o t e i n  (l t - B S A ;  4 .6 S )  i s  i n d i c a t e d  by M.
2 0 8
F r a c t io n  No
Figure  5 .8 T im e-dependent t r a n s f o r m a t i o n  o f  V e rv e t  monkey 
u t e r i n e  ER, as f o l l o w e d  by SDG a n a l y s i s .  C y to ­
s o l s  w i t h o u t  sodium m olybdate  ( c Y T ( - ) )  were 
i n c u b a t e d  on i c e  (0°C)  f o r  10 h with  1 H-E2 (5nM) 
in  the  ab s e n c e  ( t o t a l  b i n d i n g )  o r  p r e s e n c e  (non­
s p e c i f i c  b i n d i n g )  o f  a 250 f o l d  e x c e s s  DES. At the 
end o f  the  i n c u b a t i o n  the r e a c t i o n  tu bes were 
t r a n s f e r r e d  t o  a 30 °C water  ba th  f o r  d i f f e r e n t  
time i n t e r v a l s  (5 min, 10 min and 15 m in ) .  Tem­
p e r a t u r e  in du ced  a c t i v a t i o n  was te r m in a t e d  by DCC 
t re a tm e n t  on i c e  (0°C)  and the r e s u l t i n g  2000 x g ' 
s u p e r n a t a n t s  (200u£)  were s u b j e c t e d  t o  u l t r a - c e n ­
t r i f u g a t i o n  (VTi -80  r o t o r ,  5 2 0 0 0 0 x g ' x 1 20 minx2°C) 
on 10-35% s u c r o s e  d e n s i t y  g r a d i e n t s .  G r a d ie n t s  
were then f r a c t i o n a t e d  ( 4 0 x 5 - d r o p  f r a c t i o n s )  and 
the  f r a c t i o n s  m on i tored  f o r  r a d i o - a c t i v i t y .  
P o s i t i o n  o f  the  marker p r o t e i n  ( l *C-BSA; 4 .6 S )  i s  
i n d i c a t e d  by M.
F igu re  5 . 9  : E f f e c t  o f  sodium m olybdate  on the t im e -de pe n d e n t  
t r a n s f o r m a t i o n  o f  V e r v e t  monkey u t e r i n e  PR as d e t e r ­
mined by h y p e r t o n i c  ( 0 . 4  M KCl) s u c r o s e  d e n s i t y  g r a ­
d i e n t  c e n t r i f u g a t i o n .  C y t o s o l s ,  p repared  in  the  p r e ­
s e n c e  o f  20mM sodium m olybdate  ( (G Y T (+ ) )  were i n c u ­
ba ted  (0 -4 °C x 16  h) w i th  3 H-R 5020 (5nM f i n a l  c o n c e n ­
t r a t i o n )  in  the a b s e n c e  ( t o t a l  b i n d i n g )  o r  p r e s e n c e  
( n o n - s p e c i f i c  b i n d i n g )  o f  a 250 f o l d  e x c e s s  R 5020.  
I n c u b a t i o n  was f o l l o w e d  up by a temperature a c t i v a ­
t i o n  a t  30°C f o r  v a r y i n g  i n t e r v a l s  (5 min, 15 min and 
30 m in ) ,  the  r e a c t i o n s  t erm in ated  by DCC t r e a tm e n ts  
and the r e s u l t i n g  2000xg'  su p e r n a t a n t s  ( 2 0 0 p f )  sub­
j e c t e d  t o  u l t r a - c e n t r i f u g a t i o n  (VTi -80  r o t o r  152000 
x g ' x 1 2 0  min x 2°C) on h y p e r t o n i c  10-35  % s u c r o s e  den­
s i t y  g r a d i e n t s .  A c o n t r o l  s e t  o f  c y t o s o l s  were run 
s i m u l t a n e o u s l y ,  w i th  no a c t i v a t i o n  s t e p  i n d u e d ,  
p r i o r  t o  SDG a n a l y s i s .  The marker p o s i t i o n  ( C- 
BSA) i s  i n d i c a t e d  by M.
iU
F r a c t i o n  IMo
F ig u r e  5 . 1 0 :  T im e-dependent  t r a n s f o r m a t i o n  o f  V ervet  monkey u t e ­
r i n e  PR as de term ined  by h y p e r t o n i c  ( 0 . 4  M KCl) 
s u c r o s e  d e n s i t y  g r a d i e n t  c e n t r i f u g a t i o n .  C y t o s o l s ,  
p r e p a r e d  in  the  a bsence  sodium m olybdate  ( ( CYT( —) )  
were i n c u b a t e d  (0 -4 ° C  x16 h) w i t h .  3 H-R 5020 (5nM 
f i n a l  c o n c e n t r a t i o n )  in  the absence  ( t o t a l  b i n d i n g )  
o r  p r e s e n c e  ( n o n - s p e c i f i c  b i n d i n g )  o f  a 250 f o l d  
e x c e s s  R 5020.  I n c u b a t i o n  was f o l l o w e d  up by a 
t em perature  a c t i v a t i o n  a t  30°C f o r  v a r y i n g  i n t e r v a l s  
(5 min, 15 min and 30 m in ) ,  the r e a c t i o n s  t e rm in ate d  
by DCC t r e a tm e n ts  and the r e s u l t i n g  2000xg'  
su p e r n a t a n t s  ( 2 0 0 p i )  s u b j e c t e d  t o  u l t r a - c e n t r i f u g a ­
t i o n  (VT i -80  r o t o r  152000 x g ' x 1 2 0  min x 2°C) on hy­
p e r t o n i c  10 -35  % s u c r o s e  d e n s i t y  g r a d i e n t s .  A c o n t r o l  
s e t  o f  c y t o s o l s  were run s i m u l t a n e o u s l y ,  w i th  no 
a c t i v a t i o n  s t e p  i n c l u d e d ,  p r i o r  t o  SDG a n a l y s i s .  The 
marker p o s i t i o n  (1 4 C-BSA) i s  i n d i c a t e d  by M.
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Figure  5 . 1 1 :  T im e-dependent  a c t i v a t i o n  o f  V e r v e t  monkey u t e r i n e  ER 
and PR as measured by i n c r e a s e d  b i n d i n g  o f  com plexes  
t o  n u c l e i  and D N A - c e l l u l o s e .  C y t o s o l s  and n u c l e i  were 
p r e p a r e d  w ith  (DA) o r  w i t h o u t  (HA) sodium m olybdate  
(20 mM) in  h o m o g e n iz a t i o n  b u f f e r s .  A c t i v a t i o n  o f  
c y t o s o l i c  r e c e p t o r s  was a c c o m p l i s h e d  as f o l l o w s :  (a)  
f i r s t  i n c u b a t i o n  : a l i q u o t s  o f  c y t o s o l s  (100p£)  were 
c h arg e d  w i th  the r a d i o l i g a n d  (3 H-E2  o r  3 H-R5020) ;  f o r  
16 h on i c e ,  in  the ab s e n c e  ( t o t a l  b i n d i n g )  o r  p r e ­
se n c e  ( n o n - s p e c i f i c  b i n d i n g )  o f  a 250 f o l d  e x c e s s  
c o l d  l i g a n d  (DES o r  R5020) ;  (b)  second  i n c u b a t i o n  : 
a l l  tubes  were t r a n s f e r r e d  t o  a w ater  bath o f  30 °C 
f o r  d i f f e r e n t  p e r i o d s  (5 min, 15 min and 30 m in ) .  
The charged  and a c t i v a t e d  c y t o s o l s  were t r e a t e d  with  
DCC and the  2000xg '  su p e r n a t a n t s  r e i n c u b a t e d  with  
u t e r i n e  n u c l e i  o r  D N A - c e l l u l o s e  ( s e e  Flow diagram 
5 . 2 )  f o r  60 min on i c e .  The b i n d i n g  a s s a y s  were  t e r ­
minated by the  a d d i t i o n  o f  a l a r g e  volume (5 mC) 
TEDAG  ^g b u f f e r  and the  800xg '  n u c l e a r  p e l l e t  washed 
(3x)  wi th  b u f f e r ,  p r i o r  t o  the a d d i t i o n  o f  a b s o l u t e  
e t h a n o l  (1 m f ) .  The e t h a n o l  e x t r a c t s  were decan ted  
i n t o  c o u n t i n g  v i a l s ,  s c i n t i l l a t i o n  c o c k t a i l  added ( 2  
mj?) and the v i a l s  c ou n ted  in  a s c i n t i l l a t i o n  c o u n t e r  
( e f f i c i e n c y ,  30 -35% ).
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F ig u r e  5 .1 2  : Comparison o f  SDG p r o f i l e s  f o r  ER m  d i f f e r e n t  p a r t s  
o f  the  V e r v e t  monkey u t e r u s  : C y t o s o l s  were prep ared  
in b u f f e r  c o n t a i n i n g  20mM sodium m olybdate  ( (C Y T ( + ) )  
and l a b e l l e d  w i t h  3 H-E, (5nM f i n a l  c o n c e n t r a t i o n )  in  
the  a b s e n c e  ( t o t a l  b i n d i n g )  o r  p r e s e n c e  ( n o n - s p e c i ­
f i c  b i n d i n g )  o f  an e x c e s s  (250p)  o f  DES. The DCC 
t r e a t e d  2000g '  s u p e r n a t a n t s  were l a y e r e d  o n t o  hypo­
t o n i c  s u c r o s e  g r a d i e n t s  s u b j e c t e d  t o  u l t r a - c e n t r i f u ­
g a t i o n  ( V T i - r o t o r ,  5 2 0 0 0 0 x g ’ x 1 20 min x 2°C) and the 
g r a d i e n t s  f r a c t i o n a t e d  i n t o  40,  f i v e  d r o p  f r a c t i o n s .  
F r a c t i o n s  were c o u n t e d  f o l l o w i n g  the a d d i t i o n  o f  
s c i n t i l l a t i o n  c o c k t a i l  (2 m f ) : h y p o t o n i c ,  10-35% 
SDG p r o f i l e  f o r  the c e r v i x  c y t o s o l  (A ) ,  the endome­
t r i a l  c y t o s o l  (B) and the  m yometr ia l  c y t o s o l  (C ) .  
P o s i t i o n  o f  l a b e l l e d  marker p r o t e i n  ( l *C-BSA) i n d i ­
c a t e d  by M.
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F ig u r e  5 .1 3  : Comparison o f  SDG p r o f i l e s  f o r  PR in d i f f e r e n t  p a r t s  
o f  the  V e r v e t  monkey u t e r u s  : C y t o s o l s  were p r e p are d  
i n  b u f f e r  c o n t a i n i n g  20mM sodium molybdate  ( (C Y T ( + ) )  
and l a b e l l e d  w i th  3 H-R5020 ( 5nM f i n a l  c o n c e n t r a t i o n )  
in  the  a b s e n c e  ( t o t a l  b i n d i n g )  o r  p r e s e n c e  ( n o n - s p e ­
c i f i c  b i n d i n g )  o f  an e x c e s s  (250]j) o f  R5020. The 
DCC t r e a t e d  2000g '  s u p e r n a t a n t s  were l a y e r e d  o n t o  
h y p o t o n i c  s u c r o s e  g r a d i e n t s  s u b j e c t e d  t o  u l t r a - c e n ­
t r i f u g a t i o n  ( V T i - r o t o r ,  52000 0xg ' x 1 20 min x 2°C)  and 
the  g r a d i e n t s  f r a c t i o n a t e d  i n t o  40, f i v e  d r o p  f r a c ­
t i o n s .  F r a c t i o n s  were co u n te d  f o l l o w i n g  the a d d i t i o n  
o f  s c i n t i l l a t i o n  c o c k t a i l  (2 m£) : h y p o t o n i c ,  10-35% 
SDG p r o f i l e  f o r  the  c e r v i x  j y t o s o l  (A ) ,  the  endome­
t r i a l  c y t o s o l  (B) and the m yometr ia l  c y t o s o l  (C ) .  
P o s i t i o n  o f  l a b e l l e d  marker p r o t e i n  ( 1a C-BSA) i n d i ­
c a t e d  by M.
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TABLE 5.4
Summary of binding and SDG data in different parts of the
VMU
Part  o f  B inding  d a t a  S e d im e n ta t io n
u t e r u s  c o e f f i c i e n t s
(S)
ER PR ER PR
Bmax Kd Bmax Kd
( fm o l /m g  p r o t ) ( xl  O'^M) (fm ol /m g  p r o t ) ( x1 0‘ 9M)
Endome­
trium
987 0 .67 3937 1 . 1 7.1 7 . 4
Myome­
tr ium
337 0 .85 3558 4 . 0 8 . 6 7 .8
c e r v i x 370 0 .65 2032 4 . 3 7 . 6 7 .7
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F igu re  5 . 1 4 :  H y p o to n i c  s u c r o s e  d e n s i t y  g r a d i e n t  a n a l y s i s  o f  c y t o ­
s o l i c  ER and PR p r e s e n t  in  human u t e r i n e  c e r v i c e s .  
C y t o s o l s  were p r e p a r e d  in  TEDAG-MO b u f f e r  (20mM 
sodium m o lyb date )  and a l i q u o t s  (200p£)  o f  the f r e s h l y  
p r e p a r e d  c y t o s o l s  i n c u b a t e d  (30 min x 20°C)  with 
r a d i o l i g a n d  ( 3 H-E2 o r  3 H-R-5020)  in  the p r e s e n c e  
( n o n - s p e c i f i c  b i n d i n g )  o r  a bsence  ( t o t a l  b i n d i n g )  o f  
250 f o l d  e x c e s s  o f  u n l a b e l l e d  l i g a n d  ( DES o r  R5020) .  
The DCC t r e a t e d  s u p e r n a t a n t s  ( 2 0 0 0 x g ’ x10 min) were 
l a y e r e d  o n t o  l i n e a r  10-35% h y p o t o n i c  SDG. G rad ien ts  
were s u b j e c t e d  t o  u l t r a - c e n t r i f u g a t i o n  (VTi -80  r o t o r ,  
5 2 0 0 0 0 x g ' x 2 h x 2 ° C ) . G r a d i e n t s  were f r a c t i o n a t e d  (5 
d r o p s x 4 0 )  m anual ly ,  s c i n t i l l a t i o n  c o c k t a i l  added (2 
m i )  and then m o n i t o r e d  f o r  r a d i o a c t i v i t y .  M u l t i p o i n t  
t i t r a t i o n  a n a l y s e s  were per form ed  on a l l  c y t o s o l s  and 
b i n d i n g  d a t a  a n a l y s e d  ac c o r d | ^ g  t o  the method o f  
S c a t c h a r d .  Marker p r o t e i n  ( C-BSA) p o s i t i o n  i s  
i n d i c a t e d  by BSA: r e p r e s e n t a t i v e  SDG p r o f i l e s  o f  
c e r v i x  PR (A ,B ,C )  and ER(D) o f  p a t i e n t s  1 4 /8 3 ,  7 /83  
and 4 1 / 8 3 ;  r e p r e s e n t a t i v e  SDG p r o f i l e  o f  the  c e r v i x  
ER f o r  p a t i e n t  4 1 / 8 3 .
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Figure  5 . 1 5 :  H y p o to n i c  s u c r o s e  d e n s i t y  g r a d i e n t  a n a l y s i s  o f  c y t o ­
s o l i c  ER and PR p r e s e n t  i n  human u t e r i n e  e n d o m e tr ia .  
C y t o s o l s  were p r e p a r e d  in  TEDAG-MO b u f f e r  (20mM 
sodium m o ly b d a te )  and a l i q u o t s  (200p£)  o f  the f r e s h l y  
p r e p a r e d  c y t o s o l s  i n c u b a t e d  (30 min x 2 0 °C) with  
r a d i o l i g a n d  ( 3 H-E2 o r  3 H-R-5020)  in  the  p r e s e n c e  
( n o n - s p e c i f i c  b i n d i n g )  o r  a b s e n c e  ( t o t a l  b i n d i n g )  o f  
250 f o l d  e x c e s s  o f  u n l a b e l l e d  l i g a n d  (DES o r  R5020) .  
The DCC t r e a t e d  s u p e r n a t a n t s  (2 0 0 0 x g 'x 1 0  min) were 
l a y e r e d  o n t o  l i n e a r  10-35% h y p o t o n i c  SDG. G r a d i e n t s  
were  s u b j e c t e d  to  u l t r a - c e n t r i f u g a t i o n  (V Ti -80  r o t o r ,  
5 2 0 0 0 0 x g 1x 2h x2” C ) . G r a d ie n t s  were  f r a c t i o n a t e d  (5 
d r o p s x 4 0 )  m anual ly ,  s c i n t i l l a t i o n  c o c k t a i l  added ( 2  
m£) and then m o n i t o r e d  f o r  r a d i o a c t i v i t y .  M u l t i p o i n t  
t i t r a t i o n  a n a l y s e s  were per form ed  on a l l  c y t o s o l s  and 
b i n d i n g  d a t a  a n a l y s e d  a c c o r d j ^ g  t o  th e  method o f  
S c a t c h a r d .  Marker p r o t e i n  ( C-BSA) p o s i t i o n  i s  
i n d i c a t e d  by  BSA: r e p r e s e n t a t i v e  SDG p r o f i l e s  o f
th e  e n d o m e t r i a l  PR(A,B)  and ER(C,D) f o r  p a t i e n t s  5 7 /8 3  
3 8 / 8 3 .
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F igu re  5 . 1 6 :  H y p o t o n i c  s u c r o s e  d e n s i t y  g r a d i e n t  a n a l y s i s  o f  c y t o ­
s o l i c  ER and PR p r e s e n t  in  human u t e r i n e  myometr ia .  
C y t o s o l s  were prep ared  in  TEDAG-MO b u f f e r  (20mM 
sodium m o ly b d a t e )  and a l i q u o t s  ( 2 0 0 p f )  o f  the  f r e s h l y  
p r e p a r e d  c y t o s o l s  i n c u b a t e d  (30 min x 20°C) with  
r a d i o l i g a n d  ( 3 H-E2  o r  3 H-R-5020)  in  the  p r e s e n c e  
( n o n - s p e c i f i c  b i n d i n g )  o r  ab s e n c e  ( t o t a l  b i n d i n g )  o f  
250 f o l d  e x c e s s  o f  u n l a b e l l e d  l i g a n d  (DES o r  R5020) .  
The DCC t r e a t e d  s u p e r n a t a n t s  (2 0 0 0 x g 'x 1 0  min) were 
l a y e r e d  o n t o  l i n e a r  10-35% h y p o t o n i c  SDG. G r a d ie n t s  
were s u b j e c t e d  t o  u l t r a - c e n t r i f u g a t i o n  (VTi -80  r o t o r ,  
5 2 0 0 0 0 x g 1x 2 h x 2 ° C ) . G r a d ie n t s  were f r a c t i o n a t e d  (5 
d r o p s x 4 0 )  m anual ly ,  s c i n t i l l a t i o n  c o c k t a i l  added (2 
m£) and then m o n i to r e d  f o r  r a d i o a c t i v i t y .  M u l t i p o i n t  
t i t r a t i o n  a n a l y s e s  were per form ed  on a l l  c y t o s o l s  and 
b i n d i n g  d a t a  a n a ly se d  accordj . t jg  t o  the method o f  
S c a t c h a r d .  Marker p r o t e i n  ( C-BSA) p o s i t i o n  i s  
i n d i c a t e d  by BSA: r e p r e s e n t a t i v e  SDG p r o f i l e s  o f  
m yom etr ia l  PR ( A , B , ) and ER(C,D) o f  p a t i e n t s  38 /83  
and 5 7 / 8 3 .
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F ig u r e  5 . 1 7 :  H ypoton ic  s u c r o s e  d e n s i t y  g r a d i e n t  a n a l y s i s  o f  c v t o -  
s o l i c  ER and PR p r e s e n t  i n  human u t e r i n e  tumours.
C y t o s o l s  were p r e p a r e d  i n  TEDAG-MO b u f f e r  (20mM 
sodium m olyb date )  and a l i q u o t s  (200p£)  o f  the f r e s h l y  
p r e p are d  c y t o s o l s  i n c u b a t e d  (30 min x 2 0 °C) with  
r a d i o l i g a n d  (3 H-E, o r  3 H-R-5020)  in  the p r e s e n c e  
( n o n - s p e c i f i c  b i n d i n g )  o r  ab s e n c e  ( t o t a l  b i n d i n g )  o f  
250 f o l d  e x c e s s  o f  u n l a b e l l e d  l i g a n d  (DES o r  R5020) .  
The DCC t r e a t e d  s u p e r n a t a n t s  (2 0 0 0 x g 'x 1 0  min) were 
l a y e r e d  o n t o  l i n e a r  10-35% h y p o t o n i c  SDG. G r a d ie n ts  
were s u b j e c t e d  t o  u l t r a - c e n t r i f u g a t i o n  (VTi -80  r o t o r ,  
520 0 0 0 xg 1x 2 h x 2 ° C ) . G r a d ie n t s  were f r a c t i o n a t e d  (5 
d r o p sx 4 0 )  manual ly ,  s c i n t i l l a t i o n  c o c k t a i l  added ( 2  
m£) and then m o n i to re d  f o r  r a d i o a c t i v i t y .  M u l t i p o i n t  
t i t r a t i o n  a n a l y s e s  were per form ed  on a l l  c y t o s o l s  and 
b i n d i n g  da t a  a n a ly se d  a c c o r d i n g  t o  the  method o f  
S c a t c h a r d .  Marker p r o t e i n  ( l *C-BSA) p o s i t i o n  i s  
i n d i c a t e d  by BSA: r e p r e s e n t a t i v e  SDG p r o f i l e s  o f  
PR, i n  c e r v i x  carc inom a (A) and leiomyoma (C) and o f  
ER in  carc in om a  o f  the  c e r v i x  (B) and leiomyoma (D) .
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F ig u r e  5 . 1 8 :  A c o m p a r a t i v e  i n v e s t i g a t i o n  o f  the d i s t r i b u t i o n  o f  
r e c e p t o r  s p e c i e s ,  p r e s e n t  in  d i f f e r e n t  p a r t s  o f  the 
same human u t e r u s  with  the a i d  o f  SDG c e n t r i f u g a ­
t i o n  in  h y p o t o n i c  media.  C y t o s o l s  were p r e p are d  in 
TEDAG-MO b u f f e r  (20mM sodium m olybdate )  and 
a l i g u o t s  (200|i£) o f  the f r e s h l y  prep ared  c y t o s o l s  
i n c u b a t e d  (30 min x 20°C)  w ith  r a d i o l i g a n d  (J H-E2 
o r  3 H-R-5020)  in  the p r e s e n c e  ( n o n - s p e c i f i c  b i n ­
d i n g )  o r  ab s e n c e  ( t o t a l  b i n d i n g )  o f  250 f o l d  e x c e s s  
o f  u n l a b e l l e d  l i g a n d  (DES o r  R5020) .  The DCC t r e a ­
ted  su p e r n a t a n t s  (2 0 0 0 x g 'x 1 0  min) were l a y e r e d  o n t o  
l i n e a r  10-35% h y p o t o n i c  SDG. G r a d ie n ts  were sub­
j e c t e d  t o  u l t r a - c e n t r i f u g a t i o n  (VTi -80  r o t o r ,
5 20 0 0 0 xg ' x 2 h x 2 ° C ) . G r a d ie n t s  were f r a c t i o n a t e d  (5 
d r o p s x 4 0 )  m anual ly ,  s c i n t i l l a t i o n  c o c k t a i l  added (2  
m£) and then m on i tored  f o r  r a d i o a c t i v i t y .  M u l t i ­
p o i n t  t i t r a t i o n  a n a l y s e s  were per form ed on a l l  
c y t o s o l s  and b i n d i n g  d a t a  an a ly se d  a c c o r d i n g  t o  
the  method o f  S c a t c h a r d .  Marker p r o t e i n  ( l *C-BSA) 
p o s i t i o n  i s  i n d i c a t e d  by BSA: r e p r e s e n t a t i v e  SDG 
p r o f i l e s  o f  the PR p r e s e n t  in  human u t e r i n e  tumour 
( m i c r o i n f i l t r a t e d  leiomyoma,  A) ,  c e r v i x  ( B ) ,  myome­
tr ium (C) and endometrium (D) ;  SDG p r o f i l e s  o f  the 
PR p r e s e n t  in  human u t e r i n e  tumour ( m i c r o i n f i l t r a -
t e d  l e i o m y o m a , A ) , c e r v i x  (B ) ,  myometrium (C) and e n ­
dometrium ( D ) .
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Figure  5 . 1 9 :  A c o m p a r a t iv e  i n v e s t i g a t i o n  o f  th e  d i s t r i b u t i o n  o f  
r e c e p t o r  s p e c i e s ,  p r e s e n t  in  d i f f e r e n t  p a r t s  o f  the  
same human u t e r u s  wi th  the a i d  o f  SDG c e n t r i f u g a ­
t i o n  in h y p o t o n i c  media. C y t o s o l s  were p r e p a r e d  in  
TEDAG-MO b u f f e r  (20mM sodium m olybdate )  and 
a l i q u o t s  ( 2 0 0 p i )  o f  the f r e s h l y  p r e p are d  c y t o s o l s  
i n c u b a t e d  (30 min x 20°C)  wi th  r a d i o l i g a n d  ( 3 H-Ez 
o r  3 H-R-5020)  i n  the p r e s e n c e  ( n o n - s p e c i f i c  b i n ­
d i n g )  o r  a b s e n c e  ( t o t a l  b i n d i n g )  o f  250 f o l d  e x c e s s  
o f  u n l a b e l l e d  l i g a n d  (DES o r  R5020) .  The DCC t r e a ­
t e d  su p e r n a t a n t s  ( 2 0 0 0 x g 'x 1 0  min) were l a y e r e d  o n t o  
l i n e a r  10-35% h y p o t o n i c  SDG. G r a d ie n t s  were s u b ­
j e c t e d  t o  u l t r a - c e n t r i f u g a t i o r i  (VTi -80  r o t o r ,  
52 0 0 0 0 x g * x 2 h x 2 ° C ) . G r a d i e n t s  were  f r a c t i o n a t e d  (5 
d r o p s x 4 0 )  m anual ly ,  s c i n t i l l a t i o n  c o c k t a i l  added (2 
mi) and then m o n i t o r e d  f o r  r a d i o a c t i v i t y .  M u l t i ­
p o i n t  t i t r a t i o n  a n a l y s e s  were per form ed  on a l l  
c y t o s o l s  and b i n d i n g  d a t a  a n a l y s e d  a c c o r d i n g  t o  
th e  method o f  S c a t c h a r d .  Marker p r o t e i n  ( l fcC-BSA) 
p o s i t i o n  i s  i n d i c a t e d  by BSA: r e p r e s e n t a t i v e  SDG 
p r o f i l e s  o f  the ER p r e s e n t  i n  human u t e r i n e  tumour 
( m i c r o i n f i l t r a t e d  le iomyoma,  A ) ,  c e r v i x  ( B ) ,  myome­
t r iu m  (C) and endometrium (D) •
TABLE 5.5
Summary of Patient Data
____________________________________________ S values________ Ftrol/fag protein
Pat. Tissue Diagnosis Sucrose Gradients Scatchard
No Origin ER PR ER PR
41/81 Gervix
TUnour
mild chrtnic ce rv ic it is  
Adenocarcinona
4.6
7.3
8.5
4.4;7.7
174.3
192.1
279.4
485.6
37/83 Gervix CIS c  rrdcroinf iltra ticn 6.7 6.2 6.7 229.4
Ttmour Leianyona 7.6 8.4 178.0 3176.0
21/83 Gervix microinf iltra ticn tcp 3.6;6.4 405.4 878.8
Endo inactive endo 3.0;6.8 3.0,-6.1 71.7 865.7
Myo no path, changes top 3.0;6.4 152.3 1922.4
57/83 Cervix SquaTtxis metaplasia 7.2 6.4 130.0 3869.0
Ehdo. prolifera tive 7.7 7.2 540.0 6610.0
Myo no path, changes 7.9 7.2 219.0 3187.0
7/83 Cervix No path, changes top 8.0 27.0 515.0
Ehdo. (Secretory phase) 7.1 6.9 9.0 579.0
Myo Leicmyora 7.5 7.5 30.0 1266.0
11/83 Gervix Chrtnic ce rv ic it is 7.7 7.7 95.47 52.22
Ehdo Atropic 8.0 8.0 410.2 202.9
Myo. . Leicmycma 9.3 8.0 304.7 478.9
38/83 Gervix Microinf iltra ticn 6.3 6.3 160.8 976.4
Ehdo. Adaranyosis 7.8 7.5 2485.1 4431.4
M/o. No path, changes 7.8 7.5 1305.4 3003
8 0 -
40 -
20 -
Patienti2/83 Patient 37/83 Patient 38/83
Leiomyoma a - a Cervix  ( e l s ) Myometrium(normal) a - a
Cervix ( e l s . ) C e rv ix  (c.i.a)
A
/ ^
a ' /  
/
\/■
— \
i  i r 
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Activation Time ( minutes)
F ig u r e  5 . 2 0 :  N u c lear  and D N A - c e l l u l o s e  b i n d i n g  o f  a c t i v a t e d  PR- 
l i g a n d  com plexes  in  normal and abnormal human u t e r i n e  
t i s s u e  c y t o s o l s  as a f u n c t i o n  o f  the d u r a t i o n  o f  
a c t i v a t i o n  a t  3 0 °C. B inding  s t u d i e s  were e x e c u t e d  as 
d e s c r i b e d  in  S e c t i o n  5 . 4 . 2 ( b )  : P a t i e n t  12 /83  :
le iomyoma (A) and c e r v i x  with  carc inom a in  s i t u  ( ■ ) ;  
P a t i e n t  37 /83  : c e r v i x  with  carc in om a  in  s i t u  ( ■ ) ;  
P a t i e n t  38 /83  : normal myometrium (A) and c e r v i x  wi th  
carc in o m a  in  s i t u ( B ) ,
ure 5.21 : Time dep en den t  t r a n s f o r m a t i o n  o f  the PR, p r e s e n t  in
p a t h o l o g i c a l  human u t e r i n e  c e r v i x  ( carc in o m a  in  
s i t u )  in  the  absence  o f  sodium m olybdate  as a n a ly se d  
in  h y p e r t o n i c  ( 0 . 4  MKC1) 10-35% s u c r o s e  d e n s i t y  g r a ­
d i e n t s .  C y t o s o l s  were p r e p a r e d ,  i n c u b a t e d  and a n a l y ­
sed on SDG f o r  t ime dependent  s e d im e n t a t i o n  s h i f t s  
and DNS b i n d i n g  a f f i n i t y ,  as p r e v i o u s l y  d e s c r i b e d  in 
S e c t i o n s  5 . 4 . 2  t o  5 . 4 . 3 .  The p o s i t i o n  o f  the marker 
p r o t e i n  (1 '*C.BSA) i s  i n d i c a t e d  by M.
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CHAPTER 6 
DISCUSSION
The presence of specific, high affinity binding proteins or 
receptors in target cells is an important prerequisite for 
the onset of molecular processes triggered by steroid hor­
mones (60,167). Following the classical observations by 
Jensen and J acobson (19) and Gorski et a_l (25) on the accu­
mulation of steroid hormones in target tissues of the rat, 
numerous reports appeared on the occurrence and distribution 
of steroid receptors in the target tissues of a multitude of 
different species, including man (143). These findings 
brought into perspective other, equally important observa­
tions that were made by Beatson (3) in the area of clinical 
studies on breast cancer patients more than 60 years ago. 
Beatson's work has been discussed in some detail in Chapter
1. For the purpose of this discussion, it suffices to refer 
only to the deductions made in the 1960's e.g. that breast 
tumours could be classified as hormonally responsive or hor­
monally unresponsive, depending on the fact that the tumours 
contained relatively high (hormonally responsive) or low 
concentrations of oestrogen receptors (35). For the past two 
decades large numbers of breast cancer patients were treated 
by hormonal regimes which were all based on this principle 
(262). The different types of hormonal treatment regimes 
currently employed, can be briefly summarised as follows:
1. Ablative procedures (removal of endocrine glands).
1.1 Ovariectomy (castration)
1.2 Adrenalectomy
1.3 Hypophysectomy
2. Anti-hormonal therapy (anti-oestrogens)
3. Combination hormonal and chemotherapy
Large numbers of different anti-hormonal drugs were develo­
ped in the past two decades (281), but only a few are cur­
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rently employed by clinicians, e.g. tamoxifen clomiphene, 
nafoxidine, and medroxyprogesterone acetate.
Most of the drugs studied so far however did not live up to 
the expectations of the clinicians (281). Apart from un­
pleasant side effects produced by these drugs (276) their 
action (tumour regression) was of short duration (222) and 
most of the patients developed some form of resistance 
against specific drugs and eventually against hormonal 
manipulation as a whole (35). The failure of hormonal 
manipulation to meet the expected results can possibly be 
ascribed to the following factors:
A. Incomplete understanding of the underlying hormonal 
mechanisms involved.
B. Inappropriate animal model (induced rat mammary tumours) 
employed in the laboratory evaluation of hormonal drugs.
C. The appearance of resistant cells through selection from 
the initial multi-centric disease or through drug reduced 
genetic changes.
It is believed that all these reasons apply to the problem 
of failures in hormonal therapy reported in recent years 
(79). An endeavour was made to study these mechanisms in an 
animal model more closely related to Homo sapiens. With this 
object in mind it was decided to undertake investigations 
in a non-human primate, e.g. Cercopithecus aethiops pygery- 
thrus. In the light of the general finding that normal 
mammary tissues contain very low (to zero) levels of oestro­
gen and progesterone receptors it was decided initially to 
turn our attention on the uterus as a hormone responsive 
target organ.
Several reports have appeared, describing the occurrence and 
some properties of cytosolic and nuclear receptors in geni­
tal tissues of non-human primates (124-142). Some studies 
concerning oestrogen receptors in the uterus and oviduct 
(311) as well as in the liver (312) of green monkeys 
(Cercopithecus griseus) have also been reported recently.
Setchell et £l_ (130) investigated steroid excretion during 
the reproductive cycle and pregnancy in the vervet monkey, 
Cercopithecus aethiops pygerythrus and found this Old World 
monkey to have menstrual patterns very similar to that of 
man.
The findings in this investigation of the occurrence, dis­
tribution and levels of oestrogen and progesterone receptors 
in Vervet monkey uteri and the results on the molecular pro­
perties of these two receptors are briefly summarised. 
Finally, attempts will be made to explain some of the 
findings relating to the j_n vitro activation and trans­
formation of these receptors prior to binding to the nu­
clear elements.
Conditions for the assaying of ER and PR in VMU have been 
established. Most of the findings are in agreement with 
those suggested by other research groups (143-158). It is 
clear that the post-hysterectomy treatment of the uteri, 
before ER and PR are analysed, is very important in preser­
ving the labile macromolecular components in the intact tis­
sue. Both the receptors exhibited a significant decrease in 
Bmax (16-35 % for ER and 10 - 25 % PR) when uteri were not 
processed at 0-4°C. Once the cytosols were prepared it seem­
ed advisable, not to freeze and thaw again, as repeated 
freezing and thawing nearly always caused a significant 
decrease in the binding capacity of the cytosol for both ER 
and PR. Deterioration of oestradiol binding profiles on 
sucrose density gradient centrifugation could be 
illustrated. It would seem that relative large volumes of 
cytosols are best stored in small aliquots (1-2 m£), at 
-70°C, in quantities, sufficient for individual investiga­
tions, in order to avoid from repeated freezing and thawing 
of the labile cytosols.
In uteri of C^ aethiops pygerythrus levels of ER ranged from 
151 to 822 femtomoles per mg protein (mean for group assayed
is 327±165 femtomoles per mg protein). PR assays were per­
formed on the same cytosols and the levels ranged from 444 
to 2267 femtomoles per mg protein (mean of 1285±511 femto­
moles per mg protein). Mean K. values for the ER and PR-
a -10ligand complexes were found to be 3.15±1.4xl0 M and
g
2.38±2xl0 M respectively, within the group analysed (n>20). 
The ratio of PR and ER varied between 1.1 and 13.1 with a 
mean of 4.5±2.4. Only a weakly positive correlation (r = 
0.25) was found to exist between levels of ER and PR in the 
same uteri.
The values obtained for receptor levels and dissociation 
constants in the course of this investigation were consis­
tently higher than those reported for the Rhesus monkey 
(124) and for humans (79)(see Table 5.1). More recently, 
however, another group working on the Rhesus monkey reported 
values which compare favourably with ours, provided their 
published values (expressed in femtomoles per mg DNA) are 
recalculated to femtomoles per mg cytosolic protein (313). 
The same group obtained ER/PR ratios between 2.5 and 3.2 
throughout the menstrual cycle, which seem to be contradic­
tory to previous reports on the same species (124). Contra­
dictory findings on the PR levels relative to ER levels for 
human tissues have also been published (99).
Association of receptors with their respective ligands 
seemed to be very rapid, even at 0°C and the complexes were 
extremely stable at 0°C and 20°C t„ at 0°C = 7 min; tv at 
20°C = 3 min). At 37°C inactivation was speeded up t„ at
37°C = 0.5 min) probably due to increased action of proteo­
lytic enzymes or perhaps some other unknwon catalytic fac­
tors. However, these data seemed to agree favourable with 
that published by other reserchers (284). It was for this 
reason that it was decided to incubate at 20°C for a dura­
tion of 30 min when performing the ER assay. Alternative 
incubation conditions used were at 0°C for a period of 16-24 
h.
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Ligand specificity investigations indicated a much narrower 
specificity for the ER as compared to the PR. For the ER the 
ligand preference was of the order : DES > EE2 > Eg > E1 
while no affinity was observed for any of the other steroid 
hormone categories. The result also seemed largely in agree­
ment with literature reports on breast cancers(143). As for 
the PR, again in agreement with other investigators, it was 
found that this receptor had a lower specificity (224). The 
most remarkable characteristic was the high affinity of the 
PR for EE2 (91.2 %) and the relative high affinity for other 
oestrogens : E2 > E1 > E^ (see Table 3.2). It would seem 
that the VMU progesterone receptor displays a unique pro­
perty by comparison with other progesterone binding 
proteins. Published values for the relative binding 
affinities of oestrogens for the PR are much lower than the 
values found in this work (224,314).
Scatchard plots for ER, conducted in conjunction with multi­
ple non-specific binding assays, employing in 100 fold ex­
cess either DES, EE2 or E2 as unlabelled competitors, gave 
very similar Bmax and Kd values when comparing, identical 
concentrations(Fig 2.11-2.13). It could be inferred, there­
fore, that in spite of the high affinity of the progesterone 
receptor for EE2 (RBA=91.2 %) of E2 (RBA= 16.3 %), the use 
of these unlabelled competitors in the multipoint titration 
assay (Scatchard plots) did not significantly affected the 
calculated binding parameters of the ER but was slightly 
affected by the different concentration of ligand. Data 
obtained on a tissue powder, freshly prepared from a pool of 
five VMU, indicated no significant variation (+1.9 %) in the 
Bm:3v/ for the ER, when assayed with a 100 fold excess of 
unlabelled EE2 or E2 instead of DES in the determination of 
the non-specific binding (see Fig 2.11-2.13).
Using low ionic strength or hypotonic conditions (TEDAG1Q 
buffer) only an 8 S component was observed for both the ER 
and the PR (Fig 3.6) (S : svedbergs (1 S = 10"13 seconds). 
Mean sedimentation coefficients (in svedbergs) were found
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to be 7.6±0.35 S (7.2-7.9 S) for the ER and 7.20 ±0.7 S 
(range 6.64-7.7 S) for the PR in the absence of 20mM sodium 
molybdate. Sedimentation coefficients exhibited no signi­
ficant change in the presence of molybdate and were essen­
tially the same for both receptors. A marked difference was 
observed between the SDG profiles of molybdate containing 
(CYT(+)) and non-molybdate containing (CYT(-)) cytosols. It 
would seem that the molybdate prevented the formation of a 
wider range of specific binding macromolecules, differing in 
their sedimentation rates within the 10 - 35 % sucrose den­
sity gradients. It is also clear from the SDG profiles that 
a higher yield of receptors had been obtained when cytosols 
were prepared in buffers containing sodium molybdate 
(CYT(-#-)). Scatchard assays corroborated these observations : 
the oestrogen (3 H-E2 )• binding capacity for CYT(+) was 27.5 % 
higher than for CYT(-), while the progesterone (3H-R020) 
binding capacity for CYT(+) was 21.3 % higher. No effect was 
observed on the binding affinity (K^) of the receptors.
A short exposure, of the labelled receptor-1igand complexes 
to 0.4 M KC1 caused partial dissociation of both receptors 
(Fig. 4.1). Cytosols prepared in buffers containing sodium 
molybdate appeared to be somewhat more resistant towards 
dissociation, when exposed to 0.4 M KC1, followed by centri­
fugation on gradients containing 0.4 M KC1 but no molybdate 
(Fig 4.2). This finding is largely in agreement with that 
reported very recently by Eastman-Reks et aj_ (315). Sedi­
mentation coefficients for the components observed in higher 
ionic strength (hypertonic) gradients were 7.6±0.3, 4.6±0.15 
and 3.8±0.15 for the ER and 6.4±0.3 and 3.8±0.1 for the PR, 
respectively.
When cytosols were reincubated with 0.4 M KC1, prior to cen­
trifugation on the 0.4 M KCJ2 containing SDG (10-35 % su­
crose) a progressive loss of the faster sedimenting (-v 6-7 
S) entity, with a resultant increase in the slower sedimen­
ting components (^ 4 - 6 S) could be observed (Fig 4.3-4.4). 
Again, sodium molybdate only affected the yield, but not the 
relative proportions of the different molecular entities. 
The progesterone receptor-ligand complex seemed to dissocia­
te at a faster rate, compared to the ER as judged from the 
SDG proflies, but qualitatively it is following the same 
pattern. The faster sedimenting PR entity, however, seems to 
shift to lower S-values for cytosols prepared in the presen­
ce of sodium molybdate (CYT(+)), while the shift for the ER 
in the presence of sodium molybdate is towards slightly 
higher s-values Fig. 4.5).
Reversibility of the dissociation of the ER seems to be 
affected by the length of time it is exposed to 0.4 M KC1 
during a second incubation at 0 - 4°C. The dissociation at 
zero time exposure (pre-centrifugation) is practically to­
tally reversible, while a swift decrease in reversibility is 
observed, at longer precentrifugation exposure times to 0.4 
M KC1. A remarkable feature observed in this reversibility 
study is that sodium molybdate tends to cause severe aggre­
gation of the % 8 S type of molecules following exposure to 
0.4 M KC1 and aggregation increased following longer periods 
of exposure to 0.4 M KC1 (Fig 4.6 - 4.7). Quantitatively 
(Table 4.1) it can be seen that in the absence of sodium 
molybdate (CYT(-)) longer incubation in 0.4 MKC1 rendered a 
linear decrease in the ^ 8 S peaks with time, while simulta­
neously a directly proportional increase in the 4 S area was 
observed (Fig 4.8). In the case of the cytosols with or 
without molybdate (CYT(+) and CYT(-)), the rate of decrease 
in the 'v 8 S peak is 82 % greater for CYT(+) than for the 
CYT(-) cytosols (Fig 4.8).
The presence of a 3-5S species for the VMU ER or the PR was 
never observed in low ionic strength hypotonic buffers. The 
only time a 3-5 S species was observed on sucrose gradients 
was after exposure of labelled cytosols to 0.4 M KC1. Short 
exposures to high ionic strength conditions produced partial
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"dissociated" 4S species. A clear difference in the beha­
viour of the ER and the PR could be observed in this 
respect. In the case of the ER it is clear that besides the 
% 8 S entity other species were generated while the 8 S 
PR seemed to "shift" to 5 S.
The results obtained for the sucrose density gradients agree 
to a great extent with published data on uterine receptors 
in other primates (142), man (107) and a number of different 
species (82). The effect of molybdate on SDG profiles had 
also been noted before (237). Molybdate is known to affect 
the receptor yield, a finding corroborated by our own re­
sults.
The majority of studies of receptor structure, have used 
radioactive steroids of high specific activity to detect the 
steroid-receptor complexes in crude extracts of fresh or 
frozen tissues. Such extracts also contain nucleic acids, 
ribonucleoproteins, proteases, nucleases, phosphatases and 
other enzymes, which may interact with or degrade the recep­
tors during prolonged fractionation procedures. These 
effects may have contributed to the discrepancies found in 
the molecular parameters reported in the literature. Despite 
much work and significant progress on the stabilization, 
purification and structural analysis of steroid receptors 
extracted from mammalian tissues, the native state still 
remains largely unknown (298). Receptors for a single class 
of steroids from the same tissue have been detected in 
various molecular forms for at least three different func­
tional states (298). These states are known as the "un­
transformed" and "inactive" receptors and can be dis­
tinguished by differences in their affinity of the receptor 
for steroids and in the affinity of the steroid-receptor 
complex for nuclei, DNA and ionic resins( 244,245).
Isoelectric focussing patterns of VMU ER (agarose gels, am- 
pholine range pH 3-10) present in cytosols prepared in the
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absence (CYT(-)) of "stabilizing" sodium molybdate (20mM) 
exhibited 3 main peaks at pi 5.9(28.9%), 6.2(30.3 %9 and 6.8 
(40.7 %) (Fig. 3.24). IEF patterns for CYT(+) cytosols, on 
the other hand appeared more simple, yielding one major peak 
at pi 5.9 (39.9 %) with two minor peaks at pi 5.6 (13.0 %) 
and 6.8 (16.6 %), while a broad specific binding area 
could be illustrated in the pi 5.0-5.5 (30.5 %) range. The 
apparent heterogeneous character of the VMU ER was corrobo­
rated by several other observations in the course of this 
investigation (SDG, anion exchange chromatography HPLC chro­
matofocussing).
HPLC chromatofocussing data revealed an even more complex 
picture (Fig. 3.22, Fig 3.23 and Table 3.11), with more high
affinity binding ER species appearing upon chromatofocussing 
of VMU cytosols, deficient in sodium molybdate (CYT(-)) on 
an AX- 1000 (polybuffer : pH 4-8) polyamine column. Under 
similar experimental conditions, CYT(+) cytosols yielded a 
much simpler picture with only two major peaks at pi 6.1 and 
5.5. It appeared as if the molybdate affected the ionic 
properties of the ER. causing it to elute at more acidic Pi- 
values. This result could provide support for the sugges­
tions forwarded in some research papers (226, 315) recently 
namely that the molybdate oxyanion physically interacts with 
the receptor protein, possibly with charged groups, e.g. 
phosphate groups or even with thiol groups.
This view was strongly underlined by the. data obtained with 
anion exchange chromatography of the VMU ER on an AX-1000 
poly-anion column. When CYT(-) cytosols were chromato­
graphed two distinctly different ligand-binding species or 
subunits, appearing in a ratio of 51 -’49, could be eluted 
with a phosphate (HPO^ gradient (Fig. 3.20). With CYT(+) 
cytosols the same column yielded only one species}eluting at 
a salt concentration (189mM) intermediary between the 
species obtained with the CYT(-) cytosols (90 mM and 250mM) 
(Fig 3.21). This result indeed proved that the effect of the
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molybdate oxyanion and the receptor molecule must be direct.
Most, if not all of the above mentioned findings are in some 
agreement with results reported on a number of steroid hor­
mone receptors in recent times (298). Whieleet al (316) 
found similar effects of the molybdate anion of chromato­
focussing patterns of lactating mammary gland and human 
uterine oestrogen receptors.
The effect of molybdate on size and other physicochemical 
parameters have been discussed previously (223-234) and 
would seem to apply to glucocorticoid, oestrogen and proges­
terone receptors. According to literature the molecular mass 
of the molybdate stabilized complex is approximately four 
times that of the product of its dissociation in hypertonic 
molybdate-free buffer (226). It has been shown that molyb­
date prevents the shift of the oestrogen bound receptors to 
a less negatively charged state which occurs during DEAE- 
cellulose chromatography. The shift of the steroid recep­
tor complex to a less negatively charged state is charac­
teristic of the steroid-receptor complex transformed either 
under cell-free conditions (230-231) or in intact cells 
(220). In addition molybdate is known to affect the size of 
the steroid-binding complex. According to Pratt et al (226) 
in the presence of 10mM sodium molybdate, steroid receptors 
form very large complexes with sedimentation values of 8-10 
S.
Since the first report by Nielsen et al (228-229) an exten­
sive investigation has been launched by numerous workers 
(223-234) on the subject of molybdate as a stabilizing fac­
tor for steroid hormone receptors. Consensus seems to have 
been reached as far as the universati1ity of this effect 
when steroid hormone receptors is concerned (220, 228, 231). 
Some of the most important effects of the molybdate anion, 
reported in the literature and confirmed here of higher 
yields of receptors obtained in cytosols prepared in the
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presence of sodium molybdate (232) and the inhibition of 
both the receptor activation (231) and the subsequent binding 
of receptor ligand complexes to nuclei and DNA-cellulose 
(248,255). Recently, molybdate has also been implicated in 
affecting the integrity of steroid hormone receptor molecu­
les, either by causing direct or indirect inhibition of pro­
teolytic enzymes (300) and/or phosphatase enzymes (270). 
Whiele (316) reported an effect of sodium molybdate on the 
structural integrity of the oestrogen binding proteins in 
rat mammary glands and human uterine tissue, when analysed 
by high performance liquid chromatography chromatofocussing 
(HPLC-CF).
Although a host of evidence would ascribe the effect of 
sodium molybdate to its possible inhibitive action on either 
proteases (151) or phosphatases (267-268), the real physico­
chemical role of this compound remains unsolved. Some 
researchers, however claim the effect of molybdate to be 
completely reversible (231), while others reported results 
to the contrary (317). It was subsequently decided to in­
vestigate the effect of molybdate on the molecular proper­
ties of the oestrogen and progesterone receptors of the VMU.
The molecular parameters of the VMU ER and PR which were 
studied,in addition to the sedimentation properties were : 
molecular size using different columns and ionic properties 
using IEF and HPLC-CF.Gel permeation chromatography results 
of VMU ER on an AcA-22 column are in agreement with the 
results reported in literature (213). Classification of the 
data was according to Sherman's classes, numbering the forms 
of the ER from I to V in order of decreasing molecular size. 
The Stokes radii for class II and IV were found to be 8-10 % 
higher than those reported by Sherman and as those for class 
III appeared to be identical. Comparison of the Stokes radii 
results with those obtained by sucrose density gradient 
centrifugation :class I and II identify with the ^ 8 S form 
whereas classes III and IV represent the % 4 S form and
class V is the ^ 2 S form. The M W of the receptor in low. 
ionic strength cytosol was 377,258 daltons with a Stokes 
radius of r*= 60 Awhile in high ionic strength the M W of the 
£R was 112,000 daltons and r*= 41 /?_
Gel permeation or gel exclusion chromatography using 
classical columns such as Ultrogel AcA-22, AcA-32 (both 
polyacrylamide based) and Sephacryl ..(S-300, produced
different molecular species, depending on the ionic strength 
of the mobile phase employed in chromatography. Low ionic 
strength conditions tended to cause aggregation and large
5
complexes with a molecular mass(MW) ranging from 3.77 x 10
. 5 '
to 8.5 x 10 daltons were frequently obtained. Stokes
radii (r) for these species were of the order of 60-8oi?.
Physiological buffers such as TEDAG^g(with 0.154 M NaCl) 
caused dissociation of the complexes and one of the most 
frequent species obtained had a MW of 1.12 x 10^ daltons (r* 
= 41A). At very high ionic strength conditions (0.4 M KC1 
in TEDAGjq) some deterioration of the specific binding 
species was often observed. Sodium molybdate did not
significantly change the molecular size of the complexes but 
exhibited a tendency to "protect" complexes from losing
their ligand binding abilities. Gel permeation chromato­
graphy using HPLC produced an even higher tendency to aggre­
gation at low ionic strength conditions. On the Waters 1-250 
gel columns, the most frequent complex observed was a 
species of a MW of 2.11 x 10^ daltons, r = 61/? while a 
rather small entity (MW 4.34x104 daltons; r*<34$ was also 
often observed.
It was observed that molybdate inhibited the inactivation 
(loss of ligand binding capacity) of VMU ER and PR when 
cytosols were prepared in buffers containing sodium molyb­
date, without affecting the binding affinity. This obser­
vation has been reported by several groups in recent years 
(232). Furthermore molybdate did not affect the rate con­
stants of association for receptor-ligand complexes signi-
ficantly. Dissociation of both VMU ER and PR was biphasic, 
indicating the existence of slow (SDC) as well as fast (FDC) 
dissociating complexes. Rate constants of dissociation of 
the complexes significantly affected by the presence of 
sodium molybdate (Table 3.3). However the debating points 
concerning the reversibility and the mechanism of the 
inactivation have not yet been clarified. Contradictory 
results have been published on the reversibility of the 
molybdate effect (231,317).
It is clear from the result of the sucrose density gradient 
profiles obtained with CYT(+) and CYT(-) cytosols when 
developed on either GRAD(+) or GRAD(-) gradients, that the 
process of inactivation in the absence of molybdate is not 
totally reversible (Fig 3.7 & 3.8). During the centrifuga­
tion process, receptor molecules were displaced from a com­
partment either containing or not containing molybdate to a 
compartment which either contained or did not contain molyb­
date (GRAD(+) or GRAD(-)). Displacement of receptor mole­
cules from the CYT(+) cytosols to a GRAD(-) compartment 
exhibited very little, if any, inactivation,if any (Table 
3,4). On the other hand receptor molecules from a CYT(-) 
cytosol showed an inactivation of 50.9 % for the ER and 35.2 
% for the PR when developed on a GRAD(-) gradient. A 29.6 % 
and 27.4 % loss of high affinity binding were observed re­
spectively for ER and PR when CYT(-) cytosols were developed 
on GRAD(+) gradients. The resulting inactivation could only 
be partially reversed (21,3 % and 7.8 % reactivation for ER 
and PR respectively) when GRAD(+) gradients were employed. 
In all of these experiments the affinity of the receptors 
for their ligands was unaffected, while inactivation, produ­
ced in the absence of molybdate, led to lower binding capa­
cities. When cytosols (CYT(+) or CYT(-)) were first dialy­
zed against buffers containing (TEDAG-MO) or not containing 
molybdate (TEDAG1Q) and subsequently centrifuged on 
sucrose density gradients with the same constitution as the 
dialysis buffers,the general tendency appeared, to be the
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same as that found in the sedimentation dialysis experiment. 
However re-activation of the PR appeared to be much higher 
(33.5%) than that of the ER (14.1%). The slightly higher 
reactivation obtained in this experiment for the PR could 
possibly be attributed to removal of a dialyzable endogenous 
inhibitor during dialysis, a finding which might have a 
link, with the endogenous inhibitor referred to in a, recent 
paper by Leach et al (231).
Numerous reports have appeared on the effect of proteolytic 
enzymes on the properties of steroid hormone receptors 
(65,170). The effect of various proteolytic inhibitors on 
the ligand-binding characteristies have also been discussed 
by several workers (297, 300, 316). In this study synergistic 
effect on the specific receptor-1igand binding was observed 
in cytosols containing Leu (2mM). This result indicates that 
some receptor inactivation normally occurs during the prepa­
ration and processing of the cytosols, even in the presence 
of molybdate. In this particular experiment (Fig 3.10-3.11) 
the receptor destruction (inactivation) was most probably 
caused by proteolytic action which was blocked in the 
presence of 2mM Leu. When PMSF (1mM) was employed as 
proteolytic inhibitor, no synergistic effect on the binding 
capacity was noted for either of the two receptors investi­
gated and again the protective effect of molybdate could be 
clearly seen. Some reports have appeared recently, descri­
bing methodologies for the assay of receptors in the presen­
ce of 1 mM PMSF as a precautionary step in protecting 
receptor integrity (318) a finding not confirmed here. In 
spite of the protective action of the Leu both ER and PR 
still seem to be inactivated in a molybdate deficient 
environment, indicating that the mode of action of the 
molybdate can not be linked to the inhibition (direct or 
indirect) of proteolytic enzymes.
In addition to inhibiting inactivation of steroid receptors, 
molybdate reversibly blocks transformation of the bound
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steroid-receptor complex to the DNA-binding state. Inhibi­
tion of temperature-dependent transformation was first 
reported for the avian progesterone receptor by Toft & 
Nishigori (257). Later studies have shown that molybdate 
also reversibly inhibits temperature-mediated transformation 
of glucocorticoid (254), oestrogen (248), and androgen (255) 
receptors. Vanadate and Tungstate also inhibit receptor 
transformation (226). Transformation of the glucocorticoid- 
receptor complex caused by salt or by precipitation with 
ammonium sulphate is also inhibited by molybdate (256). as 
is salt-mediated transformation of progesterone receptor and 
oestrogen receptor (257).Toft observed that sodium molybdate 
only stabilizes the non-activated receptor and has no 
apparent effect on the stability of receptor that has been 
activated. Therefore, the stabilizing and inhibiting actions 
of sodium molybdate would appear to be related.The molecular 
mechanism by which molybdate stabilizes steroid receptors is 
not known. Although molybdate and some of the other group 
VI-A transition-metal oxyanions inhibit a variety of 
phosphatases (256) and some phosphohydrolases (e.g. Na+, 
K+ATPases (256), this action does not account for their 
ability to stabilize steroid receptors and inhibit receptor 
transformation. Rather, it seems clear that molybdate is 
directly interacting with the receptor. Nishigori & 
Toft(257) have examined the effect of a number of compounds 
on both progesterone-receptor transformation and endogenous 
phosphatase activity in chick oviduct cytosol. Although 
molybdate, vanadate and tungstate inhibited both phosphatase 
activity and receptor transformation, the results obtained 
with the other inhibitors suggested that these two activi­
ties might not be related. Leach et aj_ (231) found that 
molybdate inhibited inactivation and transformation of 
glucocorticoid receptors caused by salt or ammonium sulphate 
precipitation at 0°C - 4°C. As these are physical methods of 
receptor activation and transformation that are unlikely to 
involve phosphatase action. It does not seem likely that 
phosphatase inhibition plays any role in the molybdate
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effects on steroid receptors.
Other observations (224) suggest that molybdate interacts 
directly with the receptor and possibly exclusively with the 
untransformed form. The type of functional group(s) required 
for the proposed molybdate receptor interaction is not 
known. It is known that sulphydryl groups are required for 
receptor transformation as well as for steroid binding 
(298), and thus molybdate-sulphur interactions might account 
for all of the molybdate effects observed on steroid 
receptors.
A modification of Clark's method (3H-E2 exchange assay) 
(310) proved to be a valuable technique for the analysis of 
specific nuclear oestrogen-binding sites in target tissues, 
such as the uterus (310) as well as in human and experimen­
tal mammary tumours (263).
The subcellular distribution of the oestradiol receptor has 
been described before (276-278) and the results found in 
this investigation (Section 5.4.3) are in good agreement 
with the reported data. It was found that a depletion of 
receptors in the cytosol was always accompanied by an 
accumulation of receptors in the nuclear compartment (Fig. 
5.6). The uptake and distribution of ligand-receptor com­
plexes was found to be a function of both time and tempera­
ture (Table 5.3). The results were largely affected by the 
procedure employed in the extraction of nuclear receptors 
from the nuclear myofibrilar pellet. Different treatments 
were compared and the results found during this investiga­
tion agreed favourably with those employed by others (282). 
The best extraction of nuclear receptors was obtained with 
the trypsin-KCl procedure (method b in Section 5.3.2.2; Fig
5.4 and 5.5). Levels of nuclear ER found in the course of 
our investigation (1483±1236 femtomoles/mg DNA; Table 5.1) 
were in good agreement with results reported by other 
workers employing primates in their investigations (313).
The main aim behind the experiments described in Chapter 5 
was to create a model system for studying the dynamics of 
the process of activation and transformation of the ER and 
PR in the VMU and to study the effect of molybdate on the 
system. Since all the molecular events involved in these 
processes occur in vivo in the Intact cell tissue slices 
were first employed in the investigation. However the re­
sults here not quantitatively reproducible. Thus an activation 
"model" involving a cell-free system was developed to study 
the activation and transformation of ER and PR in the VMU.
It was also necessary to investigate the process of activa­
tion in abnormal tissues and since abnormal monkey tissue 
was not available for this purpose the "activation system" 
employed in this case was normal and abnormal human uterine 
tissues. Both activation and transformation were studied in 
this latter system.
It is generally accepted that, according to the classical 
two-step model (45) the receptor-ligand complex, formed in 
the cytosol must be "activated" by some unknown process to 
form a "transformed" complex which exhibits a higher affi­
nity for chromatin than the "untransformed" state (45). It 
is also accepted that this transformation process implies 
that the ^ 4 S (0.4 M KC1 gradients) specific binding species 
(untransformed, inactive) undergoes a "conformational" 
change to a ~ 5 S entity. Thus, there is a link between 
receptor transformation and activation and the % 4 S - ^  5 S 
"shift" (0.4 M KC1 gradients) on the one hand and also with 
the ability of the "activated", "transformed" state to 
"translocate" to the nuclear compartment where it binds to 
chromatin with a high affinity on the other hand. Recently,
a number of papers have appeared addressing the problem of 
receptor activation. A number of workers have employed 
inhibitors of the activation aand/or transformation process, 
in order to gain more insight into the problem of receptor 
activation (315).
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It could be illustrated that temperature-induced activation 
of receptor-1igand complexes reaches a maximum at 15 min. of 
incubation at 28°C, as measured by increased binding of the 
complexes to uterine nuclei or DNA-cellulose. Simultaneous­
ly, a clear ^ 4 S - ^ 5 S shift was observed. Both these 
processes were inhibited by the presence of molybdate. 
Similarly it was shown that dissociation of receptor-ligand 
complexes was biphasic exhibiting the existence of fast dis­
sociating (FDC) and slow dissociating complexes (SDC).
Temperature-induced activation clearly "transformed" the FDC 
to a SDC while molybdate inhibited the formation of the SDC. 
In the presence of 10mM molybdate, dissociation is still 
biphasic, implying that both FDC and SDC still exist. How­
ever, it could be illustrated that the molybdate enhances 
the dissociation of the FDC, while it slows down the disso­
ciation of the SDC.
Similar observations were made on ER & PR from normal human 
uterine tissue suggesting that these effects are universal 
for steroid hormone receptors. However, in the case of 
abnormal human uterine tissues, especially with carcinoma of 
the cervix and in benign tumours like leiomyomata no ^ 4 S - 
^ 5 S "shift" was obtained after 15 min or longer periods 
of temperature-induced activation. Nuclear binding too of 
the temperature activated complexes was abnormal in the ab­
sence of sodium molybdate. This finding would suggest an 
abnormality at the molecular level possibly leading to ab­
normal hormonal mechanisms.
There have been no previous report on any abnormality in the 
activation and binding events in pathological target tissues 
when compared to normal tissues. Wittliff et al suggested 
that defective % 8 S + ^ 4 S receptor profiles obtained on 
sucrose gradient centrifugation may be related to an abnor­
mality in the response of certain ER positive tumours to 
hormonal therapy. It is as yet not known, however, whether
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his observations are universally acceptable. For the time 
being, however it is obvious that much remains to be done 
before these findings can be regarded as the accepted 
steroid receptor mechanism in abnormal tissues. A larger 
sample of tumours should be investigated to obtain statis­
tically acceptable results on this issue.
Finally it is not clear how the work described in this 
thesis .relates to the current belief that steroid receptors 
do not exist within the cytosol of cells but are confined to 
the nucleus (45-48). Clearly the issues are still very 
controversial and will require a great deal of time and 
effort before they are finally resolved.
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